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Abstract: 
 
 
Ovothiol is a 3-methyl-5-mercaptohistidine that was first discovered in sea urchin eggs. It 
is a proficient one electron donor that is characterized by low thiol pKSH and high redox 
potential. Ovothiols have been isolated from pathogenic trypanosomes that cause human 
tropical diseases such as Chagas disease, Leishmaniasis and Sleeping sickness. The 
physiological function of ovothiol is currently unknown. Here, we report characterization 
of 5-histidyl cysteine sulfoxide synthase (OvoA), the first enzyme in ovothiol 
biosynthesis, which mediates an unusual oxidative transsulfuration reaction at the L-
histidine C-5 position using L-cysteine as sulfur donor. OvoA was found to be 
characterized by L-cysteine and L-histidine KM values of 339 ± 22 µM and 347 ± 27 µM 
respectively. The enzyme was found to be most active at pH 7.5 with acidic pKa of 6.8 
and alkaline pKa of 8.0. Sulfur acceptor specificity studies revealed that OvoA converts 
histamine and D-histidine about 7 and 20 times less efficiently respectively, than L-
histidine. Ascorbate and isoascorbate were found to increase OvoA activity by over a 100 
fold. OvoA was found to convert 2-fluorohistidine into 2-fluorohistidyl cysteine 
sulfoxide at a similar rate to L-histidine despite the high electron deficiency of 2-
fluorohistidine. The mechanism of action of OvoA was found not to be limited by proton 
transfer as judged by the observed low solvent isotope effect of just 1.2. The compound 
5-fluorohistidine inhibited OvoA activity by 80%. In a related study, 5-fluorohistidine 
inhibited ergothioneine production by Mycobacterium smegmatis by 40%. 5-
chlorohistidine inhibited both OvoA activity and ergothioneine biosynthesis by 30%. 
Understanding the mechanisms of ovothiol and ergothioneine biosyntheses and the effect 
of 5-fluorohistidine in these pathways may assist in finding inhibitor molecules that can 
be developed into drugs against bacterial and trypanosomal pathogens. 
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CHAPTER 1:  
GENERAL INTRODUCTION 
 
1. Trypanosomatids 
 
 
1.1. History of the Order Kinetoplastida  
 
The Kinetoplastida are a Class in the Phylum Euglenozoa that comprise Orders 
Trypanosoma and Bodonida. These flagellate protozoa are characterized by the presence 
of a kinetoplast, a DNA containing body present in the single mitochondrion. A 
kinetoplast consists of a network of maxi- and mini-circle DNAs, which are responsible 
for posttranscriptional editing, and are located in the single mitochondrion near the basal 
body of the flagellum (Stuart et al., 2008). The order Trypanosoma is of particular 
importance to humans, because its members cause a variety of diseases in human and 
animals in different countries. The Genera, Leishmania and Trypanosoma are parasites 
that cause human diseases such as Leishmaniasis, human African trypanosomiasis (HAT) 
(also referred to as sleeping sickness) and American trypanosomiasis (Chagas disease). 
Their parasitism can either be monogenic, involving a single host or digenic where there 
is alternation between two hosts, most commonly an insect vector and a mammal. 
 
Trypanosomatids are digenic parasites and thought to have originated from their 
monogenic ancestors at least 250 million years ago through adaptation in animals (Lake 
et al., 1988). It is widely believed that Leishmania and Trypanosoma have a common 
ancestor. While lack of fossil records makes it difficult to obtain reliable evolutionary 
information about these protozoa, application of modern molecular evolutionary methods 
and other historical incidences put the estimated time of divergence between Leishmania 
and Trypanosoma between 80 and 140 million years ago (Lake et al., 1988). The 
divergence is believed to have preceded the divergence of the American species, T. cruzi 
and the African, T. brucei, which is thought to have happened shortly before splitting of 
Gondwanaland about 80 million years ago (Lake et al., 1988). 
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1.2. History and Discovery of Trypanosomatids diseases 
 
Leishmaniasis: Leishmaniasis is one of the most ancient human parasitic diseases 
reported in both Old and New Worlds. Different forms of the disease have been 
described: Cutaneous Leishmaniasis (CL), a skin disease characterized by sores and scars 
has long been known as oriental sores in the Old World (reviewed in Cox, 2002). One of 
its clearer descriptions was found on tablets in the library of the Assyrian King 
Ashurbanipal dated back to the 7th century BC. Some of these descriptions are thought to 
have originated from earlier texts dating as far back as 1500 to 2500 BC. In the Indian 
subcontinent, the visceral leishmaniasis (VL) (also known as Kala-azar, meaning Black 
fever) was first discovered in 1824 in Jessore (reviewed in Cox, 2002). 
 
Evidence for the existence of Cutaneous and Mucocutaneous Leishmaniasis in the New 
World was obtained from pre-Inca potteries found in Ecuador and Peru (reviewed in Cox, 
2002). The potteries, dated as far back as first century AD, had representations of facial 
deformities and skin lesions, which clearly matched the lesions of Cutaneous 
Leishmaniasis sufferers. Although it can be traced back hundreds of years, the earliest 
clinical descriptions of Cutaneous Leishmaniasis were made by Alexander Russell in 
1756 after examination of a Turkish patient. On his note was written: 
 
 "After it is cicatrised, it leaves an ugly scar……..It affects the natives when they are 
children, and generally app ars in the face, though they also have some lesions on their 
extremities………., but they seldom affect the same person above once."  
 
Despite the fact that the disease had been known for such a long time the parasites that 
cause leishmaniasis were discovered only in 1903 (Ross, 1903). However, due to many 
different observations reported by early scientists in the late 19th century, there is still a 
controversy as to whom the initial discovery of the parasite responsible for Cutaneous 
Leishmaniasis should be attributed. In contrast, it is universally accepted that Scottish 
army doctor, William Leishman, and Charles Donovan, the Professor of Physiology at 
Madras University, independently discovered the parasite that causes Visceral 
Leishmaniasis in 1903. Hence, in their honour, Ross named the parasite, Leishmania 
donovani bearing both their names. 
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About 30 species of Leishmania infect mammals and about 20 of these are responsible 
for different forms of Leishmaniasis in humans. The parasites use female sand-flies as 
their transmission vector and about 30 of 500 known phlebotomine species have been 
positively identified as vectors of the disease. In the New World the disease is transmitted 
by Lutzomyia genera while in the Old world Leishmania transmission is via Phlebotomus 
genera. 
 
Chagas Disease: Chagas’ disease is a human tropical disease predominantly found in 
Latin America. The existence of Chagas disease could be dated back to 2000 BC after 
isolation of DNA of T. cruzi in the heart and oesophagus of Peruvian and Chilian 
mummies (Rothammer et al., 1985 and Guhl et al., 1997). But it was not until 1909 that 
the discovery of T. cruzi as the causative agent was made by Carlos Chagas. The 
parasites, contained in the faeces of the triatomine bugs (large blood sucking insects that 
occur mainly in Latin America) are transmitted to humans when the bug feeds on its 
human prey. Domestic animals serve as reservoirs (Rothammer et al., 1985). 
 
Sleeping sickness/ Human African trypanosomiasis (HAT): Due to a lack of fossils for the 
causative agents of HAT, it has become difficult to speculate on the origin of the disease. 
An early historic report of sleeping sickness was that of the death of a Malian emperor in 
1374 AD from a disease description of which matched that of modern sleeping sickness 
(Williams, 1996). Two subspecies of T. brucei cause different clinical infections of 
Human African trypanosomiasis in different African geographical locations (Steverding 
2008). In West Africa, T. brucei gambiense causes the chronic form of the disease while 
in East Africa T.b. rhodesiense is responsible for the acute form. In some central African 
regions, such as Uganda, however, both species have been isolated and co-infection has 
also been reported (Stich et al., 2002). Both parasites are transmitted by female tsetse 
flies of the genus Glossina. Domestic and game animals are reservoirs of the parasites. 
The animal form of the disease, nagana, is caused by infection with T. b. brucei 
subspecies which are not pathogenic to humans (Stich et al., 2002). 
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1.3. Epidemiology of Trypanosomal Diseases 
 
Different diseases caused by kinetoplastida affect many people in different countries. 
They occur mostly in geographical locations where the insect vectors are found (table 
1.1) (Stuart et al., 2008). 
  
Leishmaniasis: Leishmaniasis affects about 350 million people in 88 countries where it is 
known to be endemic. The reported infection rate stands between 1- 1.5 million for 
cutaneous Leishmaniasis (CL) and 500 000 visceral Leishmaniasis (VL) per year with 
overall infection figures standing at about 12 million people. VL is responsible for about 
50 000 deaths a year and is regarded as the second-largest parasitic killer in the world 
after malaria, (Desjeux et al., 2001). 
 
Chagas disease: Chagas’ disease is endemic in 21 Latin American countries, putting the 
lives of 100 million people in danger. There are about 200 000 new cases every year, 
leaving a total of about 18 million people infected. The death rate resulting from Chagas 
disease is approximated to be 21 000 deaths per year. 
 
Sleeping sickness: Sleeping sickness is almost exclusively found in Africa in the regions 
where the Tsetse flies, the transmission vector occur. The disease affects approximately 
60 million people living in 36 African countries located south of Sahara and north of the 
Kalahari Desert. Despite a successful programme in the 1970’s, which almost eradicated 
Human African Trypanosomiasis, there has been a steady re-emergence of the disease in 
the new millennium (WHO, 2006). It is now estimated that over 46 000 people die every 
year from the disease, which has an annual infection rate of 300 000 new cases (Mathers 
et al., 2007 and WHO, 2006). 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
5 
 
Table 1.1: Table showing diseases caused by kinetoplastidae parasites (unmodified 
from Stuart et al., 2008) 
 
 
1.4. Diagnosis  
 
The oldest and most commonly used detection method to date involves visualization of 
the live parasites. Aspirates from appropriate organs are fixed, stained and visualized 
under the light microscope. Although this method provides very reliable results, it has 
HAT/Seesping sickness Chagas disease The leaishmaniasis
Principal disease forms or stages Early (hemolymphatic) stage, late (CNS) 
stage
Acute phase, indeterminant phase,    
chronic phase (cardiac and digestive forms)
Viceral leishmaniasis (VL),                        
mucocutaneous leishmaniasis (MCL),                                           
cutaneous leishmaniasis (CL)
Causative organism T.b. gambiense, T.b. rhodesiense T. cruzi
about 21 Leishmania  species., e.g., L. donovani 
(VL), L. braziliensis  (MCL, L. major (CL)
Host cell/tissue
Extracellular, in blood, lymph, cerebral 
spinal fluid, and intercellular spaces
Intracellular, in cytoplasm of heart, smooth 
muscle, gut, CNS, and adipose tissue cells
Intracellular, in phagolysosomes of macrophages
Vectors of medical importance
Tsetse flies (about 20 Glossina  species) 
(palpalis  group, T.b. gambiense ; 
morsitans  group, T.b. rhodesiense )
Reduviid bugs (about 12 to 138 
Triatominae  species) (Triatoma , Rhodnius , 
and Panstrongylus  species
Phebotomine sandflies (about 70 species) 
(Phlebotimus  species in Old World, and 
Lutzomyia  species in New World
Transmission
Infected fly bite, congenital (rare), blood 
trasfusion (rare)
Contamination by feces of infected bugs 
(e.g., bite site, in mucous membranes, in 
food or drink), blood trasnfusion, 
conjenital, organ trasplantation (rare)
Infected fly bite
Geographical distribution Sub-Saharan Africa ( about 20 countries) South and Central America (19 countries)
South and Central America, Europe, Africa, Asia 
(88 endemic countries)
Population at risk 50 million 100 million 350 million
Infected 70 000 - 80 000 8 - 11 million 12 million
Health burden (DALYs) 1.5 million 0.7 million 2.1 million
Deaths (per annum) about 30 000 14 000 51 000 (VL)
Prevention and control measures
Active surveilance of at risk population, 
drug treatment of infected patients, 
tsetse fly traps, residual insecticides, 
sterile insect technique, tsetse habitat 
destruction to inhibit reinvasion
Treatment of homes with residual 
insecticides, blood donor screening, drug 
treatment for acute, early indeterminate 
and conjenital cases, better housing 
(plastered walls and metal roof replacing 
adobe-walled, thatch-roofed dwellings)
Surveilance and treatment of VL cases, resevoir 
(dog) control (VL); treatment of homes with 
residual insecticides; insecticide-treated bed 
nets, fabrics, and dog collars; live vaccination 
(CL)
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many limitations, relating to low parasite concentrations during chronic infections and the 
early stages of infection (Kennedy, 2008). This method also fails to differentiate early 
infection from late infection, making treatment difficult, especially for Sleeping sickness,    
where drugs for the early stage are not effective in the late stage and the drugs for late 
stage are associated with a high level of toxicity (Kennedy, 2006). 
 
To deal with low parasite concentrations in the blood, the parasites are cultured in 
appropriate media and then visualized under a microscope. However, this method cannot 
be applied in field tests due to the slow growth of the parasites in culture (Sundar and 
Rai, 2002). 
 
Indirect tests which rely on production of antibodies have a long history and some of 
them are still in use today (Rosenblatt, 2009). The principle of these tests relies on the 
presence of antibodies produced by infected persons, which selectively bind to 
trypanosome antigens and results in blood agglutination. Various agglutination tests have 
been used successfully in Chagas disease, Sleeping sickness and Leishmaniasis 
(Rosenblatt, 2009). Although these tests are sensitive, they suffer from poor selectivity as 
similar antibodies are raised in response to other pathogens (López-Antuñano et al., 
2000). Moreover, the antibodies remain in the blood of cured patients for a number of 
years which will then give false positive results (Sundar and Rai, 2002). As a result, more 
work is needed to improve the specificity and sensitivity of these methods. For example, 
the use of a parasite specific antigen (rK39 antigen) led to development of a more 
sensitive and specific ELISA test kit for Leishmaniasis. The rK39 ELISA tests kits are 
currently commercialized and have significantly improved diagnosis of Leishmaniasis 
(Sundar and Rai, 2002). 
 
Development of molecular assays that rely on the polymerase chain reaction (PCR) has 
provided more reliable and sensitive diagnostic results. In this procedure, repetitive 
sections of kinetoplast DNA are amplified and analyzed. Due to its high specificity and 
sensitivity, PCR tests are mostly recommended for cure confirmation in treated patients. 
However, these methods require skilled personnel and are very expensive, which then 
limit their application as a sole diagnostic tool for field tests. PCR based tests are 
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therefore recommended when all other tests have failed or when a confirmation is 
required (Rosenblatt, 2009). 
 
1.5. Current chemotherapy against trypanosomal diseases 
 
The first real work on the treatment of trypanosomes started can be dated back to the 
work done by Paul Ehrlich on arsenicals and dyes. Although some drugs were quickly 
developed afterwards, most of them are no longer currently in use due to high levels of 
cytotoxicity (Frézard et al., 2009). 
 
Leishmaniasis: Pentavalent antimonials, meglumine antimonate and sodium 
stibogluconate, have been used as the first line drugs for treatment of Leishmaniasis since 
the 1940s. The drugs are given parenterally daily for 20-30 days (Frézard et al., 2009). 
The drugs are believed to disrupt the parasite’s energy production pathway as their main 
mode of action while other researchers have also linked th  drugs with interference of the 
parasite’s antioxidant pathway by reacting with trypanothione (Singh, 2006).. Despite 
their anti-parasitic effect, the drugs have adverse side effects including diarrhoea, 
vomiting nausea, skin rashes and cardiotoxicity (Singh, 2006). In the recent past there has 
been a wide spread development of resistance against pentavalent antimonials in many 
countries. Antimonial resistance in Leishmaniasis is associated with drug efflux as 
resistant strains were found to express high levels of ABC transporter proteins and that 
inhibition of ABC transporters abolished resistance to antimonials (Basu et al., 2008) 
 
Pentamidine and amphotericin are the second line drugs against strains resistant to 
antimonials while miltefosine, the first orally administered drug, has recently been 
introduced for treatment of Leishmania strains resistant to antimonials (Soto et al., 2004). 
 
 
Sleeping sickness: Treatment of Sleeping sickness can be divided into two categories, the 
early stage and late stage drugs. In the early stage the parasites are present mostly in the 
haemolymphatic system and the liver. The two drugs, suramin and pentamidine are used 
in the early stage of sleeping sickness (Nok, 2003). Suramin is a poly-sulfonated 
naphthylamine and very water soluble. It is thought to bind strongly to low-density 
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lipoproteins (LDL) thereby starving the parasite of the essential cholesterol. However, 
suramin’s ionic structure has proven to be a disadvantage as it limits its penetration of the 
blood brain barrier. Hence, suramin is only used in the early stage of the disease before 
the parasites enters the brain (Nok, 2003). Pentamidine, an aromatic diamidine, was 
introduced in the 1940s to treat the early stage of T. b. gambiense Sleeping sickness 
(Luorie, 1942). Pentamidine does not cross the blood brain barrier (BBB) in reasonable 
concentrations to attain drug levels necessary for cure, and for that reason it is only used 
for treatment of the early stage. Although it is not fully understood why pentamidine is 
not effective against T. b. rhodesiense, it is thought that the high reproduction rate of T. 
rhodesiense leads to a rapid invasion of the central nervous system before the early stage 
of infection can be cleared by the drug.  Pentamidine’s mode of action is not known. 
However recent studies associate reaction of the drug with ubiquitin (Nguewa et al., 
2005). Field resistance to both pentamidine and suramin has never been reported while 
laboratory resistance of up to 300 fold can be induced. The induced resistance in both 
drugs is associated with rapid drug efflux (Nok, 2003). 
 
The late stage sleeping sickness begins when the parasites which had been in the human 
body pass through the blood brain barrier (BBB) into the central nervous system. 
Therefore, only drugs which are able to cross the BBB in the right quantities can be used 
to treat the late stage sleeping sickness. Melarsoprol and eflornithine are currently in use 
to treat patients with late stage sleeping sickness (Blum and Burri, 2002). Treatment with 
melarsoprol, however, may result in severe encephalopathy with up to 10% mortality in 
treated patients (Pepin and Milord, 1994). Severe side effects associated with melarsoprol 
are believed to occur as a result of binding to disulfide bonds of proteins. Although the 
mode of action of melarsoprol is still under investigation, the new reports link it to 
binding to thiol containing enzymes like glycerol-3-phosphate dehydrogenase (G3PDH) 
(Nok, 2003). The high mortality rate and adverse side effects of melarsoprol led to 
introduction of eflornithine as alternative drug. Despite its effectiveness, eflornithine is 
too expensive to be administered in poor African countries where it is needed most. Its 
other disadvantage is that eflornithine is not effective against T. b. rhodesiense (Iten et 
al., 1995). These and other factors make it imperative to search for more efficient drugs 
against sleeping sickness. 
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Chagas disease: Current chemotherapy for Chagas disease consists of two drugs; 
Benznidazole and Nifurtimox. Benznidazole, an azole derivative, is very effective against 
the acute phase of Chagas disease with over 80% parasitological cure. Although the mode 
of action of Benznidazole is poorly understood, it is believed to involve covalent 
modification of macromolecules such as lipids, DNA and proteins through its nitro-
reduction intermediates generated through reduction by nitro-reductases (Coura and de 
Castro, 2002). Nifurtimox, a 5-nitrofuran is an orally administered drug given to Chagas 
disease patients, 8-10 mg/Kg/day for 1-2 months. The mode of action of nifurtimox 
involves generation of nitro anion radicals, which in the presence of oxygen leads to 
generation of reactive intermediates that are responsible for eradication of the parasites 
(Coura and de Castro, 2002). However, the nitro radicals generated during the 
metabolism of the drug have also been implicated in the adverse side effects associated 
with administration of nifurtimox (Urbinal and Docampo, 2003). Both drugs have shown 
poor efficacy in treating patients with the chronic form of the disease.  As a result, some 
South American countries such as Brazil, Argentina, Chile and Uruguay stopped 
commercialization of nifurtimox in the 1980s (Urbinal and Docampo, 2003). On the 
positive side, a nifurtimox- melarsoprol combination is being investigated as potential 
alternative chemotherapy for treatment of the second stage of sleeping sickness with 
positive results (Bisser et al., 2007). With benznidazole being the only effective drug 
against the acute Chagas disease, there is a dire need for development of new 
chemotherapeutic agents to treat Chagas disease. 
 
 
1.6. Unique metabolic pathways of trypanosomatids as potential drug targets 
 
Successful development of new effective chemotherapies against trypanosomal diseases 
would need to take into account factors such as drug targets and modes of action, low 
side effects etc. It is therefore important that potential drug targets be found and 
validated. The obvious targets should be proteins or enzymes which are not only unique 
to the parasites but also significant for survival of the parasites. Some of the recently 
discovered potential drug targets are briefly discussed here. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
10 
 
1.6.1. Sterol synthesis 
 
Unlike animals which produce cholesterol to maintain membrane integrity, 
trypanosomatids and fungi synthesize unique sterols such as ergosterol (T. cruzi) and 
ergostane (Leishmania) as the final products of the sterol biosynthetic pathway (figure 
1.1). The absence of ergosterol in animals makes the enzymes involved in the ergosterol 
biosynthetic pathway suitable drug targets (Urbina et al., 2002). Amphotericin B, 
developed as an antifungal drug, was found to be very effective in the treatment of 
Sleeping sickness. It is believed to bind to the ergosterol, resulting in the formation of 
pores, which leads to cell death as ions (K+ and Na+) leak out of the cell. Amphotericin B 
however seems to have multiple binding sites, which leads to undesirable side effects 
(Urbina et al., 2003). Other inhibitors of ergosterol biosynthetic enzymes have been 
explored as potential drugs against Chagas disease. Thus, antifungals, ketoconazole and 
itraconazole (Roberts et al., 2003) and triazoles, posaconazole and UR-9825 all known 
for their interference with ergosterol biosynthesis have been tested for anti-trypanosomal 
activity with positive outcomes. Treatment with UR-9825 and posaconazole results in 
diminished proliferation of epimastigotes and amastigotes coincident with  the depletion 
of sterols, while in animal studies the drug resulted in 50% cure rate of mice infected 
with T. cruzi strains that were resistant to Nifurtimox, benznidazole and ketoconazole 
(Roberts et al., 2003). 
 
Leishmania species produce ergostane rather than ergosterol (figure 1.1). Due to 
structural similarities with ergosterol, biosynthesis of ergostane can also be interrupted by 
inhibitors of ergosterol biosynthesis, ketoconazole and itraconazole. As such these drugs 
have also been tried successfully against Leishmania (Roberts et al., 2003). 
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Figure 1.1: Chemical structures of ergosterol and ergostane. 
 
However treatment of blood parasites with anti-sterols tends to be ineffective in parasites 
which possess mechanisms whereby they can assimilate sterol from the host cells 
(Roberts et al., 2003). That is the case with T. brucei species which, even with ergosterol 
biosynthesis completely inhibited, assimilate cholesterol from the host serum lipoproteins 
and as such cannot be treated with Amphotericin B and th  antifungals, ketoconazole and 
itraconazole (Balaña-Fouce et al., 1998, and Roberts et al., 2003). 
 
 
1.6.2. Glycosomal enzymes 
 
Trypanosomatid parasites like all other living organisms require energy for their normal 
metabolism. But unlike their mammalian hosts, trypanosomatids do not have a functional 
TCA cycle or mitochondrial respiratory chain and rely entirely on glycolysis for ATP 
supply (Michels et al., 2006). The parasites have fully functional glycolysis with all ten 
required glycolytic enzymes. However it is the organization of the glycolytic enzymes 
that sparked interest among researchers. Seven of the glycolytic enzymes that convert 
glucose to 3-phosphoglycerate are located in specialized peroxidase-like organelles called 
glycosomes (Michels et al., 2006). That is different from other organisms where 
glycolysis is completely cytosolic with all enzymes located in the cytosol. This 
organization and the distant divergence of trypanosomatids from mammals have endowed 
trypanosomal enzymes with unique characteristics (Nowicki, 2008).  
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Although the amino acid similarities for most glycolytic enzymes amongst the 
trypanosomatid family ranged between 80 and 95%, some striking differences were 
observed when such enzymes were compared with their mammalian counterparts, 
showing similarities of only about 20 to 47% (Nowicki, 2008). One of the mostly studied 
glycolytic enzymes in T. brucei is phosphofructokinase (PFK) which mediates the 
synthesis of fructose-1, 6-bisphosphate from fructose 6-phosphate using ATP as phospho 
donor. It is a tetrameric enzyme which is also located in the glycosome. It shares only 
about 20% sequence homology with its human isoenzymes suggesting that the enzyme 
can be selectively inhibited. In a recent study, the PFK selective inhibitors showed strong 
potency against T. brucei and Leishmania parasites (Guido et al., 2008). 
 
Another important glycolytic enzyme is glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) structure of which is highly conserved among trypanosomal family members 
(90% similarity) (Guido et al., 2008). GAPDH catalyzes the oxidative phosphorylation of 
D-glyceraldehyde-3-phosphate into 1,3-bisphosphoglyc rate. Trypanosomal GAPDH 
possesses only 45% amino acid similarity with the mammalian GAPDH form and 
provides unique structural features exploitable for drug development. A striking example 
is that of an inhibitor of GAPDH, 2’-deoxy-2’-(3-methoxybenzamido) adenosine, which 
could selectively inhibit the GADPH of T. brucei and L.mexicana while showing 
marginal inhibition of the human enzyme (Callens and Hannaert, 1995). Molecular 
docking and other advanced techniques are currently used to find selective inhibitors of 
trypanosomal GAPDH (Guido et al., 2008). 
 
1.6.3. Purine salvage pathway 
 
Unlike their mammalian host, trypanosomatids cannot synthesize purines de novo and 
therefore are solely reliant on purine salvage pathways for nucleotide biosynthesis. As 
such, enzymes involved in this pathway present good drug targets (El Kouni, 2003). Of 
particular importance in this pathway is that trypanosomatids use a single enzyme, 
Hypoxanthine-guanine phosphoribosyltransferase (HGPRT), to convert bases to 
ribonucleotide. Recent molecular docking studies revealed significant differences 
between trypanosomal and mammalian HGPRT and proved that selective inhibition of 
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the trypanosomal HGPRT is possible (Zuccotto, 1999). Therefore a search for HGPRT 
inhibitors is becoming a crucial goal to achieving new drugs against the parasites. 
 
1.6.4. Special hydrolases  
 
Cruzain is a member of the papain C1 family of cysteine proteases and is a primary 
cysteine protease in T. cruzi. It is essential for the survival of T. cruzi, because of its 
involvement in crucial reactions such as differentiation and intracellular replication (Hart 
et al., 1993). Unlike mammalian enzymes, which are located in the lysosome, cruzain is 
cytosolic in T. cruzi (McKerrow et al., 1999). The different sub-cellular location and 
observed lack of redundancy make cruzain an attractive drug target. Recent studies have 
confirmed eradication of T. cruzi parasite from infected J744 macrophages (mammalian 
culture) after treatment with specific reversible and irreversible inhibitors of cruzain, with 
acyloxymethyl ketone inhibitors and aryloxymethyl ketone inhibitors showing potential 
for new drugs against Chagas disease (Brak et al., 2008). 
 
DNA topology is an important process during cell division and gene expression. The 
alteration of cellular DNA is catalyzed by topoisomerase II. The function of 
topoisomerase II is to cut both strands of double stranded DNA and allow tangling or de-
entanglement of DNA. It is a crucial enzyme for replication as it enables separation of 
newly formed daughter strands. This is a crucial enzyme to target for the development of 
anti-trypanosomal drugs because of extra kDNA located in the kinetoplast. Inhibition of 
trypanosomal topoisomerases II resulted in inhibition of both differentiation and 
proliferation in the parasites causing major damage to nucleus and kinetoplast. Other 
potential drug targets are enzymes involved in folate biosynthesis. Dihydrofolate 
reductase (DHFR), the enzyme involved in reduction of dihydrofolate to tetrahydrofolate, 
has been successfully targeted for drug development in other ailments such as cancer, 
malaria and bacterial infections (Coura and de Castro, 2002). Although previously less 
attention was focused on trypanosomal DHFR, recent studies have reported high activity 
of selective inhibitors of trypanosomal DHFR against trypanosomatids (Khabnadideh et 
al., 2005). 
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1.6.5. Oxidative metabolism: The role of low molecular thiols 
 
Like all aerobic organisms, trypanosomes are subjected to reactive oxygen and nitrogen 
species, which need to be detoxified. Mammalian parasites are subjected to even higher 
amounts of oxidant species produced as result of the mammalian immune response 
(Droge, 2002). Unlike their mammalian counterparts, trypanosomatids lack catalase and 
glutathione peroxidase, the two important enzymes involved in detoxification of reactive 
oxygen species in mammals. Instead trypanosomatids possess a different detoxification 
pathway in which superoxides are converted into hydrogen peroxide by iron containing 
superoxide dismutase (Fe-SOD), instead of Mn- or Zn-SODs found in mammals (Scheme 
1.1). Fe-SOD has been proven to be important for survival of the parasites in the 
mammalian hosts. T. chagasi mutants generated through deletion of one gene resulted in 
hypersensivity of the mutants to peroxides (Plewes et al, 2003). Fe-SOD overexpression 
in T. cruzi was found to result in increased benznidazole resistance (Temperton et al, 
1998). That is because benznidazole is believed to produce high amounts of superoxides 
which will then be reduced by highly expressed Fe-SOD. 
 
 
Scheme 1.1: Trypanothione dependent detoxification system (Irigoín, 2008). 
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In the absence of efficient enzymatic detoxification system, trypanosomes have evolved 
an efficient non-enzymatic oxidant detoxification system comprising of ascorbate-
dehydroascorbate and low molecular thiols, glutathione, glutathionylspermidine, 
trypanothione, and ovothiol to play similar role (Irigoín, 2008) (scheme 1.1) 
 
1.7. Trypanothione 
 
Trypanothione is an aliphatic dithiol synthesized from conjugation of two molecules of 
glutathione to one molecule of polyamine spermidine in two ATP requiring steps, 
mediated differently within trypanosomatids genera (Comini, 2003) (scheme 1.2). 
Conjugation of a glutathione molecule to spermidine, results in the formation of 
glutathionylspermidine, an intermediate which itself serves as an antioxidant. 
Conjugation of the second glutathione to glutathionylspermidine results in trypanothione 
(Scheme 1.2). In T. brucei and T. cruzi both steps are catalyzed by a single enzyme, 
trypanothione synthetase, and each step requires an ATP molecule (Comini, 2003 and 
Oza, 2002). In contrast, two distinct enzymes are required to catalyze the two steps in C. 
fasciculata (Smith, 1992). Glutathionylspermidine synthetase catalyses the first step to 
form glutathionylspermidine and trypanothione synthetase catalyses the second step to 
make glutathione. 
 
 
Scheme 1.2: Trypanothione biosynthetic pathway (Irigoín, 2008). 
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Trypanothione biosynthesis is not limited to trypanosomatids as other organisms such as 
Entamoeba histolytica and Euglena gracilis were also reported to produce trypanothione 
(Montrichard et al, 1999). The role of trypanothione in these organisms is, however, yet 
to be established. 
 
 
1.7.1. Functions of trypanothione in trypanosomatids 
 
Trypanothione plays a central role in redox regulation in trypanosomatids by being 
directly involved in the detoxification of reactive oxygen species (ROS). Trypanothione 
can be seen as replacing glutathione in trypanosomatids and is a better antioxidant than 
glutathione. With a thiol pKa value of 7.4 compared to 8.6 for glutathione, trypanothione 
is more reactive in thiol disulfide exchange reactions than glutathione at physiological pH 
(Mountiez et al., 1994). 
 
In vitro studies have shown trypanothione as a spontaneous reductant of glutathione 
disulfides, ovothiol disulfides, thioredoxin, and is also expected to perform similar 
functions in vivo. It has also been found to be an efficient reductant of radiation induced 
radicals and peroxynitrite (Mountiez et al., 1994). 
 
Other studies have linked trypanothione to the resistance of Leishmania to trivalent 
arsenics and antimonials. Trypanothione is thought to bind to the drugs and form adducts 
which are then sequestrated out of the cell through a P-glycoprotein-like protein A 
(PGPA). Indeed the PGPA overexpression was observed in multidrug resistant parasites 
(Goyeneche-Patino et al., 2008). 
 
Perhaps of particular importance in trypanosomatids is the fact that trypanothione serves 
as an electron donor for the reduction of tryparedoxins. The trypanothione-tryparedoxin 
system probably accounts entirely for the ability of trypanosomatids to deal with 
oxidative stress (Krauth-Siegel and Comini, 2008). 
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1.7.2. Enzymes of trypanothione metabolism as potential drug targets 
 
The absence of trypanothione metabolism in mammalian hosts, its major contribution 
towards redox metabolism in trypanosomatids and the susceptibility of trypanosomatids 
to oxidative stress make enzymes involved in trypanothione metabolism attractive drug 
targets. The evidence for sensitivity of the parasites to oxidative stress was provided by a 
study done using a potent inhibitor of glutathione biosynthesis, buthionine sulfoximine 
(BSO). In that study it was found that treatment with BSO resulted in prolonged survival 
of or even cure of mice infected with African trypanosomes (Arrick et al., 1981). BSO 
treatment was also found to reverse nifurtimox and benznidazole resistance by African 
trypanosome (Faundez et al., 2005). Treatment with BSO results in diminished 
glutathione which would lead to low levels of trypanothione and ultimately impaired 
capacity to detoxify oxidants such as reactive oxygen and reactive nitrogen species. 
However, BSO cannot be used as a drug against trypanosomes since it does not 
differentiate between mammalian and parasite enzymes (Huynh et al., 2003). 
 
 
1.7.2.1. Polyamine biosynthesis 
 
Spermidine is a polyamine on which two molecules of glutathione are linked to form 
trypanothione. Its biosynthesis is similar in parasite and their mammalian hosts. 
Spermidine is synthesized by conjugation of putrescine and decarboxylated S-
adenosylmethionine in an enzymatic reaction catalyzed by spermidine synthase (Tabor 
and Tabor, 1984). No structural differences have been found between parasite and 
mammalian spermidine synthases and both enzymes were found to be very stable. As a 
result, the parasite’s spermidine synthase is not attractive drug target. 
 
However, putrescine and decarboxylated S-adenosylmethionine are themselves 
synthesized separately in the reactions catalyzed by ornithine decarboxylase (ODC) and 
S-adenosylmethionine decarboxylase (AdoMetDC), respectively. Although both parasites 
and their mammalian hosts possess ODC, the parasite enzyme displays significant 
differences exploitable for development of selective inhibitors. Unlike the mammalian 
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enzyme, parasite ODC lacks the C-terminal degradation signal, resulting in decreased 
enzyme turnover (Ghoda et al., 1990). This is a crucial factor because the inactivated 
mammalian enzyme is quickly replenished unlike parasite enzyme because rapid enzyme 
degradation in a cell is balanced by rapid synthesis. This is the basis for the trypanostatic 
activity of α-difluoromethylornithine (DFMO) (Ghoda et al., 1990). 
 
Because T. brucei has diminished putrescine uptake it cannot replenish the polyamine 
shortage through putrescine uptake from the host blood (Heby et al, 2003) and therefore, 
treatment with DFMO leads to diminished levels of polyamines and trypanothione in T. 
brucei and Leishmania species. Hence, DFMO is currently used as drug to treat Sleeping 
sickness caused by T. b. gambiense. T. cruzi lacks ODC and cannot synthesize putrescine 
de novo and therefore all ODC inhibitors are ineffective against T. cruzi (Carrillo et al., 
1999). T. cruzi transports polyamine quite efficiently across the membrane, making it 
difficult to use polyamine synthetic pathway as target for drug development against these 
parasites. However, inhibitors of polyamine transporters should provide good drug 
candidates, considering that the parasites lack ODC to make putrescine. Leishmania 
species known to have high resistance to polyamine biosynthetic inhibitors were found to 
overproduce ODC, AdoMetDC or Spermidine synthase (Heby et al., 2003). 
 
Studies on development of selective inhibitors of parasites’ S-adenosylmethionine 
decarboxylase are also producing promising results (Heby et al., 2007). 
 
 
1.7.2.2. Trypanothione synthetase 
 
Validation of trypanothione synthetase as a drug target was first reported in 2003 by 
Comini et al. Using double-stranded RNA interference they knocked out the 
trypanothione synthetase gene, resulting in diminished trypanothione and 
glutathionylspermidine levels, proliferation arrest and impaired viability in the T. brucei 
mutants. The mutants also showed high sensitivity to the natural oxidants like H2O2 and 
tert- butyl hydroperoxide (Comini et al., 2003). The results of Comini’s group were later 
confirmed by Wyllie et al (2009) using a different system. This group preferred gene 
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replacement by homologous recombination over RNA interference. Mutants of 
trypanothione synthetase single-gene knockdown by gene replacement displayed similar 
effects reported by Comini et al (2003). Using the same technique the researchers 
developed a mutant that overexpressed trypanothione synthetase to make a clear 
comparative study. Both mutants were treated with the selective trypanothione synthetase 
inhibitor, DDU 86439 (N-(3-(dimethylamino)propyl)-2-(3-(3-ﬂuorophenyl)-1H-indazol-
1-yl)acetamide). The mutants that overexpressed the enzyme tolerated the compound 
while the gene knockdown mutants were killed by the compound. Although more work is 
still needed on this subject, it is clear that trypanothione synthetase makes an attractive 
drug target (Wyllie et al., 2009). 
 
 
1.7.2.3. Trypanothione reductase 
 
The parasites’ trypanothione reductase and the host glutathione reductase belong to the 
same family of flavoprotein-disulfide oxidoreductases. However, the mutual 
exclusiveness between the two with regard to the disulfide substrates (Shames et al., 
1986) means selective inhibition of the parasite’s enzyme is possible. 
 
 
1.8. Ovothiols 
 
Ovothiols are 3-methyl-5-mercaptohistidines derivatives first isolated from sea urchin 
eggs where they were initially thought of as cofactors for cyanide-insensitive NAD(P)H 
oxidase of ovoperoxidase (Tuner et al., 1985 and 1986) . Three types of ovothiols exist; 
denoted Ovothiol A, B, and C, and they differ only in the degree of methylation at the -
amino group of histidine. Ovothiol A does not have a methyl group, whereas ovothiol B 
contains one methyl group and ovothiol C two methyl groups (Turner et al., 1987). High 
amounts of ovothiols were found in trypanosomes where they are believed to protect the 
parasites against oxidants. 
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Figure 1.2: Chemical structures of ovothiol 
 
 
 
1.8.1. Properties of ovothiols 
 
Ovothiols are aromatic thiols as opposed to the aliphatic thiols of glutathione and 
trypanothione. Their aromatic nature confers desirable properties to ovothiols such as 
resistance to oxidation by Fe3+. Unlike glutathione which has a pKa of 8.65 (Holler and 
Hopkins, 1990), ovothiol A has pKSH of 1.42 (Weaver and Rabenstein, 1995), meaning 
they exist under physiological conditions as imidazolium thiolate zwitterions. The 
thiolates are stronger nucleophiles than thiols, and as such are more reactive towards 
electrophiles than thiols (Holler and Hopkins, 1988). Ovothiols were found to be very 
efficient as one-electron donors showing a second order rate of reduction of cytochrome 
C compared to insignificant reduction by glutathione under similar conditions (Holler and 
Hopkins, 1988). The thiolate not only makes ovothiols efficient as a one-electron donor, 
but also as good radical scavengers. The one-electron donating potential of ovothiols is 
comparable to that of ascorbic acid and Trolox C. Ovothiol aromatic radicals were also 
found to be more stable towards oxygen reduction than glutathione thiyl radicals (Holler 
and Hopkins, 1990). That is an important factor because higher radical stability means 
low radical propagation. 
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Although they react slowly with oxygen, ovothiols react spontaneously with hydrogen 
peroxides. Ovothiols were found to inhibit pyrogallol oxidation 50 times faster than 
glutathione, meaning they can decompose hydrogen peroxide 50 times faster than 
glutathione (Holler and Hopkins, 1990). In vitro studies showed ovothiol analogues as 
scavengers of superoxides and linoleate peroxyl radicals, a property which is believed to 
be shared by ovothiols in vivo (Hand et al., 2005). 
 
 
1.8.2. Proposed biological role of ovothiols 
 
The discovery of ovothiol emanated from observation of a cofactor that confers cyanide-
resistant peroxidase activity to ovoperoxidase in sea urchin eggs, and that the factor 
existed in millimolar concentrations (3 to 6.8 mM) (Turner et al., 1986). Isolation and 
characterization led to the identification of the cofactor as 3-methyl α-N,N-dimethyl-5-
mercaptohistidine (ovothiol C). Fertilization in sea urchin eggs is followed by 
development of the fertilization envelope, which is believed to protect the egg from 
multiple sperm invasion. The process is characterized by massive consumption of oxygen 
and production of corresponding hydrogen peroxide (Foerder and Shapiro, 1977). 
Hydrogen peroxide production from oxygen is catalysed by NADPH dependent oxidase. 
The produced hydrogen peroxide is then used as an oxidant in forming the fertilization 
envelop. The envelope forms by cross-linking tyrosine residues of the adjacent proteins 
utilizing hydrogen peroxide in a reaction catalysed by ovoperoxidase. Although this is a 
well regulated process taking place near the plasma membrane, diffusion of the hydrogen 
peroxide into the egg may be very toxic (Shapiro, 1991). In the absence of the glutathione 
peroxidase system which is normally used for detoxification of peroxides in mammalian 
cells, sea urchin eggs utilize ovothiols for decomposition of hydrogen peroxides that may 
dissolve into the eggs during envelope formation. Although there is coexistence of 
glutathione and ovothiols in urchin eggs, ovothiols have been found to be 50-fold 
superior as hydrogen scavengers as compared to glutathione (Bailly et al., 2000).  
 
Discovery of ovothiols in other different organisms has led to the assumption that its 
physiological role could be wider than that of an antioxidant. For example, the 
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Steenkamp group have shown that ovothiols convert long-lived S-nitrosoglutathione and 
S-nitrosotrypanothione to short-lived NO and the free thiols, which then reduce ovothiol 
disulfide back to reduced ovothiols (Vogt and Steenkamp, 2003). Ovothiol disulfides 
have been isolated from a unicellular green alga, Dunaliella salina, where it was thought 
to act as a reductant of the chloroplast ATP synthase complex (Selman-Reimer et al., 
1991). The identification of ovothiols as male pheromones for the marine polychaete 
Platynereis dumeriliihas, has also been reported (Röhl et al., 1999). 
 
 
1.8.3. The prevalence of ovothiol in trypanosomatids 
 
Although Turner et al 1986, it was Steenkamp who in 1993 discovered the presence of 
ovothiol A in C. fasciculata, a non-human insect parasite (Steenkamp, 1993 and 
Steenkamp and Spies, 1994). Subsequent studies led to further isolation of ovothiols from 
all life cycle stages of trypanosomatid parasites. Ovothiols were later isolated in 
millimolar concentrations from the  insect forms of all tested Leishmania species and in 
some cases the ovothiol content was even higher than that of trypanothione (table1.2) 
(Ariyanayagam and Alan H. Fairlamb, 2001). High amounts of ovothiols observed in the 
amastigotes are believed to protect the parasites against harsh oxidative stress produced 
by the host immune response. However, the amounts of ovothiol were found to be low in 
all bloodstream parasites (table 1.2). Generally ovothiols were found in higher amounts in 
intracellular parasites (Leishmania and T. cruzi) than in intercellular parasites (T. brucei) 
although the reason is not known (table1.2) (Ariyanayagam and Alan H. Fairlamb, 2001). 
Studies in M. smegmatis found that ergothionine is 26-fold increased in MSH deficient 
mutants and is also excreted into the medium (Ta et al, 2011and Sao Emai et al, 2013).  
Similar studies in trypanosomatids have not been done but would be relevant 
 
Like all thiol antioxidants, ovothiols are oxidized to form disulfides through reaction with 
oxidants. Most reduced thiols, such as glutathione in mammals and trypanothione in 
trypanosomes, are regenerated from their disulfides through enzymatic reactions with 
their specific reductases. However, no ovothiol disulfide reductase has been identified as 
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yet, and based on in vitro studies the oxidized ovothiols are thought to be reduced by 
trypanothione in vivo (Weaver and Rabenstein, 1995). 
 
 
 
Table 1.2: Ovothiol in different life-cycle stages of trypanosomatid parasites. Values 
were expressed as a percentage of total thiols (Ariyanayagam and Fairlamb, 2001). 
 
 
 
 
 
 
 
 
 
 
Although the physiological role of ovothiols in trypanosoma98tids is not yet fully known, 
it could be assumed from the in vitro studies to be that of antioxidants (Holler and 
Hopkins, 1990, and Vogt and Steenkamp, 2003). High ovothiol concentrations observed 
in the human infective parasites in the insect forms (table 1.2) could be seen as preparing 
the parasites for human invasion. In L. major, promastigotes and amastigotes have the 
same ovothiol levels. It is not known whether this is a property that distinguishes 
Leishmania spp responsible for cutaneous Leishmaniasis from those causing visceral 
forms of the disease. Inhibition of the ovothiol biosynthetic pathway will therefore shed 
some light on physiological functions of ovothiol, and its redox potential makes it an 
efficient antioxidant. 
 
1.8.4. Biosynthesis of Ovothiols 
 
Biosynthesis of ovothiols starts with formation of S-(5’-L-histidyl)-L-cysteine sulfoxide 
(3) from conjugation of cysteine and histidine in an enzymatic reaction catalyzed by 
sulfoxide synthase (Vogt et al., 2001) (Scheme 1.3). The only previous report that 
Organism Life cycle stage Ovothiol (%) Trypanothione (%) 
L. donovani Promastigote 35 43 
Amastigote <3 76 
L. major Promastigote 58 25 
Amastigote 58 25 
T. cruzi Epimastigote 7 76 
Trypomastigote 28 55 
T. brucei Procyclic trypomatigote  4 67 
Bloodstream trypomastigote <1 32 
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described the formation of such a unique imidazolyl sulfoxide had been that of Ishikawa 
et al (1974). These workers described the conjugation of a cysteine sulphur to C-2 of 
hercynine as a step in the biosynthesis of ergothioneine. Formation of the sulfoxide 
proceeded   with retention of the histidine double bond at the site of substitution in a 
redox reaction in which oxygen served as the final electron acceptor. The mechanism for 
5-histidyl cysteine sulfoxide formation is yet to be understood. In the second step, 5-
histidyl cysteine sulfoxide undergoes lysis to form 5-mercaptohistidine and pyruvic acid 
in a reaction mediated by cysteine sulfoxide lyase. An in vitro study showed that the 
lyase reaction requires pyridoxal phosphate (Vogt et al., 2001). Very recently the group 
of Seebeck identified two enzymes that catalyze the biosynthesis of ovothiol, designating 
them OvoA and OvoB for the synthase activity that catalyzes formation of 5-histidyl 
cysteine sulfoxide and the lyase which converts 5-histidyl cysteine sulfoxide in to 5-
mercaptohistidine, respectively. OvoA was found to have a C-terminal methyl tranferase 
domain which is believed to be responsible for the last methylation step (scheme 1.3). 
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Scheme 1.3: Ovothiol biosynthetic pathway 
 
Understanding the mechanism of ovothiol biosynthesis will provide a platform for 
designing inhibitors which eventually will shed light on the physiological role of 
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ovothiols in human pathogens, such as trypanosomes. The uniqueness of the ovothiol 
biosynthetic pathway would make OvoA and OvoB good targets for selective inhibition.  
 
Some hypotheses have been made on the mechanism of the transsulfuration mediated by 
OvoA and EgtB. For example, one study suggested that ferrous peroxysulfur (i.e., 
FeOOS) oxidises histidine to form a HisNδ(-H)
• which then attacks the bound iron to 
form the sulfoxide product (Bushnell et al., 2012). Ishikawa and his co-workers showed 
that the thioether β-amino-β-carboxyethylergothionine can be utilized as an intermediate 
(Ishikawa et al., 1974), suggesting that sulfoxide formation in ergothioneine biosynthesis 
may be occuring via a thioether intermediate even though the thioether intermediate was 
never isolated from the reaction mixture. Due to the lack of the corresponding thioether, 
Steenkamp and his co-workers could not study the involvement of thioether as a potential 
precursor for sulfoxide synthesis in ovothiols A biosynthesis (Steenkamp, 2002). 
 
In this study, a sulfoxide synthase (OvoA) from the bacterium, E. tasmaniensis was 
characterized with respect to substrate specificity, Michaelis-Menten constants, solvent 
isotope effect and inhibition by histidine analogues. Where the required histidine 
analogues were not available commercially, they were either obtained from researchers 
who had reported their preparation, or were synthesized from readily available 
precursors. Data from evaluation of activity of some of these analogues contributed 
evidence towards a proposed mechanism of the transsulfuration reaction, while that from 
other analogues revealed the role played by the amino acid moiety on the location of 
sulfur transfer on imidazole ring of sulfur acceptors.  
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AIM AND OBJECTIVES 
 
The aim of this project was to provide insights on the mechanism of the oxidative 
transsulfuration step mediated by sulfoxide synthase, by characterizing the activity of 
OvoA (sulfoxide synthase) from E. tasmaniensis with chemically synthesized and 
commercially available histidine analogues. A better understanding of mechanisms of 
enzymes involved in the biosynthesis of ovothiol and ergothioneine would then inform 
the design and development of specific inhibitor molecules that can be later investigated 
as drugs against trypanosomal and bacterial human pathogens.  
The main objectives of this project were: 
1. Design and synthesis of histidine analogues that can act as inhibitors and/or 
alternative substrates of 5-histidyl cysteine sulfoxide synthase (OvoA). 
2. Optimization of the OvoA assay 
3. Characterization of sulfoxide synthase kinetic constants 
4. Evaluation of histidine derivatives as inhibitors and/or alternative substrates of 
OvoA. 
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CHAPTER 2:  
DESIGN AND CHEMICAL SYNTHESIS OF HISTIDINE 
ANALOGUES AS POTENTIAL INHIBITORS AND ALTERNATIVE 
SUBSTRATES OF SULFOXIDE SYNTHASE (OVOA) 
 
 
2.1. Overview  
 
Despite identification of the intermediates (Vogt et al., 2001) and the enzymes 
(Braunshausen and Seebeck, 2011) involved in ovothiol biosynthesis, the mechanism that 
leads to formation of S-(5’-L-histidyl-L-cysteine sulfoxide, 3 (here referred to as 5-
histidyl cysteine sulfoxide) (Scheme 1.3) in the first step of the pathway remains poorly 
understood. The reaction involves oxidative transsulfuration of histidine, while retaining 
the double bond on the histidine moiety, using cysteine as the sulfur donor. This is a 
unique biological reaction for which there has only been one literature precedent: in 
ergothioneine. In ergothioneine biosynthesis, a sulfoxide intermediate is formed from 
conjugation of γ-glutamylcysteine to the C-2 of hercynine in a reaction mediated by 
EgtB, a homologous sulfoxide synthase found in mycobacteria (Braunshausen and 
Seebeck, 2011). 
 
OvoA and EgtB are iron-dependent enzymes, involved in activating the oxygen molecule 
to oxidize their respective substrates. The mechanism underlying sulfur transfer in 
ovothiol and ergothioneine biosynthesis is still unclear, and in particular the oxidation of 
the sulfur on the product because such a modification is not carried through into the 
subsequent steps. Therefore more work is required to elucidate the unique mechanism of 
sulfoxide synthesis mediated by these two enzymes. Three mechanisms were proposed as 
plausible alternatives for the oxidative transsulfuration step (Braunshausen and Seebeck, 
2011). Initial characterization revealed OvoA as a promiscuous enzyme when it comes to 
the selection of sulfur acceptors. Even though the enzyme used only cysteine as sulfur 
donor it utilized α-N-methylhistidine and α-N,N-dimethylhistidine derivatives as sulfur 
acceptors (Braunshausen and Seebeck, 2011). 
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Scheme 2.1: Proposed plausible mechanisms of the transsulfuration reaction of 
OvoA: C-S bond formation is initiated by (A) formation of a histidyl sp2 radical, (B) 
formation of a histidyl π- radical, and (C) electrophilic attack of the iron-coordinated 
cysteine sulfoxide on histidine (Braunshausen and Seebeck, 2011). 
 
To exploit the loose selection of sulfur acceptors, more histidine derivatives were 
envisaged as possible alternative substrates and/or inhibitors of OvoA. Histidine 
analogues with halogens at the imidazole ring might be potential subversive substrates in 
a reaction that follows mechanism C in scheme 2.1, with 5-fluorohistidine in particular 
having promise because of the strong C-F bond which will be difficult to break in an SN2’ 
nucleophic elimination. Iodine and bromine are good leaving groups, sometimes even as 
radicals, a characteristic which makes them good candidates to study mechanisms A and 
B. Other derivatives bearing alkyl groups (e.g. methyl) on the imidazole ring would also 
be of interest to study the OvoA mechanism. 
 
Here we report successful synthesis of 5-chloro, 5-bromo and 5-iodo-histidine using a 
succinimide based reagent. Fluorinating agents such as selectfluor, Diethylaminosulfur 
trifluoride (DAST) and N-fluorobenzenesulfonimide were used in an attempt to obtain 2- 
or 5-fluorohistidine, but without success. Synthesis of histidine analogues with alkylation 
at positions 1 and 3 is also reported. Histidine derivatives that could be used to prepare C-
5 functionalized histidine analogues were also synthesized. 
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2.2. Objective 
 
 
Histidine derivatives were invasaged as good candidate for use as either OvoA inhibitor 
and or affinity ligands for purification of the enzyme from the host cell. Histidine 
derivatives some containing halogen and other having different amino acid functional 
groups were designed and synthesed. 
2.2.1. Synthesis of imidazole-halogenated histidines as sulfoxide synthase (OvoA) 
inhibitors. Set (A) 
 
Halogens are often used to study reactions where a loss of hydride is proposed. Fluorine 
in particularly is more suitable as hydrogen replacement as it provides a much stronger C-
F bond without significantly increasing the size of the molecule. Therefore, objectives of 
this work were to synthesize and evaluate the effect of 5-halogenated histidines (figure 
2.1) as potential inhibitors or alternative substrates of sulfoxide synthase (OvoA). 
 
 
 
 
 
 
 
 
 
Figure 2.1: 5-halohistidines as potential sulfoxide synthase (OvoA) inhibitors and/or 
substrates.  
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2.2.2. Synthesis of other histidine derivatives. Set (B) 
 
Histidine analogues in figure 2.2 were synthesized, with the objective that they could be 
used as alternative substrates of OvoA and as potential affinity ligands which could be 
used for the purification of novel sulfoxide synthases (OvoA) from host organisms. The 
last step in the biosynthesis of ovothiol A is the methylation of 4-mercaptohistidine at N-
3 of the imidazole ring. It would therefore be important to investigate if 3-methylhistidine 
(15) and 1-methylhistidine (14) are substrates of the sulfoxide synthase step, because it 
will suggest an alternative biosynthetic route to ovothiol. Other histidine analogues 16 
and 17 bearing modifications on -amino were also envisaged as potential affinity 
ligands for the purification of the sulfoxide synthase (figure 2.2). 
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Figure 2.2: N-Alkylated histidine derivatives as sulfoxide synthase (OvoA) inhibitors 
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2.2.3. Synthesis of 5-alkylated histidines as potential inhibitors of sulphur oxidation 
step (Set C) 
 
Alkylated histidine derivatives listed in figure 2.3 were targeted as potential inhibitors of 
OvoA and OvoB, based on structural similarities of these compounds with 5-histidyl 
cysteine sulfoxide, the product of OvoA and substrate for OvoB (figure 2.3). 
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Figure 2.3: Analogues of 5-histidyl cysteine sulfoxide as potential inhibitors or 
alternative substrates of sulfoxide synthase. 
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2. 3. RESULTS AND DISCUSSION 
 
 
2.3.1. Synthesis of ring N-alkylated histidine derivatives as sulfoxide synthase 
alternative substrates. (Set C) 
 
 
The first step in the biosynthesis of ovothiol is the formation of S-(5’-L-histidyl-L-
cysteine sulfoxide, 3, scheme 1.3 (here referred to as 5-histidyl cysteine sulfoxide). 
Availability of histidine derivatives would therefore provide useful analogues for 
characterization of the enzyme involved. The methyl group was thought to be the best 
candidate for this purpose for two main reasons: (a) the methyl group is present in the 
final product (ovothiol) of this biosynthetic pathway (therefore 3-methyl-histidine would 
be evaluated as potential natural substrate), (b) the methyl group is the smallest and least 
sterically-demanding alkylating agent. Moreover, as a result of imidazole tautomerization 
it would also be interesting to evaluate whether the position of the alkyl group (or N-H) 
on the imidazole ring played a role in ovothiol biosynthesis. 
 
Synthesis of N(1)-methylhistidine (14) and N(1)-methylhistamine (38) required prior 
protection of both the 3-nitrogen and the -amino group (Jain and Cohen, 1996;  
Narayanan et al., 2001). Reaction of N,N’-carbonyldiimidazole with 35a (Scheme 2.2), 
obtained by methylation of histidine, or 35b in refluxing acetonitrile afforded cyclic ureas 
36a and 36b respectively. Alkylation of 36a and 36b with methyl iodide at reflux 
afforded quaternary iodide salts 37a and 37b which upon deprotection in dilute 
hydrochloric acid provided the desired N-alkylated derivatives 14 and 38 in 72% and 
77% overall yields respectively (Scheme 2.2). 
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Scheme 2.2: Synthesis of N(1)-methyl-histidine and N(1)-methyl-histamine: Reagents 
and conditions: i) Thionyl chloride, MeOH, reflux, 16 h; ii) N,N’-carbonyldiimidazole, 
CH3CN, reflux, 18 h; iii) MeI, CH3CN, reflux, 18 h, iv) 6 N HCl, 70
oC, 20 h. 
 
Identification of final products was based on appearance of the N-methyl group protons 
at  3.65 in the 1H NMR spectra, which were in agreement with the literature values (Jain 
and Cohen, 1996). It was interesting to note that the acylation at the N(3) did not reduce 
the nucleophilicity of the N(1) enough to prevent alkylation step iii (Scheme 2.2). 
 
Similarly, synthesis of N(3)-methylhistidine and N(3)-methylhistamine required prior 
protection of 3-nitrogen and the -amino group (Chivikas and Hodges, 1987). The cyclic 
ureas 36a and 36b (Scheme 2.3) proved ideal starting materials and were alkylated with 
an alkylating group which could be selectively removed at the end of the reaction. Thus, 
36a and 36b were reacted with 2-bromo-2’-acetonaphthone (BAN) in refluxing 
acetonitrile to give compounds 39a in 71% yield and 39b in 74% yield. The 1H NMR 
spectra of 39a and 39b each displayed overlapping signals in the aromatic region of the 
spectrum integrating for seven protons, and a signal at  6.27 ppm for the two N(1)-CH2 
protons, clearly indicating the presence of the BAN group (see experimental section). 
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Scheme 2.3: Synthesis of N(3)-methyl-histidine (15) and N(3)-methyl-histamine (43): 
Reagents and conditions: i) 2-Bromo-2’-acetonaphthone, CH3CN, reflux, 18 h; ii) 
MeOH, DIEA, reflux, 16 h; iii) MeI, CH3CN, reflux, 24 h; iv) Zn, HOAc-MeOH (1:1), 
sonicate, 3 h. 
 
Quaternary salts 39a and 39b on treatment with N,N-diisopropylethylamine in methanol 
at reflux afforded fully protected histidine and histamine derivatives 40a and 40b 
respectively, in good yields. Appearance of the singlet at  3.70 ppm in the 1H NMR 
spectra of the compound confirmed the presence of the methyl ester. Alkylation of 
compounds 40a and 40b with methyl iodide in refluxing acetonitrile for 24 hours, led to 
the formation of the quaternary salts 41a and 41b. Consumption of the starting material 
and formation of the new product with lower Rf value (monitored by tlc) was enough to 
show that the quaternary salts were formed. However, because of their highly 
hygroscopic nature it was recommended not to isolate the compounds 41a and 41b 
(Chivikas and Hodges, 1987). The crude quaternary salts were therefore dissolved in 
acetonitrile, and the resultant solution was added drop wise to vigorously stirring dry 
ethyl ether. The resultant solution was immediately treated with glacial acetic 
acid/methanol (1:1) and zinc dust under ultra-sonication conditions as previously 
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described (Chivikas and Hodges, 1987). However, when the reaction mixture was 
examined by tlc, it showed multiple products which proved difficult to separate by 
column chromatography. Repeated efforts to obtain 42a and 42b were not successful. 
 
After unsuccessful preparation of N(3)-methylhistidine, attention was then shifted to 
obtaining a different N(3)-alkylated histidine, 45 (scheme 2.4). Compound 45 was easily 
synthesized in excellent yield from commercially available starting material, 44, by acid 
cleavage of the Boc protecting group in 20% TFA/DCM (Sprout et al 2005). The absence 
of the up field signals for the t-butyl protons in the 1H NMR spectrum confirmed the 
complete removal of the Boc group. 
 
 
N N
CO2H
NH2
O
N N
CO2H
NHBoc
O
i
44 45
86%
 
 
Scheme 2.4: Synthesis of 2-amino-3-(1-((benzyloxy)methyl)-1H-imidazol-5-
yl)propanoic acid:  Reagents and conditions: i) 20% TFA/DCM, rt, 2 h. 
 
 
 
2.3.2. Synthesis of ring halogenated histidine derivatives as potential sulfoxide 
synthase inhibitors 
 
Synthesis of ring halogenated histidine and histamine derivatives can be achieved by a 
number of methods. However, most procedures utilize unprotected starting materials and 
harsh, acidic conditions, with large excesses of halogenating reagents, resulting in low 
yields and many side products, possibly due to the participation of the free -amino 
group. Therefore, a method reported by Jain and co-workers was preferred since it 
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required prior protection of the α-amine by labile protecting groups, which could be 
removed under mild conditions to obtain the product in high yields (Jain et al., 1998). 
Protected histidine 46 was chosen as the starting material because of its commercial 
availability and the 5-halohistidines 7, 8 and 9 were duly obtained in 54-68% overall 
yields (Scheme 2.5). 
N NH
HN
O
O
O
O
N
NH
N
H
O O
O
O
X
N
NH
N
H
O OH
O
O
X
N NH
NH2
O
OH
X
i ii
iii
46 47
48
a: X= Cl
b: X= Br
c: X= I
X= Cl(7), Br(8), I(9)   
Scheme 2.5: Synthesis of ring halogenated histidines: Reagents and conditions: i) N-
halo(Br, Cl, I)-succinimide, CH3CN, N2, dark, rt, 2 h; ii) LiOH, MeOH, rt, 2 h; iii) TFA 
(20% in CH2Cl2), CH2Cl2, rt, 2 h.  
 
Electrophilic halogenation of 46 with 1 molar equivalent of N-halosuccinimide gave 5-
halohistidine derivatives 47 in moderate to good yield. Unprotected histidine has 1H 
NMR signals at  6.8 and  7.6 ppm for H-5 and H-2 respectively, and since electrophilic 
halogenation is not restricted to the C-5 position, identification of the 5-halohistidine 
product was confirmed by disappearance of the signal at  6.8 in the 1H NMR spectrum. 
The 2,4-dihalohistidine derivatives were also isolated in 8-30% yield and were easily 
identified by the absence of both H-2 and H-5 signals in the 1H NMR spectrum. The 
regio-selectivity of halogenation at C-5 was found to be in the order: Cl > Br > I with the 
2,4-diiodohistidine derivative isolated in higher yield than the 2,5-dichloro- and 2,5-
dibromohistidine derivatives (8% and 18%, respectively). A similar phenomenon has 
been previously observed (Jain et al., 1998). 
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Hydrolysis of the methyl ester with LiOH using a method described by Boger and 
Yohannes (1988) gave Boc-protected derivatives, which were not isolated but subjected 
immediately to treatment with 20% (v/v) TFA in DCM, followed by removal of the 
cations using an ion-exchange column (Dowex 50W, H+, 100 mesh) to afford the 5-
halohistidines (Jain et al., 1998). The absence of signals for the methoxy and t-butyl 
protons at  3.61 ppm and  1.42 ppm respectively was an indication of complete 
deprotection. The two-step deprotection sequence reported here was preferred to the acid 
hydrolysis reported by Jain et al. because the acid hydrolysis required 72 hours while the 
two-step sequence needed just 5 hours to obtain the product. In some cases the acid 
hydrolysis was also reported to lead to regiospecific electrophilic dehalogenation at C-5 
(Jain et al., 1998). 
 
Fluorohistidines could however not be synthesized by the same method due to the 
unavailability of 4-fluorosuccinimide. Instead, alternative strategies using different 
fluorinating agents were employed, such as selectfluor, diethylaminosulfur trifluoride and 
N-fluorobenzenesulfonimide. However these attempts failed to produce the desired 
fluorohistidines (data not shown).  
 
 
2.3.3. Synthesis of affinity ligands for potential use in the purification of sulfoxide 
synthase (OvoA). 
 
Compounds 17 and 16 were identified as potential affinity ligands for sulfoxide synthase 
(OvoA) purification, based on their chemical similarities with histidine substrate, and the 
incorporation of an amine-terminated linker for coupling to a solid support. These target 
compounds, without modification on the -amino group, were synthesized from a 
suitably protected N(α),N(3)-protected starting material, 44, (scheme 2.6). 
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Scheme 2.6: Synthesis of histidine ethylenediamine: Reagents and conditions: i) N, 
N’-carbonyldiimidazole, ethylenediamine, THF, -10oC to rt, 2.5 h; ii and iv) 20% (v/v) 
TFA/DCM, rt, 2 h; iii) Formic acid, Hydrazine hydrate, Pd-C, MeOH, 24 h. 
 
Synthesis of the target compounds began with reaction of commercially available 
protected histidine 44 with N, N’-carbonyldiimidazole to form an activated carboxyl 
group, which was then reacted with excess ethylenediamine to form amide 49 in excellent 
yield (Tolbert and Wong, 2000). Compound 49 had a low Rf value compared to the 
starting material and a positive reaction with ninhydrin indicated the presence of a more 
hydrophilic primary amine group on the compound. The 1H NMR of 49 displayed 
multiplets at  3.17 ppm integrating for two protons, and  3.09 ppm also integrating for 
two protons, consistent with the presence of the N-(2-aminoethyl)-amido group. Acid 
cleavage of 49 in 20% TFA/DCM at room temperature afforded 17 in good yield (Jain et 
al., 1998). The absence of the tert-butyl group singlet at  1.41 ppm in the 1H NMR 
spectrum and  28 ppm in the 13C NMR spectrum of 17 was a confirmation of the 
successful removal of the Boc group from 49. 
 
Alternatively, hydrogenolysis of 49 over Pd/C in methanol at room temperature with 
formate serving as hydrogen donor, gave 50 in 42% yield (Gowda and Mahesh, 2002). 
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Analysis of 50 by 1H NMR spectrum showed the absence of the aromatic protons in the 
benzyl group which provided enough evidence for the successful synthesis of 50. 
Removal of the Boc protecting group from 50 gave the target compound 16 in 52% yield. 
Compound 16 could also be synthesized from 17 by hydrogenolytic cleavage of the Bom- 
protective group over Pd-C as in the formation of 50 from 49 as described above. 
 
 
2.3.4. Synthesis of 5-histidyl cysteine sulfoxide analogues as affinity ligands 
 
Purification of sulfoxide synthase (OvoA) by affinity chromatography using the 
analogues of the 5-histidyl cysteine sulfoxide (the product of the sulfoxide synthase 
catalysed reaction) would allow characterization of the novel enzyme. The 5-histidyl 
cysteine sulfoxide analogues bearing different functionality at the histidine C-5 position 
(figure 2.4) were envisaged as potential ligands for sulfoxide synthase purification. 
 
 
 
HN N
CO2H
NH2
S
OH2N
CO2H
HN N
CO2H
NH2
XH2N
CO2H
X = H, O, OH, halogen
S-(5'-l-histidyl) cysteine sulfoxide
(Sulfoxide)
Sulfoxide analogues
3
 
Figure 2.4: Structural analogues of 5’-histidyl cysteine sulfoxide 
 
Thus, the synthesis of the 5-histidyl cysteine sulfoxide analogues in figure 2.3 was 
envisaged to start from coupling of a suitably protected and activated histidine 
(Nucleophile) and suitably protected homoserine aldehyde (Electrophile) as outlined in 
the retrosynthetic analysis in scheme 2.7 below. 
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HN N
CO2H
NH2
XH2N
CO2H
N N
PAI
OPA
PG
PA = protected amino acid moiety
PG = protecting group
NucleophileElectrophile
 
Scheme 2.7: Retrosynthetic analysis of 5-histidyl cysteine sulfoxide structural 
analogues 
 
 
A metal-halogen exchange reaction was investigated in order to prepare the histidine 
derivative for the coupling step. Groziak and Wei have successfully synthesized 5-
formylated imidazole (55) derivatives using a metal-halogen exchange reaction (Groziak 
and Wei, 1991) and these conditions were thus used to carry out the synthesis of 5-
formylated imidazole 55 as a model study for the histidine functionalization experiments. 
Substituted imidazole 53 (scheme 2.8) was synthesized in two steps from 51 in good 
overall yield by iodination followed by N-protection. Compound 53 was then reacted 
with nBuLi in THF at -78oC to form the lithiated species 54, which after rapid quenching 
with DMF gave the formylated product 55 in 60% yield (Groziak and Wei, 1991). 
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Scheme 2.8: Synthesis of formylated imidazole using metal-halogen exchange 
reaction: Reagents and conditions: i) 0.04 N NaOH, I2, Hexane, 0
oC -rt, 18 h (a); ii) 
DCM, K2CO3, BomCl, rt, 16 h; iii) nBuLi, DMF, THF, -78
oC, 10 min; iv) H2O, -78
oC–rt, 
2 h.  
 
The 1H NMR of the formylated product displayed a diagnostic aldehyde proton at  
9.740, which was in agreement with the literature value (Groziak and Wei, 1991). 
 
Encouraged by these positive results, the application of a similar metal-halogen exchange 
reaction was attempted in order to substitute the C-5 position of histidine. From our 
retrosynthetic analysis in scheme 2.7, protected 5- iodohistidine 57 (scheme 2.9) was 
anticipated to provide a good starting material for the coupling step. The 5-formyl 
derivative 58 would then provide a good intermediate for the subsequent steps leading up 
to the target compounds. 
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Scheme 2.9: Attempted synthesis of 5-functionalized histidines using metal-halogen 
exchange:  Reagents and conditions: i) NIS, CH3CN, rt, N2, dark, 2 h; ii) NaH, 
thiophenol, isopropanol, 35oC, 30 min; iii) BomCl, Et3N, DCM, rt, 24 h; iv) nBuLi, 
DMF, THF, -78oC, 10 min. 
 
Iodination of commercially available histidine derivative 46 using 1.5 equivalents of NIS 
in acetonitrile provided the desired tert-butyl 1-(methoxycarbonyl)-2-(4-iodo-1H-
imidazol-5-yl)ethylcarbamate 47c in 36% yield together with the 2,5-diiodo derivative 56 
derivative in 58% yield (Jain et al., 1998). The latter could however be converted to the 
mono-iodinated derivative 47c in good yield through regio-specific deiodination at C-2 
using sodium thiophenolate (Iddon et al., 1987). The appearance of the signal for H-2 at  
7.59 in the 1H NMR spectrum was evidence for the presence of 47c. Treatment of 47c 
with benzyloxymethyl chloride (BomCl) in dichloromethane in the presence of 
triethylamine afforded 57 in good yield. Protected iodide 57 was then reacted with 1.1 
equivalents of n-butyl lithium (BuLi) before addition of DMF. The TLC of the reaction 
mixture showed multiple overlapping spots, indicating multiple products which became 
difficult to separate. Because of the apparent substrate instability in the presence of 
nBuLi it became apparent that a more stable substrate was required for the lithium 
mediated coupling step. As a result the focus was turned to investigation of the possibility 
of protecting both the carboxyl and primary amino groups in histidine, converting them 
into more stable oxazolidine or oxazoline derivatives. 
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2.3.4.1. Synthesis of the electrophile for the lithium mediated C-C coupling reaction 
 
tert-Butyl 4-(formylmethyl)-2,2-dimethyloxazolidine-3-carboxylate 63 (Scheme 2.11) 
was identified as a suitable aldehyde (electrophile partner) for the lithium mediated 
coupling at the histidine C-5 position. Following a literature review, it was noted that 63 
could be easily synthesized from an aspartic acid derivative (Paintner et al, 2005). Thus, 
the commercially available, selectively benzylated aspartic acid, 58, was treated with 
methyl iodide in DCM to form methyl ester 59 in excellent yield (scheme 2.10). The 
reaction product did not require further purification and analysis by 1H NMR showed a 
diagnostic methoxy signal at  3.69. 
 
 
BnO
O
CO2H
NHBoc
BnO
O
CO2Me
NHBoc OH NHBoc
OH
i ii
58 59 60
98% 74%
 
Scheme 2.10: Synthesis of N-Boc-protected 2-amino-1,4-propane-diol. Reagents and 
conditions: i) MeI, K2CO3, DCM, rt, 16 h; ii) NaBH4, MeOH/THF, 50
oC, 20 min. 
 
Reduction of 59 with five equivalents of NaBH4 in a mixture of MeOH and THF at 
reflux, afforded the diol 60 in good yield (Hou et al, 2001). Appearance of signals in the 
1H NMR spectrum for two sets of coupled ethylene protons together with the absence of 
signals for the aromatic and methoxy groups provided evidence for complete reduction of 
59 to form 60. However, reduction with commonly used ester reducing agent, LiAH4, 
afforded the same product but in very low yield. This could be due to the higher 
reactivity of LiAH4 which results in removal of the Boc protecting group. Treatment of 
60 with 2.2-dimethoxypropane at 40°C in the presence of a catalytic amount of para-
toluenesulfonic acid resulted in formation of the cyclic oxazolidine derivatives 61 and 62 
in 42% and 19% yield respectively (Scheme 2.11). The 1H NMR spectrum of the latter 
compound displayed a broad peak at  5.14 for N-H, which supported the assignment of 
the structure whereas the absence of the N-H peak in the 1H NMR spectrum of 61 
confirmed the participation of the -nitrogen in the ring closure. Furthermore, 
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comparison of the 13C NMR spectra of 61 and 62 showed that the -C in 61 ( 58.69) 
resonated significantly further downfield to that in 62 ( 48.61), consistent with chemical 
shifts of C-4 in five membered oxazolidine rings. Swern oxidation of 61 gave tert-butyl 
4-(formylmethyl)-2,2-dimethyloxazolidine-3-carboxylate 63 in good yield. The 
diagnostic signal for the aldehyde proton at  9.79 in the 1H NMR spectrum of 63 was 
noted (Paintner et al, 2005). 
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Scheme 2.11: Synthesis of the electrophile for the lithium mediated C-C coupling 
reaction: Reagents and conditions: i) 2,2-dimethoxypropane, TsOH (cat), rt, N2, 18 h; ii) 
DMSO, Et3N, oxalyl chloride, DCM, -78
oC – rt, 3 h. 
 
 
2.3.4.2. Synthesis of the nucleophile for the lithium mediated C-C coupling reaction 
 
2.3.4.2.1. Synthesis of oxazolidine based nucleophile 
 
Compound 46 (Scheme 2.12) which is commercially available was chosen as the starting 
material for the synthesis of suitably protected histidine, 67 (Scheme 2.13), needed for 
coupling. Thus, treatement of 46 with NaBH4 in a mixture of MeOH and THF at 50
°C 
provided Boc-protected -amino alcohol 64 in good yield (Kumar et al, 2002). 
Halogenation of the resulting alcohol 64 using NIS in acetonitrile afforded a mixture of 
mono-iodo and di-iodo derivatives 65a and 65b in 30% and 42% yields, respectively 
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(Jain et al, 1998). The di-iodo compound was regioselectively deiodinated at C-2 to give 
65b in 71% yield by reaction with sodium thiophenolate in isopropyl alcohol (Iddon et al, 
1987). 1H NMR spectra of 65b showed a signal at  7.56 for H-2 on the imidazole ring. 
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Scheme 2.12: Synthesis of 5-iodo histidinol. Reagents and conditions: i) NaBH4, 
MeOH/THF, 50oC, 20 min; ii) NIS, CH3CN, N2, dark, rt, 2 h; iii) NaH, thiophenol, 
isopropanol, 35oC, 30 min. 
 
Since the C-C coupling reaction utilizes strongly basic nBuLi, it was necessary to remove 
all acidic protons from the starting materials. The oxazolidine ring structure as a 
protecting group for -amino alcohols was found ideal for this purpose (Kise et al, 1998). 
Thus, compound 65b upon treatment with a large excess of 2,2-dimethoxypropane in dry 
DCM, gave a mixture of cyclic oxazolidine 67 and the alternative 7-membered ring 
analogue 66 in 19% and 26% yield respectively (scheme 2.13). Both cyclic products 
displayed diagnostic six-proton signals in their 1H NMR spectra. Compound 66 displayed 
singlets for two methyl groups at  1.68 and  1.77 while compound 67 showed two 
three-proton singlets further up-field at  1.45 and  1.47. However, a significant 
difference, which helped with the assignment of the structures was the appearance of a 
signal for the -N-H proton in the 1H NMR spectrum of 66, which was absent in the 
spectrum of 67. 
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Scheme 2.13: Synthesis of oxazolidine based nucleophile: Reagents and conditions: i) 
2,2-dimethoxypropane, DCM, TsOH (cat), reflux, 18 h. 
 
 
Since compound 66 was not suitable for coupling because of the -N-H acidic proton, 
attempts were made to synthesis 67 exclusively by first protecting the participating 
imidazole’s N-1 in 65 prior to ring closure (scheme 2.14). 
 
Thus, compound 68 (Scheme 2.14), obtained by protecting the carboxyl group of 
compound 44 (Vaz et al, 2003), was reduced with NaBH4 in MeOH-THF mixture to form 
alcohol 69. This was then subjected to the oxazolidine ring-forming conditions described 
in Scheme 2.13 but the reaction produced the mixed acetal 70 instead, without any traces 
of 71 even after stirring the mixture at reflux for 3 days. 70 was identified by 1H NMR 
analysis, with the proton spectrum showing a methoxy signal at  3.13. 
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Scheme 2.14: Attempted synthesis of oxazolidine based nucleophile. Reagents and 
conditions: i) NaBH4, MeOH/THF, 50
oC, 20 min; ii) 2, 2-dimethoxypropane, DCM, 
TsOH (cat), reflux, 3 days. 
 
 
 
2.3.4.2.2. Synthesis of oxazoline based nucleophile 
 
Failure to synthesize the oxazolidine derivatives in reasonable amounts led to the 
adoption of a different approach to synthesizing suitably protected histidine derivatives 
for the proposed lithium-mediated coupling reaction shown in scheme 2.7. A variation on 
protection as a cyclic derivative was proposed, whereby the -amino alcohols were 
protected by the oxazoline ring system. 
 
Compound 72 (scheme 2.15) was proposed as suitable starting material for the synthesis 
of oxazoline-protected histidine derivatives 80a and 80b (scheme 2.17). Protected -
amino alcohol 73 was prepared in good yield by reduction of commercially available 72 
with NaBH4 in MeOH-THF (Kumar et al, 2002). The absence of the methoxy proton 
signal coupled with the presence of signals for the new -protons in the 1H NMR 
spectrum of 73, clearly confirmed the formation of the amino alcohol. Treatment of 73 
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with 2.1 equivalents of para-toluenesulfonyl chloride in dichloromethane afforded fully 
protected oxazoline product 75 albeit in poor yield (21%) together with the N-tosyl 
amino alcohol 74 in moderate yield (66%) after 24 hour (scheme 2.15) (Peer et al, 1996). 
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Scheme 2.15: Synthesis of oxazoline derivative of histidine: Reagents and conditions: 
i) NaBH4, MeOH/THF, 50
oC, 20 min; ii) and iii) TsCl, Et3N, DCM, rt, 16 h. 
 
Isolated and purified amino alcohol 74 was treated with another 2 equivalents of para-
toluenesulfonyl chloride under similar conditions for a further 24 hours, giving the 
product 75 in excelle t yield, and showing that the reaction needed a larger excess of 
para-toluenesulfonyl chloride reagent to go to completion. Attempts were made to 
halogenate 75 using N-iodosuccinimide to obtain either 2,5-di-iodinated derivative 77 or 
mono-iodinated, 78, but without success. A previous study had found that certain 
protective groups prevent imidazole halogenation (Crich and Banerjee, 2006). 
 
It therefore became apparent that the removal of the N-tosyl group from 75 may be 
necessary in order to achieve halogenation of imidazole ring of the oxazoline derivatives. 
Thus, compound 75 was reacted with caesium carbonate in a mixture of anhydrous 
methanol and THF at 50oC for 2 hours to give the deprotected product 76 in excellent 
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yield, albeit on a small scale (scheme 2.16) (Bajwa et al, 2006). However, on scaling up, 
small amounts of starting material remained unreacted, and it proved difficult to separate 
the product from the remaining starting material on a large scale. This problem could be 
overcome by halogenation of the crude reaction products containing 76 using 
electrophilic halogenating  reagents (N-iodo- and N-bromo-succinimide) in acetonitrile, 
to afford the ring halogenated oxazoline derivatives in moderate to good yields (scheme 
2.16). The attempted iodination of the crude 76 with 1.1 equivalents of N-
iodosuccinimide did not go to completion, though it gave a mixture of the di-iodo 
derivative 77 as the major product, and the desired 5-iodo derivative 78 as the minor 
product (scheme 2.16) However, bromination with N-bromosuccinimide afforded the 
desired 5-bromo derivative 79 in good yield without noticeable amounts of the di-bromo 
derivative (scheme 2.16). 
 
Identification of the halogenated compounds was accomplished mainly by analysis of the 
1H NMR spectra which did not show a signal at  6.88 corresponding to H-4 on the 
imidazole ring. In 78 the 1H NMR spectrum showed that both imidazole protons signals 
had disappeared, indicating substitution of both protons by iodine. 
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Scheme 2.16: Synthesis of 5-iodinated histidine oxazolines: Reagents and conditions: 
i) Cs2CO3, MeOH-THF, 50
oC, 2 h; ii) NIS, CH3CN, N2, dark, rt, 2 h; iii) NaH, 
thiophenol, isopropanol, 35oC, 30 min.; iv) NBS, CH3CN, N2, dark, rt, 2 h. 
 
Regio-selective deiodination of 77 with sodium thiophenolate in MeOH-THF mixture 
gave 78 in good yield and the product had the same analytical profile as the one obtained 
by direct iodination in step ii, also showing the H-2 signal at  7.64 ppm (Iddon et al, 
1987). Synthesis of the target halogenated histidine, suitably protected for lithium 
mediated coupling, was concluded with N-tosyl protection of compounds 78 and 79, 
using tosyl chloride in dichloromethane to give the desired 80a and 80b in good yields 
(scheme 2.17) (Peer et al, 1996).  
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Scheme 2.17: Synthesis of protected 5-iodinated histidine oxazolines: Reagents and 
conditions: i) TsCl, Et3N, DCM, rt, 16 h. 
 
The 1H NMR spectra of the products 80a and 80b displayed signals for the methyl group 
at  2.4 and for the aromatic protons, thus confirming the presence of N-tosyl group. 
 
 
2.3.5. C-C coupling of oxazoline nucleophile and oxazole electrophile mediated by 
lithium  
 
Having successfully synthesized the electrophile (63) and halogenated histidine 
derivatives (80a and 80b), the stage was set for the lithium mediated coupling reaction. 
This would provide a crucial intermediate (scheme 2.7) from which the target compounds 
in figure 2.3 could be prepared. 
 
Success of a lithium mediated coupling reaction relies on successful lithium-halogen 
exchange, and generation of a reasonably stable lithium species that can then be 
quenched with a suitable electrophile to generate a C-C bond (Carver et al., 1997). 
 
 
 
2.3.5.1. Quenching oxazole-lithium species with water 
 
Many N-protecting groups are labile towards nBuLi even at low temperatures (Carver et 
al., 1997). It was therefore necessary to obtain preliminary evidence that the lithiated 
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species could be formed by treatment with nBuLi, and could undergo further reaction 
without compromising the protecting groups.  
 
Compound 80a was therefore reacted with 1.1 equivalents of nBuLi in dry THF at -78oC, 
and the presence of lithium species 81 (not isolated) investigated by quenching the 
reaction with water. This gave 75 in good yield (scheme 2.18), as was evident from the 
1H NMR spectrum which showed the presence of the imidazole’s H-5 proton signal at  
6.92. NMR also revealed that the N-tosyl group had not been removed, with a singlet at  
2.48 for the methyl group and multiplets at  7.83–7.33 for the aromatic protons. 
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Scheme 2.18: Quenching lithium-carbon species with water: Reagents and conditions: 
i) nBuLi, THF, -78oC, 10 min; ii) H2O, rt, 1 h. 
 
 
2.3.5.2. Quenching oxazole-lithium species homoserine aldehyde electrophile (63) 
 
Results obtained in scheme 2.18, provided some confidence that lithium mediated 
nucleophilic C-C coupling reaction in histidine C-5 could be possible. Thus, a 
nucleophilic lithium species was generated by reacting protected halogenated histidine 
derivative 80a with nBuLi in dry THF (scheme 2.19). Subsequent quenching of the 
reaction with homoserine aldehyde 63 afforded the coupled product 82, albeit in poor 
yield, 19 % (Scheme 2.19). The identification of the product was by analysis of the 1H 
and 13C NMR spectra. The aromatic ( 7.32-7.97) and tert-butyl ( 1.41) proton signals 
were evident in the 1H NMR spectrum, and the corresponding carbon signals were 
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evident in the 13C NMR spectrum. The methyl protons in the tosyl group gave a singlet at 
 4.45. 
 
While the successful formation of cross-coupled product 82 was encouraging, attempts to 
improve the yield of product 82 by repeating step i in scheme 2.19 were unsuccessful. 
Instead, more of dehalogenated side product 75 was obtained, which suggested that the 
lithiated species was forming and that aldehyde 63 contained some residual water that 
quenched the lithium species.  This problem could not be overcome, even after prolonged 
drying of reactants under high vacuum. This problem was investigated by attempting to 
repeat the reaction using an alternative aldehyde as described below. 
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Scheme 2.19: Quenching lithium-histidine species with homoserine aldehyde 
electrophile: Reagents and conditions: i), nBuLi, THF, -78oC, 10 min.  
 
 
2.3.5.3. Quenching oxazole-lithium species with dimethylformanide DMF 
 
Lithiated species 81 (scheme 2.18) was generated from bromo-derivative 80a and 
quenched immediately with DMF in an attempt to generate formyl derivative 83. 
However, as before, the formation of the C–C bond was not successful (scheme 2.20), 
with only the debrominated product 75 being isolated, showing again the successful 
formation of the lithiated species but rapid quenching by protons. 
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Scheme 2.20: Quenching of the histidine-lithium species with DMF: Reagents and 
conditions: i) nBuLi, DMF, THF, -78oC, 10 min. 
 
 
 While working on protected imidazoles, Groziak and Wei (1991) noted that exchange of 
lithium from C-5 to C-2 took place via an inter-molecular process, particularly if the 
reaction was not quenched rapidly after addition of nBuLi (Scheme 2.21). However we 
did not find any evidence for C-2 formylated product after the reaction described in 
scheme 2.20. 
 
 
 
 
 
 
Scheme 2.21: Exchange of lithium from C-5 to C-2 
 
Due to time constraints no further attempts were made to quench lithiated species 80 
using other aldehydes. However, the initial success demonstrated in this reaction, and the 
evidence obtained for successful formation of the lithiated species suggest that future 
optimization of this method is worth pursuing, as a method for preparation of novel 
histidine derivatives with C-C functionalization. 
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CHAPTER 3:  
CHARACTERIZATION AND INHIBITION OF OVOA FROM 
ERWINIA TASMANIENSIS 
 
 
3.1. Introduction 
 
3.1.1. Dioxygen activation in biological systems 
 
OvoA and EgtB are iron-dependent sulfoxide synthases which activate molecular oxygen 
in order to afford oxidative sulfur transfer onto their respective substrates in ovothiol and 
ergothioneine biosynthesis (Seebeck, 2010 and Braunshausen and Seebeck, 2011). 
Ovothiol and ergothioneine are small molecule thiols believed to play a role as 
antioxidants in pathogenic trypanosomes and mycobacteria, respectively (Hollar et al., 
1988 and Melville et al., 1957). Enzymes involved in dioxygen activation have been 
subjects of interest to scientific researchers, because they mediate biological reactions 
that have environmental, pharmaceutical, and medical significance (Bruijnincx et al., 
2008). Dioxygen activating enzymes can be classified as either heme or nonheme 
containing enzymes. Although reactions catalyzed by these enzymes may be similar, the 
enzymes differ in the way they coordinate the iron metal. Heme containing enzymes 
utilize a heme cofactor while nonheme enzymes make use of amino acid side chains to 
coordinate the iron metal. A classical example of heme containing enzymes is 
cytochrome P450, which mediates a variety of important biological reactions, such as 
conversion of polyunsaturated fatty acids into active molecules, metabolism of drug and 
xenobiotics etc. (Denisov et al., 2005). 
 
 
3.1.2. Nonheme iron enzymes 
 
The nonheme iron enzyme superfamily itself can be divided into two groups called 
mononuclear and binuclear nonheme iron enzymes. Methane monooxygenase is a 
binuclear iron enzyme that catalyzes the very difficult reaction of oxidation of methane to 
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methanol (Bruijnincx et al., 2008). Availability of enzyme crystal structure data in the 
past twenty years has allowed classification and characterization of the mononuclear 
nonheme iron enzymes and the way they coordinate to iron metal (Costas et al., 2004). An 
iron-binding structural motif consisting of two histidine residues and one carboxylate of 
either glutamate or aspartate was identified in more than thirty of the crystal structures of 
mononuclear nonheme iron enzymes. The ligands were found to be facially coordinated 
to the iron metal and on that basis a 2-His-1-carboxylate facial triad was coined to 
describe the structural feature of the mononuclear iron enzyme subfamily (Bruijnincx et 
al., 2008). 
 
 
3.1.3. 2-His-1-carboxylate facial triad and mechanism of oxygen activation  
 
In the metal resting state, the carboxylate ligand can either be monodentate (single 
coordination) or bidentate (double coordination) (schem  3.1). The other two or three 
available binding sites are vacant or occupied by solvent, such as water molecules in 
biological systems. At the resting stage the metal center has very low affinity toward 
molecular oxygen. Binding of the substrate to the complex, sometimes by replacing a 
water molecule, increases dioxygen binding affinity of the complex (B). Coupling 
reactivity with substrate binding is believed to be a protection mechanism against self-
inactivation (Bruijnincx et al., 2008). 
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Scheme 3.1: General mechanistic pathway of 2-His-1-carboxylate iron dependent 
enzymes. 
 
Binding of dioxygen to the metal center evokes formation of iron(III)-superoxide through 
oxidative electron transfer from the iron metal to the molecular oxygen (C  D). From 
this point different reactions can happen. For most characterized mechanisms of 
mononuclear iron enzymes, another electron transfer to the peroxide breaks the O-O bond 
leading to formation of water and a high-valent iron(IV)-oxo (FeIVO) species (E) which is 
believed to be the actual substrate oxidant mainly through hydrogen abstraction 
(Bruijnincx et al., 2008). The existence of an even stronger oxidant, such as high-valent 
iron(V)-oxo (FeVO) species has also been postulated as the main oxidant (Costas et al., 
2004). 
 
 
3.2. OvoA and EgtB as mononuclear iron enzymes 
 
The first step in ovothiol biosynthesis involves oxidative addition of cysteine at C-5 of 
histidine, in a reaction that requires molecular oxygen, and is mediated by OvoA (Vogt et 
al., 2001 and Braunshausen and Seebeck, 2011) (scheme 3.2). OvoA is a synthase enzyme 
whose activity was first reported by Steenkamp and colleagues (Vogt et al., 2001).  In their 
work the researchers found that the activity required molecular oxygen and addition of 
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iron. This was a unique enzyme-catalyzed reaction of which the only precedent had been the 
corresponding ergothionine biosynthetic enzyme, which was found to mediate oxidative 
transsulfuration at the C-2 position of hercynine using cysteine as substrate (Ishikawa et 
al., 1974). Recently, Seebeck identified EgtB as the enzyme involved in the 
transsulfuration step in ergothioneine biosynthesis and found γ-glutamylcysteine as the 
possible natural substrate (Seebeck, 2010) for the enzyme (scheme 3.2). On the basis of 
the similarity of reactions of these systems, the Seebeck group later identified the 
synthase which mediates the transsulfuration step in ovothiol biosynthesis and named it 
OvoA (Braunshausen and Seebeck, 2011). In vitro characterization of the enzymes 
confirmed that both EgtB and OvoA were iron-dependent enzymes which utilize iron to 
activate dioxygen to afford the unique oxidative sulfur transfer. In line with the structural 
requirement of mononuclear iron enzymes, the group found that both OvoA and EgtB 
possess a conserved motif consisting of HX3HXE, believed to be the iron binding site. 
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Scheme 3.2: OvoA and EgtB catalysed reactions 
 
Gene sequence search identified homologous genes for OvoA in a number of other 
organisms, including bacteria.  In the initial characterization of the enzyme from Erwinia 
tasmaniensis and Trypanosoma cruzi, which had been cloned in E. coli, it was found that 
the bacterial enzyme was more stable and active than the trypanosomal enzyme.  The 
enzyme also displayed high selectivity towards the sulfur donor, preferring cysteine over 
other naturally occurring sulfur donors that were tested (Braunshausen and Seebeck, 
2011). Mechanistic aspects of the OvoA and EgtB reactions still remain elusive and this 
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was the driving force for initiation of this study, which was oriented towards 
understanding the transsulfuration reaction mechanism mediated by OvoA and EgtB. A 
series of chemically synthesized and naturally occurring histidine analogues were thus 
used to characterize the OvoA reaction. 
 
In this study we show that OvoA is activated by ascorbate and isoascorbate, and that the 
enzyme used a series of histidine analogues as sulfur acceptors. Kinetic characterization 
showed similar KM for cysteine, histidine and histidine analogues but higher specificity 
for histidine. The enzyme displayed maximum activity at pH 7.5, and was limited by low 
substrate specificity at low pH. Enzyme inhibition was poor with many of the evaluated 
histidine analogues, with only 5-fluorohistidine showing about 80% inhibition. Although 
most amino acid metabolizing enzyms are enantioselective, OvoA was found to turnover 
both D- and L-histidines. However, using D-histidine as substrate, two products were 
obtained, one corresponding to transsulfuration at C-2 and the other corresponding to 
transsulfuration at C-5, suggesting that the outcome of transsulfuration was dependent on 
the orientation of the imidazole unit in the active site in OvoA. Lack of solvent isotope 
effects was observed, suggesting that the transsulfuration step does not happen via acid-
base proton exchange and that iron(III)-superoxide seems to be the initial oxidant that 
activates sulfur to attack the histidine imidazole ring. Detailed evidence for these 
conclusions is presented in the following discussion.  
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3.2. MATERIALS AND METHODS 
 
 
3.2.1. Materials 
 
All standard reagents were purchased from Aldrich/Sigma if not otherwise stated. 
Histidine, 4(5)-methylimidazole and ammonium sulphate were purchase from Fluka. 
Cysteine, Tryptophan, Imidazole, FeSO4 and NaCl were purchased from Acros Organics.  
Histidinamide, 2-thiohistidine, 3-pyridyl alanine, 2-pyridyl alanine, H-(3Me)-His-OH and 
Histidine methyl ester were purchase from Bachem. D2O and Ni-NTA were purchased 
from Roth and QIAGEN, respectively. 5-fluorohistidine and 2-fluorohistidine were a 
generous gift from Kenneth Kirk, National Institutes of Health, DHHS, Bethesda; 5-
chlorohistidine, 5-bromohistidine and 5-iodohistidine were chemically synthesized as 
described here in chapter 2 and experimental section. 
 
3.2.2. Standard OvoA assay conditions 
 
A 250 μL reaction mixture contained 2 mM TCEP, 2 mM ascorbate, 1 μM FeSO4, 20 
mM NaCl, 20 mM Tris-HCl buffer, pH 8.0 at 26oC. Concentration of substrate and 
enzyme were not always the same, and these differences were recorded on figure legends 
in the results section. After incubation for various times as required, reactions were 
stopped with addition of half a volume of 1 M phosphoric acid before analysis by HPLC. 
For larger scale, up to 1 mL reaction was prepared with reaction components added 
proportionally. Substrates and reagents were all prepared in 20 mM Tris-HCl, pH 8, 
except for iron-ascorbate mixture which was kept at pH of about 5.5 in 20 mM Tris-HCl 
buffer. Tris-HCl buffer was herein referred to as Tris buffer). 
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3.2.3. HPLC 
 
All HPLC analyses were performed on Shimadzu Prominence HPLC system using Luna 
5µ SCX 100A cation exchange column. The system was first equilibrated with relevant 
buffers before injection. A volume of 20 μL sample was injected for all qualitative 
analyses while up to 100 μL samples were injected for larger scale. The flow rate was 
maintained at 1 mL/min. The ASCII files from HPLC were analyzed on Origin Pro 8 
program. For qualitative measurements, products were separated on 1 mM NaCl gradient 
in 20 mM phosphate buffer, pH 2 (method 1), and a gradient of 500 mM ammonium 
formate at pH 5.5 was used to separate products for further characterization. For 
identification purposes HPLC was run using ammonium formate based buffers in method 
2 amd method 3. Method 2: samples were analysed with 10% gradient of 10 mM 
ammonium formate to 500mM while for Method 2, samples were analysed with 25% 
gradient of 10 mM ammonium formate to 500mM. 
 
 
3.2.4. Product Identification 
 
OvoA reaction mixtures were separated by HPLC using either HPLC method 2 or 3 (see 
section 3.2.3 above). Enzyme products of L-histidine, D-histidine and 2-fluorohistidine 
were separated using HPLC method 2 while products of histidinamide, histamine, 
histidine methyl ester and 4(5)-methylimidazole were separated using HPLC method 3. 
Products of enzyme reaction were collected from HPLC, the fractions pooled together 
and lyophilized. The products were re-dissolved in minimal volumes of nano pure water 
before being analysed by either electro-spray ionization mass spectrometry (ESI-MS), 
nuclear magnetic resonance (NMR), high resolution mass spectrometry (HRMS) or 
HPLC-Mass spectroscopy. 
 
3.2.5. Isotope effect 
 
 Reaction mixtures, (2 x 1 mL) contained 800 μM cysteine, 800 μM histidine, 2 mM 
TCEP, 2 mM ascorbate, 1 μM FeSO4, 20 mM NaCl and 20 mM Tris buffer. Reaction 
mixtures were lyophilized overnight, one was re-dissolve in 1 mL H2O (control) and the 
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other in 1 mL D2O (experimental). The samples were re-lyophilized overnight. The 
control sample was re-dissolved in H2O while the experimental sample was re-dissolved 
in D2O. The samples were split to make 250 μL volumes into which about 283 nM OvoA 
was added to start the reactions. The assays were performed in triplicates. 
 
3.2.6. pH dependence assays 
 
For pH dependence assays 50 mM Britton-Robinson buffer was used instead of 20 mM 
Tris. Assays were carried out at various pH values ranging from 5.5 to 10.0 in Britton-
Robinson buffer. Substrates and reagents were prepared in 50 mM Britton-Robinson 
buffers at relevant pH, except for the iron-ascorbate mixture which was kept at pH of 
about 5.5. Britton-Robinson buffer: 50 mM H3BO3, 50 mM H3PO4, 50 mM CH3COOH, 
pH adjusted with NaOH solution. 
 
 
3.2.7. Inhibition 
 
Reaction mixtures (250 μL) contained 50 μM histidine, 5 mM inhibitor, 1 mM cysteine, 2 
mM TCEP, 2 mM ascorbate, 10 μM FeSO4, 20 mM NaCl and 20 mM Tris-HCl, pH 7.5, 
280 nM OvoA. At intervals of 1, 2, 4 and 8 minutes, 40 μL samples were quenched with 
20 μL 1 M phosphoric acid solution and analyzed by HPLC method 1. 
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3.3. RESULTS AND DISCUSSION 
 
 
3.3.1. Purification of OvoA 
 
OvoA enzyme from Erwinia tasmaniensis was produced in the laboratory of Prof. Florian 
Seebeck using the described method (Braunshausen and Seebeck 2011). Recombinant E. 
tasmaniensis OvoA was cloned and expressed in Escherichia coli, BL-21 cells using 
IPTG induction and then purified on Ni-NTA agarose. Before use the enzyme purity was 
evaluated by SDS-Page with staining using Coomassie blue stain. No visible protein 
contaminants were observed, even in the lane where the enzyme was loaded two fold 
(lane A, figure 3.1). E. tesmaniansis OvoA is a relatively large protein, a monomer with 
567 amino acids and a theoretical weight of about 85 kDa. On the basis of SDS-Page 
analysis, the enzyme was regarded as about 90 % homogeneous and suitable for the 
enzyme kinetics.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: SDS-PAGE analysis of OvoA. Molecular weight marker (M), OvoA 2 x 
concentrated (A), OvoA 1x concentrated (B)  
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3.3.2. Characterization of OvoA 
 
3.3.2.1. OvoA assay optimization  
 
3.3.2.1.1. OvoA assay and product identification  
 
OvoA was assayed according to the method described in the methods section with 
cysteine and histidine at 1000 μM concentration. HPLC analysis of the assay mixture 
after three hours of incubation led to identification of a new peak with a retention time of 
about 3.2 minutes (figure 3.2). The new product had absorption at both 220 nm and 254 
nm, while the histidine substrate did not absorb at 254 nm. The product peak was well 
resolved from both ascorbate and histidine peaks, which eluted at 2.1 and 5.2 minutes, 
respectively. 
Figure 3.2: HPLC chromatogram of OvoA reaction with natural substrates. A 
reaction mixture containing 20 mM Tris pH 8.0, 20 mM NaCl, 2 mM TCEP, 2 mM 
ascorbate, 1μM FeSO4, 1000 μM cysteine, 1000 μM histidine, 283 nM OvoA was 
incubated for three hours at 26oC. About 30 μL of the reaction was quenched with 
addition of 15 μL before analyzed using HPLC method 1. 
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The product peak was collected using HPLC method 2, which utilizes ammonium 
formate buffer (described in section 3.2.3). After lyophilization and dissolution in nano 
pure water, the product was analyzed by ESI-MS, which revealed a product with m/z 
291.0, corresponding to M+1 for 5-histidyl-cysteine sulfoxide. The sodium ion mass ion 
signal at m/z 313.0 for M+Na also provided confirmation of the identity of the product. 
 
 
3.3.2.1.2. Effect of iron and ascorbate on OvoA reaction 
 
Ascorbate is a good electron donor and is used widely in iron dependent reactions. 
Depending on the oxidant, ascorbate can undergo either one or two electron oxidations. 
One electron oxidation results in ascorbate radical while a two electron oxidation leads to 
the formation of a more stable form, dehydroascorbate.  The ability of ascorbate to donate 
electrons coupled with the stability of its radical makes it a good antioxidant in biological 
systems. Here ascorbate was used in OvoA reaction mixture to keep iron within the 
enzyme in the ferrous state. 
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Figure 3.3: Effect of Iron and ascorbate on OvoA reaction: Reaction mixtures 
contained 20 mM Tris pH 8.0, 20 mM NaCl, 2 mM TCEP, 1000 μM cysteine, 1000 μM 
histidine, 283 nM OvoA, 1 μM FeSO4 and or 2 mM ascorbate and were incubated at 
26oC. At intervals of 1, 2, 4 and 8 minutes, 30 μL aliquots of the reactions were quenched 
by addition of 15 μL 1 M phosphoric acid and analyzed using HPLC method 1. 
 
 
The effect of 2 mM ascorbate on the OvoA reaction was evaluated. Our earlier study had 
shown that at 2 mM ascorbate, the optimal iron concentration was 1 μM (see appendix 
for results). Results in figure 3.3 show the importance of ascorbate as an activator of 
OvoA, since its omission from the reaction mixture (“None” and “FeSO4”) leads to very 
little enzyme activity even in the presence of 1 μM iron (FeSO4). By adding ascorbate 
alone, about 60 % of the enzyme activity was restored while in the presence of 1 μM 
FeSO4, ascorbate restored 100% OvoA activity. These results indicated that OvoA 
retained about 60% of its iron cofactor throughout the purification process but possibly in 
the wrong oxidation state, which then required ascorbate for re-activation. However it 
could not be ruled out that activation of OvoA by ascorbate was a result of possible direct 
binding to the enzyme or ascorbate being utilized by OvoA as one of its substrates. For 
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example ascorbate was found to bind into the active site of ACC oxidase, a nonheme iron 
containing enzyme that mediates the last step in biosynthesis of ethylene, a plant 
hormone. (Thrower et al, 2001). Since ascorbate is a chiral molecule, its binding to OvoA 
could be strictly stereo-selective. With this in mind OvoA was assayed with isoascorbate, 
the enantiomer of ascorbate to investigate if OvoA could differentiate between the 
isomers. 
 
 
 
 
 
 
Figure 3.4: Chemical structures of ascorbate and isoascorbate 
 
The results showed that OvoA did not differentiate between ascorbate and isoascorbate 
because the same reaction rates were obtained when OvoA was assayed in the presence 
of the two compounds (see appendix). Flashman et al. (2010), showed that isoascorbate 
could activate prolyl hydrolase, a nonheme iron enzyme, to the same extent as did L-
ascorbate. Future work to investigate how OvoA is activated by the isomers of ascorbate 
could be fruitful: for example, crystallizing the enzyme in the presence of the compounds 
could lead to location of the binding site on the enzyme molecule. 
 
 
3.3.2.2. Determination of kinetic constants of OvoA substrates 
 
Having established assay conditions, the stage was set for determination of enzyme 
kinetics. The best assay conditions obtained were as follows: 20 mM Tris pH 8.0, 20 mM 
NaCl, 2 mM TCEP, 2 mM ascorbate and 1 μM FeSO4 at 26
oC. The enzyme was therefore 
assayed by integration of product peaks, using a standard curve generated by allowing 
complete conversion of known concentrations of histidine substrate into 5-histidyl 
cysteine sulfoxide product (3, scheme 1.4) (see standard curve in appendix section). 
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Previous results of OvoA assays with numerous naturally occurring sulfur donors showed 
cysteine as the only sulfur donor (Braunshausen and Seebeck, 2011). Therefore in this 
study there was no further evaluation of other potential sulfur donors, and consequently 
this study was limited to a determination of the kinetic constants for cysteine as the 
sulphur donor. For the sulfur acceptor, the kinetics of histidine and other naturally 
occurring analogues were determined. Thus OvoA activity was assayed in the presence of 
various substrates using standard reaction conditions described earlier, and kinetic results 
shown in table 3.1 were determined using Michaelis-Menten graphs (Appendix). OvoA 
was characterized by a KM value of 347 ± 27 μM for cysteine, a kcat of 3.13 s
-1 and kcat / 
KM of 9.02x10
3 (Table 3.1). The enzyme had similar kinetic constants with L-histidine 
while displaying about 20 fold low specificity towards the D-histidine substrate. High 
KM, 818 μM, showing suboptimal binding of D-histidine to the enzyme, was the probable 
reason for the low kinetics constant of 0.35 s-1 found. 
 
Table 3.1: Michaelis-Menten kinetics of OvoA substrates 
Substrate 
 
Vmax 
(x10-9M/s) 
OvoA 
(x10-9 M) 
Kcat 
(s-1) 
KM 
(x10-6 M) 
kcat/KM 
(s-1M-1) 
Histidine 943 ± 45 289 3.26 339 ± 22 9617 
Cysteine 920 ± 44 294 3.13 347 ± 27  9020 
Histidinamide 156 ± 3 371 0.42 308 ± 27 1364 
Histamine 99.9 ± 1.4  377 0.26 227 ± 6 1145 
D-Histidine  121 ± 0.06  346  0.35 818 ± 12   427 
 
Histidine analogues, histidinamide and histamine were turned over by OvoA with just 7 
times less efficiency than L-histidine and cysteine, with specificity constants of 1364 s-
1M-1 and 1145 s-1M-1, respectively. Although histidinamide and histamine also bear an 
imidazole ring, the kinetic constants were influenced by structural changes in the side 
chain, presumably the loss of the negative charge on the carboxyl group. The result with 
D-histidine also shows that the specificity of the enzyme is determined not only by the 
imidazole ring. 
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3.3.2.3. Effect of pH on OvoA reaction with histidine substrates 
 
pH plays an important role in biological systems including enzyme catalyzed reactions. 
The ionization state of substrates and amino groups in the active site of enzymes can 
influence the kinetic parameters of the enzymes. Histidine and cysteine, natural substrates 
of OvoA, also contain ionizable side chains, the ionization of which affects their 
turnover. The enzyme also contains two histidine residues in the active site involved in 
iron metal coordination in what is referred to as a 2-His-1-carboxylate facial triad. 
 
The effect of pH on the OvoA reaction was determined using the Britton-Robinson buffer 
over a pH range of 6.0 to 8.5 under the standard reaction conditions described in the 
methods section. Michaelis-Menten graphs were used to determine the kinetic constants. 
At low pH, Michaelis-Menten graphs were more linear while at high pH the graphs were 
more hyperbolic (figure 3.5, A).  Above pH 8.5 very little activity was observed. 
 
 
 
Figure 3.5: Effect of pH on histidine kinetics. 250 μL reaction mixtures at 26oC 
contained 800 μM cysteine, histidine (12.5 – 1000 μM), 2 mM TCEP, 2 mM ascorbate, 1 
μM FeSO4, 20 mM NaCl, 283 nM OvoA in 50 mM Britton-Robinson buffer at different 
pHs (6 – 8.5). At intervals of 1, 2, 4 and 8 minutes, 40 μL sample were quenched with 20 
μL 1 M phosphoric acid solution and analyzed by HPLC using method 1. (A): Michaelis-
Menten graphs and (B): KM vs pH. 
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A sharp decrease in KM from pH 6.0 to pH 6.5 as observed in figure 3.5 suggested that an 
ionizable group either on the substrate (possibly the histidine imidazole unit) or the 
enzyme significantly affected binding of substrate into the active site. Such a decrease in 
KM might have also implied that the protonated histidine substrate species was not 
recognized as substrate by OvoA. This would follow from the fact that a reduction in pH 
simultaneously increased the concentration of protonated histidine species and reduced 
that of deprotonated species by the same amount. Investigation of the hypothesis that the 
observed high KM was as a result of protonation of the histidine imidazole ring would 
have required utilization of histidine analogues with low imidazole pKa such as 2-
fluorohistidine (pKa = 1.8). However, because of limited the limited amounts of 2-
fluorohistidine available, such a study could not be performed at this time. 
 
The KM remained unchanged between pH 7 and pH 8, implying that there was no 
significant acid-base ionization involving side chains in the enzyme structure or the 
substrates. 
 
 
pKa = 8.7
R-Sq = 0.92
pKa1 = 6.8
pKa2 = 8.0
R-Sq = 0.98
Figure 3.6: Effect of pH on histidine specificity and kinetic constant. 250 μL reaction 
mixtures at 26oC contained 800 μM cysteine, histidine (12.5 – 1000 μM), 2 mM TCEP, 2 
mM ascorbate, 1 μM FeSO4, 20 mM NaCl, 283 nM OvoA in 50 mM Britton-Robinson 
buffer at different pHs (6 – 8.5). At intervals of 1, 2, 4 and 8 minutes, 40 μL sample were 
quenched with 20 μL 1 M phosphoric acid solution and analyzed by HPLC using method 
1. (A): kcat vs pH, (B): kcat/KM vs pH. 
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The effect of pH on the specificity of OvoA towards histidine substrate was characterized 
by a bell a shaped curve (figure 3.6, B) with pKas of 6.8 and 8.0 and maximum activity 
observed at pH 7.3 (figure 3.6). The observed pKas indicated involvement of 
protonation/deprotonation of two amino acids. pKas values of 6.8 and 8.0 corresponded to 
the pKas of the histidine imidazole and cysteine sulfur, respectively, again suggesting 
involvement of cysteine and histidine side chains. The kinetic constant was found to be 
limited only at high pH with pKa of about 8.7. At low pH the enzyme required saturating 
concentrations of histidine. Although the results indicated protonation/deprotonation as 
the probable limiting factor at high pH, binding destabilization on iron metal at high pH 
could not be overruled as the limiting factor. 
 
The log kcat/KM graph assisted in the estimation of the amount of ionizable groups 
involved during catalysis. To the acid side from pH 7.0 to 6.0, there was a change in log 
kcat/KM of about 0.8 per pH unit, suggesting involvement of one ionisable group, such as 
the histidine imidazole. On the alkaline side, the same change of about 0.8 log kcat/KM 
was observed from pH 8.0 to 8.5, again implying involvement of one ionisable group, 
such as the cysteine side chain (figure S4, appendix). 
 
 
3.3.2.4. Effect of pH on OvoA kinetics using histidinamide and histamine substrates 
 
To investigate association of high KM and low pH, histidinamide and histamine were used 
as substrate. Because of their low pKa, it was expected that at specific activity curves will 
shift to the left with low pKa corresponding to the pKa of the substrate imidazole. 
According to pKa data in table 3.2, histamine and histidinamide have low pKas. 
 
Table 3.2: pKas of imidazole rings of histidine and some histidine analogues  
 Imidazole1 Histidine1 Histamine2 Histidinamide3 2-fluorohistidine4 
pKa 7.0 6.2 5.0 5.3 ~1 
1. Giralt et al., 1979, 2: Dawson et al., 1959, 3: Giralt et al., 1985, 4: Wimalasena et al., 2007. 
 
Thus the optimal pH for OvoA reaction with histidinamide and histamine as sulfur 
acceptors was determined using 1 mM concentrations for all the substrates and specific 
activities were obtained. 
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Figure 3.7: Michaelis-Menten graph of OvoA with histidinamide substrate. Reaction 
mixtures containing 20 mM Tris pH 8.0, 20 mM NaCl, 2 mM TCEP, 2 mM ascorbate, 1 
μM FeSO4, 800 μM cysteine, histamine or histidinamide (25 – 2000 μM) and 371 nM 
OvoA were incubated at 26°C. After intervals of 2, 4, 8 and 16 minutes, 30 μL aliquots of 
the reactions were quenched by addition of 15 μL 1 M phosphoric acid and analyzed for 
the formation of 5-histidinamidal cysteine sulfoxide using HPLC method 1. Data plotted 
here were averages of two determinants. 
 
For these analogues, OvoA shows maximum activity at similar pH of 7.8 and 8.0 for 
histidinamide and histamine, respectively. Unexpectedly, the analogues showed higher 
pKas than those obtained with histidine (figure 3.6). This phenomenon could not be 
explained but may be related to the lack of a carboxylic group in these substrates. Half of 
maximum velocities were reached at pH 7.1 and 9.3 for histamine while for histidinamide 
half velocities were achieved at pH 7.0 and 8.6. These unexpected results could have 
been caused by the different functional groups on the amino group moieties of the 
substrates to that of histidine. Therefore, a more accurate comparative study would be to 
use histidine isosteric compounds, like 2-fluorohistidine which is characterized by a very 
low pKa of around 1.0 (Wimalasena et al., 2007). This was again not possible in this work, 
due to the limited amounts of 2-fluorohistidine available. 
 
 
3.3.2.5. Solvent isotope effect of OvoA reaction 
 
A chemical isotope effect on the OvoA catalysed reaction was not observed for the 
OvoA-mediated transsulfuration reaction during initial characterization of the enzyme. 
The histidine substrate of which C-Hs had been replaced by C-Ds was found to be used at 
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a similar rate to normal histidine by OvoA (Braunshausen and Seebeck, 2011). Here the 
solvent isotope was investigated to establish whether proton exchange was the rate 
limiting step in transsulfuration reaction. Two reactions were performed in duplicates, 
one using D2O while the other reaction used H2O as liquid medium.  The reaction rates of 
16 μM/min in D2O and 19 μM/min in H2O were obtained (figure 3.8). This solvent 
isotope effect of 1.2 is not considered significant, suggesting that hydrogen exchange was 
not the rate limiting step. 
 
 
Figure 3.8: Isotope effect on OvoA reaction. Reaction mixtures (250 μL) containing 
800 μM cysteine, 800 μM histidine, 2 mM TCEP, 2 mM ascorbate, 1 μM FeSO4, 20 mM 
NaCl, 283 nM OvoA in 20 mM Tris buffer, pH 8.0 were incubated at 26°C. One reaction 
was performed in H2O (control) and the other took place in D2O (experimental), as 
described in materials and methods. The results were averages of three determinants. 
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3.3.2.6. Inhibition of OvoA by histidine and imidazole analogues 
 
Different histidine structural analogues were then tested as potential inhibitors of OvoA. 
Some of the compounds were commercially sourced while others were chemically 
synthesized (as described in Chapter 2 and the experimental section). Some of these 
compounds bore modifications on the amino acid while others contained modifications 
on the imidazole side chain. Also included were structures lacking the amino acid moiety, 
and those that had imidazole replaced by pyridyl rings. 
 
Inhibition assays were performed using standard reaction condition with 50 μM histidine 
at pH 7.5. Inhibitor concentration was increased 100 fold with respect to the histidine 
substrate. 
 
Figure 3.9: OvoA inhibition histidine structural analogues. 250 μL reaction mixtures 
containing 50 μM histidine, 5 mM inhibitor, 1 mM cysteine, 2 mM TCEP, 2 mM 
ascorbate, 10 μM FeSO4, 20 mM NaCl, 20 mM Tris buffer, pH 7.5 and 280 nM OvoA 
were incubated at 26oC. At intervals of 1, 2, 4 and 8 minutes, 40 μL sample was 
quenched with 20 μL 1 M phosphoric acid solution and analyzed using HPLC method 1. 
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Only three compounds displayed significant inhibition, viz. 5-fluorohistidine (80%), H-
(3-Me)-his-OH (50%) and imidazole (40%). Some compounds such as carnosine, 4-
chlorohistidine and hydroxymethylimidazole exhibited very mild inhibition of about 30% 
while most compounds did not show inhibition (figure 3.9). An important observation 
was the significant inhibition of the enzyme by 4-fluorohistidine. The data indicated that 
modification of the imidazole ring by the larger halogens iodine, bromine and chlorine 
abolished inhibitory effect observed with 4-fluorohistidine. These large halogens possibly 
contributed to very limited interaction of the imidazolyl compound with the enzyme due 
to steric hindrance. 
 
Although OvoA accepted α-N-methylated histidine as substrate (figure 3.20), the enzyme 
did not turnover nor was inhibited by α-N-acetylhistidine. There seemed to be a slight 
activation of OvoA by 5-iodohistidine, though the presence of traces of histidine 
contaminants may have accounted for this. 2, 5-diiodohistidine was found to be unstable 
in the presence of TCEP, with removal of iodine seem d to be occurring (results not 
shown). 
 
 
3.3.2.7. Evaluation of histidine analogues as OvoA substrates 
 
Although OvoA was found to have high selectivity towards a sulfur donor, the enzyme 
was however found to be promiscuous when it came to sulfur acceptors. In addition to 
histidine, α-N-methylhistidine and α-N,N,-dimethylhistidine were also found to be OvoA 
substrates (Braunshausen and Seebeck, 2011). Therefore a further range of naturally 
occurring and chemically synthesized histidine analogues were evaluated as sulfur 
acceptors in OvoA reaction. 
 
 
3.3.2.7.1. D-histidine 
 
D- and L-histidines are enantiomers. Evaluation of D-histidine as an OvoA substrate was 
crucial as it would provide valuable information about the orientation of the amino acid 
in the active site. Analysis of the OvoA reaction mixture on HPLC showed a new peak 
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with retention time similar to that obtained with L-histidine. The new product had the 
HPLC characteristics of sulfoxide as it displayed absorption at both 220 nm and 254 nm 
wavelengths (figure 3.10). 
Figure 3.10: HPLC chromatogram of OvoA reaction with D-histidine substrates. A 
reaction mixture containined 20 mM Tris pH 8.0, 20 mM NaCl, 2 mM TCEP, 2 mM 
ascorbate, 1 μM FeSO4, 1000 μM cysteine, 1000 μM D-histidine and 283 nM OvoA. 
After overnight reaction (about 16 hours) 40 μL reaction mixture was quenched with 20 
μL 1 M phosphoric acid solution and analyzed using HPLC method 1. Insert shows mass 
of new product as determined by ESI-MS. 
 
Analysis of the new peak by high resolution mass spectroscopy after separation using 
HPLC method 2 produced a component with mass 291.0757 which corresponded with 
M+H of the D-histidine-5-sulfoxide (figure 3.10). On closer inspection it was noted that 
the product peak of D-histidine had a stronger absorption at 254 nm than that of L-
histidine in figure 3.2. Further analysis of the product using NMR revealed that it was a 
mixture of 37% 2-histidyl cysteine sulfoxide and 63 % 5-histidyl cysteine sulfoxide 
(figure 3.11). 
 
HRM 
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Figure 3.11: NMR of OvoA reaction product with D-histidine.  
 
Therefore, the high absorbance at 254 nm was associated with sulfoxidation at the C-2 
position, and this was used as another distinguishing feature of the position of 
transsulfuration when other histidine analogues were tested.  More work comparing D- 
and L-histidine reactions was carried out and the results are discussed in a separate 
section (section 3.3.2.7.10).  
 
 
 
3.3.2.7.2. 2-fluorohistidine 
Substitution of a hydrogen by a fluorine on a carbon atom of an organic molecules leads 
to changes in electronic properties. Due to its high electronegativity, fluorine withdraws 
bonding electrons from carbon making it electron deficient. The presence of fluorine in 2-
fluorohistidine reduces the pKa of the imidazole from about 6.2 to around 1.0 
(Wimalasena et al., 2007) making the nitrogen less reactive than in normal histidine. 
Evaluation of 2-fluorohistidine as an OvoA substrate would therefore provide some 
insights on the interaction of the histidine imidazole with the iron metal cofactor of 
OvoA. Using HPLC method 4, analysis of the OvoA reaction mixture with 2-
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flourohistidine as sulfur acceptor produced a new peak with a retention time of 4.8 
minutes. Using the same method, analysis of the OvoA reaction mixture containing both 
2-fluorohistidine and histidine in the same reaction mixture as sulfur acceptors lead to 
appearance of two well separated product peaks, a peak for 2-flourohistidyl cysteine 
sulfoxide at 4.8 minutes and one for 5-histidyl cysteine sulfoxide at 7.2 minutes (figure 
3.12). 
Figure 3.12: HPLC profile of OvoA reaction with 2-fluorohistidine and histidine. 
Reaction mixture (250 μL) contained 20 mM Tris buffer, pH 8.0, 1000 μM cysteine, 
1000 μM histidine, 1000 μM 2-fluorohistidine, 2 mM TCEP, 2 mM ascorbate, 1 μM 
FeSO4, 20 mM NaCl and 283 nM OvoA. After 16 minutes 40 μL sample was quenched 
with 20 μL 1 M phosphoric acid solution and analyzed using HPLC method 1. 
 
After separation using HPLC method 2, a compound with mass 309.1 m/z was detected 
by ESI-MS, corresponding to M+H for 2-fluorohistidyl cysteine sulfoxide. Also found 
were signals at 331.1 and 353.0 indicating the presence of M+Na and M+2Na, 
respectively (figure 3.13). 
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Figure 3.13: ESI spectrum of 2-fluorohistidyl cysteine sulfoxide. 
 
 
The substrate specificity of OvoA toward 2-fluorohistidine was compared to that of the 
histidine substrate. As seen in figure 3.14, the enzyme turned over 2-fluorohistidine at a 
similar rate to histidine, with rates of 10.2 μM/min and 9.5 μM/min observed, 
respectively. However, due to lack of sufficient quantities of 2-fluorohistidine, no kinetic 
constants were determined. 
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Figure 3.14: OvoA reaction; comparison of L-histidine and 2-Fluoro-L-histidine. 
250 μL reaction mixtures incubated at 26oC, contained 20 mM Tris buffer, pH 8.0, 1000 
μM cysteine, 1000 μM L-histidine or 2-fluoro-L-histidine, 2 mM TCEP, 2 mM ascorbate, 
1 μM FeSO4, 20 mM NaCl and 283 nM OvoA. At points 1, 2, 4 and 8 minutes, 40 μL 
sample was quenched with 20 μL 1 M phosphoric acid solution and analyzed using 
HPLC method 4. 
 
 
 
 
3.3.2.7.3. Histidinamide 
 
Histidinamide is a histidine analogue with a primary amide group replacing the carboxyl 
group. Such a modification increases the overall charge and decreases the pKa (table 3.2) 
of the molecule. Evaluation of histidinamide as sulfur acceptor in the OvoA reaction was 
envisaged to provide more insights into the interaction of amino acids in the enzyme 
active site with the amino acid moiety of sulfur acceptors. 
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A new peak with retention time of 4.5 minutes was detected when a standard reaction 
mixture containing histidinamide as sulfur acceptor was analysed on HPLC (figure 3.15). 
 
Figure 3.15: HPLC profile of OvoA reaction with histidinamide substrate. A 250 μL 
reaction mixture containing 20 mM Tris buffer, pH 8.0, 1000 μM cysteine, 1000 μM L-
histidinamide, 2 mM TCEP, 2 mM ascorbate, 1 μM FeSO4, 20 mM NaCl and 283 nM 
OvoA was incubated at 26oC. After three hours, a 40 μL sample was quenched with 20 
μL 1 M phosphoric acid solution and analyzed using HPLC method 1. 
 
Analysis of the product by ESI-MS after separation using HPLC method 3, led to 
detection of a component with m/z 290.0, which corresponded with M+H for 5-
histidinamidal cysteine sulfoxide. The M+Na signal was also detected at 312.0 m/z, 
(figure3.15). 
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3.3.2.7.4. Histamine 
 
Evaluation of histamine as a sulfur acceptor in the OvoA reaction was predicted to 
provide information concerning the requirement and significance of the histidine 
carboxyl group for catalysis. The HPLC profile of three-hour OvoA reaction mixture 
using histamine as the substrate, showed a new peak eluting at about 5.3 minutes (figure 
3.16). The peak was well resolved from the histamine starting material which eluted at 
about 6.7 minutes. The new peak and that of histamine appear relatively late compared to 
histidine and 5-histidyl cysteine sulfoxide, perhaps because of increased positive charge 
on histamine. 
 
 
 
Figure 3.16: HPLC profile of OvoA reaction with histamine substrate. A 250 μL 
reaction mixture at 26oC contained 1000 μM cysteine, 1000 μM histamine, 2 mM TCEP, 
2 mM ascorbate, 1 μM FeSO4, 20 mM NaCl, 283 nM OvoA and 20 mM Tris buffer, pH. 
After three hours, a 40 μL sample was quenched with 20 μL 1 M phosphoric acid 
solution and analyzed using HPLC method 1. 
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The new product was isolated using HPLC method 3 and analysed by ESI-MS. The 
observed ion at m/z 269.1 corresponded with M+Na+H for 5-histamine cysteine 
sulfoxide. 
 
3.3.2.7.5. Histidine methyl ester (HOMe) 
 
The importance of the substrate amino acid group in the OvoA reaction was further 
investigated by evaluation of histidine methyl ester (His-Ome). This was envisaged to 
provide further insights on the effect of less reactive hydrophobic methyl ester on 
substrate OvoA reaction. Analysis of the OvoA reaction mixture with histidine methyl 
ester using HPLC method 1 revealed the presence of two new peaks. The first peak eluted 
at 3.5 minutes while the second one eluted at 5.5 minutes (figure 3.17). The peak at 3.5 
minutes was later found to be due to 5-histidyl cysteine sulfoxide that could have resulted 
from histidine contamination, although HPLC analysis of the His-Ome alone did not 
show histidine contamination (data not shown). This suggests that histidine may have 
been produced enzymatically in situ from histidine methyl ester. 
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Figure 3.17: OvoA reaction with L-histidine methyl ester substrate. A 250 μL 
reaction mixture contained 1000 μM cysteine, 1000 μM L-histidine methyl ester, 2 mM 
TCEP, 2 mM ascorbate, 1 μM FeSO4, 20 mM NaCl and 283 nM OvoA wt, 20 mM Tris 
buffer. After three hours, a 40 μL sample was quenched with 20 μL 1 M phosphoric acid 
solution and analyzed using method 1. Dashed line: Ab 220 nm and solid line: Ab 254 
nm. 
 
 
Analysis of the peak eluting at 5.4 minutes by ESI-MS revealed an ion at m/z 305 
corresponding to HOMe cysteine sulfoxide (figure 3.17). However, because of an 
apparent competing reaction with the histidine contaminant noted above, no kinetic 
constants were determined for HOMe substrate. Further studies using more stable 
histidine esters such as ethyl ester could be fruitful. 
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3.3.2.7.6. 4(5)-Methylimidazole 
 
Evaluation of 4(5)-methylimidazole as sulfur acceptor in OvoA reaction was imperative 
as it would provide crucial information about requirement with regard to the imidazole 
amino groups in histidine for catalysis. HPLC analysis of the OvoA reaction using HPLC 
method 1 showed two new very small peaks at 4.0 minutes and 6.0 minutes (figure 3.18). 
The reaction mixture was analysed using HPLC method 3 which contained ammonium 
formate buffer, allowing for easy removal by lyophilization. However, using this method 
the two peaks could not be separated and were therefore collected and analyzed together. 
After repeated lyopholization, the residue was analysed by HPLC-mass spectroscopy and 
an ion at m/z 218.1 was detected, which corresponded to M+H for methylimidazole 
cysteine sulfoxide. 
 
Figure 3.18: OvoA reaction with 4(5)-methylimidazole. A 250 μL reaction mixture 
contained 1000 μM cysteine,1000 μM 4(5)-methylimidazole, 2 mM TCEP, 2 mM 
ascorbate, 1 μM FeSO4, 20 mM NaCl, 283 nM OvoA in 20 mM Tris buffer, pH. After 
three hours, a 40 μL sample was quenched with 20 μL 1 M phosphoric acid solution and 
analyzed by HPLC method 1. Solid: Ab 220 nm dashed line: Ab 254 nm and. The HPLC 
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program ended before the substrate peak had fully eluted, however no peaks were 
observed after the 4(5)-methylimidazole peak when the program was extended by 3 more 
minutes (data not shown). 
 
The two peaks were identified as 4(5)-methylimidazole products having the sulfoxide 
moiety at different positions on the imidazole ring, one with a C-2 sulfoxide (rt: 4.1 min 
and the other having the sulfoxide at the C-5 position on imidazole. This conclusion was 
based on the previous observation (figure 3.10) that sulfoxidation at C-2 produced a 
product that absorbs more strongly at 254 nm than the product with the C-5 sulfoxide. As 
seen in figure 3.18, the enzyme turned over 4(5)-methylimidazole to make more of C-2 
sulfoxide intermediate (dashed line, figure 3.18) than the C-5 sulfoxide intermediate 
(solid line, figure 3.18). 
 
 
3.3.2.7.7. α-N-methyl histidines 
 
From the previous observations in this study, it became apparent that the amino group of 
histidine was not required for OvoA catalytic transsulfuration and formation of sulfoxide. 
Ovothiol A, B and C are mercaptohistidine derivatives differing only in the extent of 
methylation at the α-amino group. Ovothiol A lacks methylation while ovothiol B and 
ovothiol C contain one and two methyl groups, respectively. It is not clear whether 
methylation at the amino acid happens before or after the transsulfuration step. Therefore 
evaluation of α-amino methylated histidine derivatives as sulfur acceptors in the OvoA 
reaction would provide significant insights. When the reaction mixture from the OvoA 
reaction using α-N-methyl histidine as sulfur acceptor substrate was analysed using 
HPLC method 1, two new peaks were detected (figure 3.19). 
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Figure 3.19: OvoA reaction with α-N-methylhistidine. A 250 μL reaction mixture at 
26oC contained 1000 μM cysteine,1000 μM α-N-methylhistidine, 2 mM TCEP, 2 mM 
ascorbate, 1 μM FeSO4, 20 mM NaCl, 283 nM OvoA and 20 mM Tris buffer, pH 8.0. 
After overnight, a 40 μL sample was quenched with 20 μL 1 M phosphoric acid solution 
and analyzed by HPLC method 1. Solid line: Ab 220 nm, dashed line: Ab 254 nm.    
 
Again, as shown in figures 3.10 and 3.18, difference in absorption characteristics at 254 
nm was used to identify the two products, with the C-2 sulfoxide eluting at 3.3 minutes 
followed by the C-5 i termediate at 3.6 minutes (figure 3. 19). The results also confirmed 
earlier observations made by Braunshausen and Seebeck, 2011 that OvoA utilizes α-N-
methylhistidine as an alternative substrate. 
 
3.3.2.7.8. α-N,N-dimethylhistidine 
 
Analysis of the OvoA reaction mixture using α-N,N-dimethylhistidine as sulfur acceptor 
produced two new peaks with retention times of 4.0 minutes (B) and 4.6 minutes (A) 
(figure 3.20). On the basis of their absorption at 254 nm, the products were identified as 
before as the C-2 intermediate (A) and C-5 intermediate (B).  
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Figure 3.20: OvoA reaction with α-N,N-dimethylhistidine. A 250 μL reaction mixture 
at 26oC contained 1000 μM cysteine, 1000 μM α-N,N-dimtheylhistidine, 2 mM TCEP, 2 
mM ascorbate, 1 μM FeSO4, 20 mM NaCl, 283 nM OvoA and 20 mM Tris buffer, pH 
8.0. After overnight, a 40 μL sample was quenched with 20 μL 1 M phosphoric acid 
solution and analyzed using HPLC method 1. Solid line: Ab 220 nm and dashed line: Ab 
254 nm. 
 
 
A further observation was that the C-5 sulfoxide intermediates eluted earlier than the C-2 
intermediate for all products formed with histidine analogues used in this study. The 
utilization of α-N,N-dimethylhistidine by OvoA was first reported by Braunshausen and 
Seebeck, 2011, and was confirmed in the current study. This will be important because it 
will mean that the two enzymes mediating the last two steps in ovothiol biosynthesis also 
utilize α-amino methylated intermediates as substrates. Attempts were made to use a 
chemically- synthesized histidine betaine as sulfur acceptor without success. The reason 
for this failure was not apparent but poor substrate stability and high affinity of the 
substrate for the column were suggested as probable reasons. Continuation of this work in 
future will be very important in the light of possibility the OvoA could synthesis 
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intermediates of the ergothioneine biosynthetic pathway, a system found in different 
organisms. 
3.3.2.7.9. Evaluation of other histidine analogues as OvoA substrates 
 
In the quest for further potential cysteine sulfur acceptors in the OvoA reaction, more 
histidine analogues were evaluated (figure 3.21). Pyridylalanines in group B in figure 
were selected to test if OvoA could transfer sulfur onto other aromatic rings other than 
imidazole. Successful sulfuration of 4(5)-methylimidazole observed here, led to 
evaluation of other imidazole derivative in group A. Group C contained histidine 
analogues bearing modifications at α-amino and imidazole ring. However, none of the 
compounds in figure were found to be OvoA substrates as determined by HPLC analysis 
of their respective reaction mixtures (data not shown). 
 
 
 
 
Figure 3.21: OvoA substrate specificity: A list of compounds tested as cysteine sulfur 
acceptors in OvoA reaction. Standard reaction mixtures contained 1 mM compound, 283 
nM OvoA and 1 mM cysteine. 
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3.3.2.7.10. OvoA and OvoB reactions: conversion of 5-histidyl cysteine sulfoxides 
into 5-thiohistidines 
 
In ovothiol biosynthesis, OvoA mediates the transsulfuration step to form 5-histidyl 
cysteine sulfoxide from histidine and cysteine substrates. The lysis step mediated by 
OvoB involves formation of 5-mercapto-histidine from the 5-histidyl cysteine sulfoxide 
substrate (Braunshausen and Seebeck, 2011). Reactions of OvoA and OvoB using L-
histidine and D-histidine were monitored by HPLC. In the first reaction (L-His OvoA), 
OvoA was incubated with L-histidine until most substrate was converted to 5-histidyl 
cysteine sulfoxide, thereby providing substrate for the second reaction mediated by OvoB 
(L-His OvoB). Using HPLC method 1, the OvoA product 5-L-histidyl cysteine sulfoxide 
eluted at about 3.3 minutes (figure 3.22), while the OvoB product (L-His OvoB) eluted 
later at about 3.5 minutes. It was clear that after 10 minutes of incubation all 5-histidyl 
cysteine sulfoxide was consumed. 
 
Figure 3.22: OvoA and OvoB reactions with L-Histidine: A 1 mL μL reaction mixture 
contained  1.2 mM cysteine, 1 mM L-histidine, 2 mM TCEP, 2 mM ascorbate, 1 μM 
FeSO4, 20 mM NaCl and 680 nM OvoA in Tris buffer pH 8,  was incubated at 26
oC 
overnight. The reaction was split into 2 x 500 μL. OvoB was added into one sample while 
the other served as a control without OvoB. Reactions were incubated at 26°C for 10 min, 
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before 40 μL of the reactions were quenched with 20 μL 1 M phosphoric acid and 
analyzed using HPLC method 1. 
 
In the next experiment, separate reaction mixtures of OvoA and OvoB which had been 
stopped by acid (L-His OvoA + L-His OvoB) were combined prior to injection on HPLC. 
The HPLC chromatogram showed two distinct overlapping peaks (L-His OvoA + L-His 
OvoB, figure 3.22). None of the OvoA and OvoB produced a peak that corresponded to 
the one produced by 2-mercapto-histidine (2-mercapto-His). This confirmed that no 
transsulfuration happened at C-2 when L-histidine was used as substrate. When similar 
experiments were performed using D-histidine as substrate, different results were 
obtained. The OvoA reaction mixture with D-histidine (D-His OvoA, figure 3.23) 
produced one broad peak eluting at about 3.3 minutes, the same elution time as the 
product obtained when L-histidine was used as substrate (L-His OvoA, figure 3.22). 
However, when OvoB was added into the OvoA reaction mixture, two distinct peaks 
were observed, one at 2.6 minutes and the other one at 3.5 minutes (figure 3.23). 
Figure 3.23: OvoA and OvoB reactions with D-Histidine: A 1 mL reaction mixture 
contained  1 mM cysteine, 1 mM D-histidine, 2 mM TCEP, 2 mM ascorbate, 1 μM 
FeSO4, 20 mM NaCl and 680 nM OvoA in Tris-HCl pH 8,  was incubated at 26
oC 
overnight. The reaction was split into 2 x 500 μL. OvoB was added into one sample while 
the other served as a control without OvoB. Reactions were incubated at 26°C for 10 min. 
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The first peak at 2.6 minutes had the same retention time as 2-mercaptohistidine (2-
mercapto-His) while the second peak eluted at the same time as the product produced in 
the reaction of OvoB with L-histidine intermediate (L-His OvoB, figure 3.22). Two 
distinct products were therefore produced when D-histidine was used as OvoA substrate. 
However, the chemical structures of the two products were so similar that they could not 
be separated by HPLC under conditions used here, hence the broad peak observed for the 
(D-His OvoA) experiment. Based on HPLC analysis, it was confirmed that OvoA 
mediated transsulfuration at both C-2 and C-5 of D-histidine but only at C-5 of L-
histidine. Also important was the observation that OvoB was able to turn over both the C-
2 and C-5 sulfoxide intermediates into their respective mercaptohistidine products. 
Another significant observation was the potent smell emerging from OvoB reaction 
mixtures, suggesting formation of thiols from 5-histidyl cysteine sulfoxide precursors. 
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CHAPTER 4:  
EFFECT OF HALOGENATED HISTIDINES ON ERGOTHIONEINE 
BIOSYNTHESIS IN MYCOBACTERIUM SMEGMATIS 
 
 
4.1 INTRODUCTION 
 
Ergothioneine is a trimethylbetaine of 2-thio-L-histidine that was first isolated in 1909 by 
Tanret from ergot fungus, Claviceps purpurea (Tanret, 1909). Ergothioneine was found 
to be produced by non-yeast fungus and various Actinobacteria (Melville et al., 1956, 
Melville et al., 1957). It is widely present in vertebrates and plants where is taken up 
from nutrients. Ergothioneine has been found to accumulate in specific human cells and 
tissues such as liver, erythrocytes, lens and cornea of eyes, seminal fluid and kidney 
(Cheah and Halliwell, 2012). Accumulation of ergothioneine in these human cells and 
tissues is associated with expression of SLC22A4 gene, which encodes a transport protein 
(OCTN1). This organic cation transporter has been found to be specific for ergothioneine 
transport across cellular membrane.  At physiological conditions, ergothioneine exists as 
a thione form as opposed to thiol form. It has high thiol-redox potential of – 0.06 V in 
contrast to – 2 and – 32 V of other naturally occurring thiols and unlike glutathione, 
ergothioneine does not readily undergo autoxidation which can generate free radicals 
(Cheah and Halliwell, 2012). Physiological roles of ergothioneine are still a subject of 
speculations. Various functions have been attributed to ergothioneine including metal 
chelation, regulation of gene expression, immune regulator and antioxidant. In vitro, 
ergothioneine has been found to be a powerful scavenger of hydroxyl radicals, 
hypochlorous acid and peroxynitrite (Van Lear et al, 2013 and Cheah and Halliwell, 
2012). 
 
Genes involved in biosynthesis of ergothioneine were recently identified in 
Mycobacterium smegmatis (Seebeck et al, 2010). The ergothioneine biosynthesis begins 
with formation of histidine betaine (84), transulfuration at C-2 of histidine betaine using 
γ-glutamylcysteine as sulfur donor to form product 85, hydrolysis of the glutamate and 
finally lysis of pyruvate to form ergothioneine, 87 (scheme 4.1). The key reactions were 
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found to be the formation of histidine betaine and transsulfuration steps (Seebeck et al, 
2010. The transsulfuration step in ergothioneine biosynthesis is similar to that found in 
ovothiol biosynthesis and such a rare chemical reaction has not been found in any other 
biological systems. Therefore understanding the mechanism of transsulfuration step in 
ergothioneine might provide insights on the same reaction in ovothiol and vice versa.  
 
 
 
Scheme 4.1: Biosynthesis of ergothioneine (adapted form Seebeck et al, 2010) 
 
On the basis of structural similarities with the betaine, halogenated histidines in figure 4.1 
were envisaged as potential inhibitors of EgtB, the enzyme mediating the transsulfuration 
step. Fluorinated histidines were of particular interest because although the fluorine atom 
has almost a similar size as hydrogen, it confers different electronic properties to the 
molecule. The presence of fluorine at C-2 and C-5 of the imidazole ring of histidine 
might also shed light on the electron transfer mechanism involved in the transsulfuration 
reaction in ergothioneine biosynthesis as this still remains a mystery. Synthesis of these 
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compounds was described in other chapter 2 here, except for 2- and 5-fluorohistidine 
which were a gift from Prof. Kenneth Kirk.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Chemical structures of halogenated histidines used in the study of 
ergothioneine biosynthesis 
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4.2. MATERIALS AND METHODS 
 
 
4.2.1. Materials 
 
All standard reagents were purchased from Aldrich/Sigma if not otherwise stated. Bacto 
Middlebrook was purchased from Dicfo. Perchloric acid and luna 5μ C-18 HPLC column 
were purchased from BDH and Phenomenex, respectively. 
 
 
4.2.2. Effect of halogenated histidines on the growth of M. smegmatis 
 
M. smegmatis cells, harvested at the late log phase, were diluted to OD of 0.1 in Bacto 
Middlebrook 7H9 medium pH 7.8, containing 0.05% Tween 80 and 5% glycerol as the 
only carbon source. The cells (20 mL) were transferred into 10 x 50 mL sterilized 
Erlenmeyer flasks. A 250 μL aliquot of 5-chloro, 5-bromo, 5-fluoro- and 5-Iodo-histidine 
solutions, which had been prepared in water, was added into the flask to achieve 250 μM 
final concentrations. The cultures were shaken in an incubator at 200 rpm at 37oC until 
they reached stationary phase. The cells were harvested by centrifugation. For 2-
fluorohistidine, 500 nM concentration was used as it had earlier been found that the 
compound was very toxic towa ds M. smegmatis cells (see section 4.2.3 and figure 4.2). 
 
 
4.2.3. The growth of M. smegmatis in varying concentrations of 2-fluorohistidine 
 
The M. smegmatis cells harvested at late log phase were diluted into the Middlebrook 
medium as in section 2.1 above. The cultures were grown to early exponential phase and 
10 mL quantities of the cells were then transferred into 25 mL conical flasks. 2-fluoro-
histidine was then added from stock solution of 20 mM in water to obtain final 
concentrations of 25, 50, 200 and 500 nM.  Cultures lacking 2-fluorohistidine were used 
as controls. The flasks were incubated, with shaking at 200 rpm at 37oC. The OD600 of 
the cultures were recorded at 3, 6, 9 and 12 hour. 
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4.2.4. Evaluation of the effect of halohistidines on ergothioneine biosynthesis in M. 
smegmatis and derivatization of thiols. 
 
4.2.4.1. Treatment of M. smegmatis culture with halohistidine 
 
The cells were treated and cultured as described in section 2.2. The cells, 1 mL, were 
harvested when they reached the early stationary phase at OD600 of 9.6. The harvested 
pellets were suspended in a 200 μL extraction buffer [acetonitrile: 0.75M perchloric acid, 
(2 : 1)]. The mixtures were vortexed for 3 x 20 seconds. The denatured proteins and other 
cellular debris were removed by centrifugation at 13200 rpm for 5 minutes at room 
temperature. The supernatants were transferred into new Eppendorf tubes and then 
centrifuged for a further 5 minutes at 13200 rpm. The supernatants (about 157 μL) were 
neutralized by adding13 μL of a 2 M K2CO3 solution.  The mixtures were centrifuged to 
remove potassium perchlorate. 
 
4.2.4.2. BAN derivatization of thiols 
 
A 20 μL of 50 mM Li2CO3 (pH 9.0) buffer was added to 170 μL of the neutralized 
mixtures, followed by 10 μL of 10 mM 2-bromo-2’-acetonapthone (BAN) in acetonitrile. 
The reaction mixtures were allowed to react for 2 hrs at room temperature in the dark. A 
100 μL quantity of the reaction mixture was diluted two-fold by addition of 100 μL 0.1% 
trifluoroacetic acid to lower the acetonitrile concentration to about 15% prior to analysis 
on HPLC.  
 
 
4.2.4.3. HPLC analysis of derivatized thiols 
 
The BAN derivatized thiols were analysed by HPLC on a Luna 5μ phenyl-hexyl column 
(250 x 4.60 mm) that had been equilibrated with a mixture of 95% solution A (0.1% 
TFA) and 5% solution B (100% acetonitrile) at a flow rate of 0.8 ml/min. The column 
was eluted as detailed in Table 1 below.  
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Table 4.1: Analysis of BAN derivatized thiols 
Time 
(min) 
0 5 10 40 45 50 55 
Solution A  95% 80% 70% 20% 10% 10% 95% 
Solution B 5% 20% 30% 80% 90% 90% 5% 
 
The column effluent was monitored by measuring absorbance at 248 nm and the fractions 
corresponding to derivatized thiols were collected for analysis by mass spectroscopy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
99 
 
4.3. RESULTS AND DISCUSSION 
 
 
4.3.1. Effect of halohistidines on the growth of M. smegmatis 
 
Halogenated histidine analogues have been shown to inhibit microbial growth (Howard et 
al., 1986). It was therefore crucial to look at the growth profile of M. smegmatis in 
increasing concentrations of these compounds before the study on ergothioneine 
biosynthesis could start. A concentration of 250 μM was found to be the most tolerable 
one for all the compounds except for 2-fluorohistidine. Even at 250 μM 2-fluorohistidine 
was found to be toxic to the cells (see figure 4.2). 
 
 
 
Figure 4.2: Effect of halogenated histidines (250 µM) on growth of M smegmatis 
cells. 
 
Growth inhibition by 2-fluorohistidine was previously observed in malaria parasites 
(PANTON et al., 1988 and Howard et al., 1986). The growth inhibitory effect of 2-
fluorohistidine could be attributed to the fact that they can be incorporated into proteins 
(Torrence et al., 1979 and Eichler et al., 2005). The presence of fluorine on the imidazole 
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ring of histidine reduces the imidazole pKa from 6.8 to ~ 1.0 (Yeh et al. 1975 and 
Wimalasena et al., 2007). The reduced pKa may negatively impact on the function of the 
histidine imidazole side chain found in the active site of many enzymes. Although it is 
not clear how it inhibited growth of M. smegmatis, 2-fluorohistidine was found to inhibit 
histidine uptake in malaria parasites (Panton et al., 1988), and in other studies was found 
to be more readily incorporated into proteins than 4-fluorohistidine (Eichler et al., 2005).  
 
 
4.3.2. Growth of M. smegmatis culture in varying concentrations of 2-fluorohistidine 
 
Due to high levels of toxicity displayed by 2-fluorohistidine to M. smegmatis cells (figure 
4.2), it was necessary to establish the sub-lethal concentrations of the compound prior to 
investigating its effect on ergothioneine biosynthesis. M. smegmatis cultures were 
subjected to varying concentrations of 2-fluorohistidine. At 500 nM concentrations of 2-
fluorohistidine, the culture grew to just over halve the cell density of the control culture 
after 12 hours (figure 4.3). The subsequent studies to evaluate the effect of 2-
fluorohistidine on ergothioneine biosynthesis were therefore carried out using 500 nM 2-
fluorohistidine. 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
0 3 6 9 12
Time (hrs)
O
D
 (
6
0
0
)
(-)  Control
25nM
50nM
200nM
500nM
O
D
 (
6
0
0
)
Figure 4.3: Effect of 2-fluorohistidine on growth of M. smegmatis cells. 
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4.3.3. Identification of M. smegmatis thiols by HPLC 
 
The amounts of ergothioneine from cultures treated with halogenated histidines were 
compared to that of untreated cultures. M. smegmatis cultures were exposed to 
halogenated histidines at early exponential phase, and then harvested once they had 
reached the stationary phase. Cell-free extracts were prepared and thiols derivatized by 
incubation with BAN as outlined in the methods section. After 2 hours of derivatization 
the mixtures were analysed by HPLC at 248 nm. The mixture of BAN derivatized thiol 
produced well resolved peaks on HPLC, with significant components eluting at 3.84, 
22.26, 23.45, 35.64 and 36.80 min (figure 4.4). The BAN reagent itself eluted at 36.80. 
Peaks at 3.84 22.26 and 35.64 were collected and analysed by mass spectroscopy for 
identification.  
 
Figure 4.4: A typical HPLC elution profile of BAN derivatized thiols from M. 
smegmatis cells. Peaks at 22.26 and 23.45 minutes were later identified by mass 
spectrometry as BAN derivatized ergothioneine (ESH) and mycothiol (MSH) 
respectively. 
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The mass of the product eluting at 22.64 minutes was 398.4, corresponding to the mass of 
BAN derivatized ergothioneine (figure 4.5). The 23 minute peak gave a mass of 656 
which corresponded to the BAN derivatized mycothiol (figure 4.6). The 3.84 minutes 
peak was found to have a mass of 481 and could not be identified.  
 
The same HPLC profiles were observed for M. smegmatis cells treated with halogenated 
histidines and cells not treated with halogenated histidines, indicating that the 
halogenated histidines were either not substrates or their respective thiols could not be 
derivatized with BAN.  
 
 
HN N
N
O
OH
S
O
Figure 4.5: Mass spectrum of BAN derivatized ergothioneine from M. smegmatis. 
Mass spectrum of a compound that eluted at 22 minutes from in the HPLC run shown in 
Fig 4.4 of BAN derivatized M. smegmatis cell fraction. The major peak at 398.3 
corresponds to the BAN derivatized ergothioneine.  
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Figure 4.6: Mass spectrum of BAN derivatized mycothiol from M. smegmatis. Mass 
spectrum of a compound eluted at 23.45 minutes in the HPLC run of Fig 4.4. The major 
peak at 655.7 corresponds to the BAN derivatized mycothiol. These results were of the 
M. smegmatis culture not treated with any halogenated histidines. The peak at 677.6 is 
probably a sodiated species, but the ones at 674.6 and 672.5 are difficult to assign. 
 
 
 
4.3.4. Effect of halohistidines on ergothioneine biosynthesis 
 
Having successfully separated the ergothioneine derivative from the mycothiol derivative 
the effect of halohistidines on the biosynthesis of ergothioneine in M smegmatis could 
then be investigated. The peak area of mycothiol peak at 23.45 min was used to correct 
any variation on ergothioneine, the assumption being that mycothiol production would 
not be affected by halogenated histidines.  
 
The cells were first grown to the early stationary phase before they were treated with 
halogenated histidines (OD600 of 9.6). Due to its toxicity cells were only then treated with 
500 nM 2-fluorohistidine, while for the other compounds concentrations of 250 μM were 
used. The cells were harvested, thiols derivatized by BAN and the mixtures analysed by 
HPLC. The effect of halogenated histidines on ergothioneine biosynthesis was monitored 
by changes in ergothioneine peak area relative to a control which contained histidine. 
Ergothioneine produced in control sample was regarded as 100%.  
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Figure 4.7: Inhibition of ergothioneine biosynthesis by 5-halogenated histidines. 
Ratios (ergothioneine/mycothiol) of BAN derivatized ergothioneine to BAN derivatized 
mycothiol showing the effect of halogenated histidines on ergothioneine biosynthesis in 
M. smegmatis. The cultures were treated with 250 μM halogenated histidines except for 
2-fluorohistidine, in which case the concentration was 500nM. The ratios indicated are 
averages of two determinations. 
 
The 5-halohistidines showed significant inhibition of ergothioneine formation, with 5-
fluorohistidine showing most inhibition at over 40% (table 4.2). In contrast 2-
fluorohistidine did not show any significant reduction in ergothioneine amounts, perhaps 
due to the low concentration used for the compound. Use of higher concentrations than 
250 μM would have provided crucial information about the effect of 5-halogenated 
histidine on ergothioneine biosynthesis, but toxicity observed at concentration above 250 
μM prevented such a study.  
 
Table 4.2: Inhibition of ergothioneine biosynthesis by 5-halogenated histidines  
Compound 2-F-His 5-F-His 5-Cl-His 5-Br-His 5-Iodo-His 
ESH inhibition (%) 5 42 31 25 33 
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The validity of a study of the effect of compounds on a biosynthetic pathway using whole 
cells would be limited by the possibility that the substrate may be channelled into other 
pathways. For example, the toxicity of 2-fluorohistidine suggests that the compound may 
have been used up in a manner other than in the ergothioneine biosynthetic pathway since 
the compound’s toxicity did not correlate with ergothioneine reduction. Furthermore it 
should be pointed out that when this work was conducted, no enzymes of ergothioneine 
and ovothiol biosynthetic pathway were available. With all enzymes in both pathways 
now identified, it will be crucial to re-investigate the effect of halogenated histidines on 
ergothioneine biosynthesis.  
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CHAPTER 5:  GENERAL DISCUSSION 
 
Ovothiol is a 3-methyl-5-mercaptohistidine which was discovered in sea urchin eggs and 
later isolated from other organisms including pathogenic trypanosomes. The ovothiol 
biosynthetic pathway was first elucidated using a cell extract of Crithidia fasciculata 
(Vogt et al., 2001). Following elucidation of the corresponding genomes the sulfoxide 
synthase activity was purified from homologous genes in E. tasmaniensis and 
Trypanosoma cruzi and was named OvoA (Braunshausen and Seebeck, 2011). OvoA was 
confirmed as an iron dependent enzyme that activates molecular oxygen to convert 
histidine and cysteine into 5-histidyl cysteine sulfoxide.  
 
Here recombinant OvoA was purified from E. coli B21 cells using Ni-NTA agarose as 
described before (Braunshausen and Seebeck, 2011) and SDS-Page analysis showed that 
the enzyme was more than 90% homogenous (figure 3.1). Components of the OvoA 
reaction mixture were separated on HPLC using ion exchange column and the reaction 
products were monitored by absorption at 220 nm and 254 nm wavelengths while the 
histidine substrate had absorption only at 220 nm. HPLC was able to detect as little as 30 
ng of the sulfoxide product from the OvoA reaction mixture (calibration curve, 
appendix). The isolated sulfoxide products were identified by mass and strong 
absorbance at 254 nm. 
 
Assay optimization showed that addition of 2 mM ascorbate activated OvoA activity over 
100 fold (figure 3.3). A similar phenomenon has been reported in another nonheme iron-
dependent enzyme, where the ascorbate binding site was also found located in the 
enzyme pocket (Thrower et al, 2001). OvoA was also found to be activated to the same 
level by isoascorbate (D-ascorbate), the enantiomer of ascorbate (L-ascorbate). 
Isoascorbate activation of iron depend enzymes was also reported on prolyl hydrolase 
(Flashman et al., 2010). Nonheme iron enzyme are characterized by poor retention of the 
iron metal, but here OvoA was found to have retained about two thirds of the iron metal 
because addition of FeSO4 into the reaction mixture increased OvoA activity by about 
40% (figure 3.3). The optimal OvoA assay mixture was found to contain 20 mM NaCl, 
20 mM Tris-HCl, pH 8.0, 2 mM TCEP and 1 μM FeSO4 at 26
oC.  
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
107 
 
 
OvoA was characterized by histidine and cysteine KM of 339 and 347 μM, respectively. 
The enzyme was found to be most active at pH 7.5 flanked by acid and alkaline pKas of 
6.8 and 8.0 respectively (table 3.1), which indicated the presence of ionizable groups that 
affected the reaction. The ionizable group with pKa of 6.8 was believed to be the 
imidazole of the histidine substrate. At high pH the enzyme was thought to be limited by 
ionization of the cysteine side chain, or perhaps by a loss of iron metal above pH 9. The 
histidine KM was found to be low and constant between a pH of 6.0 and 8 (figure 3.5, B), 
indicating no effect of ionizable group on the enzyme reaction. Here, the effect of 
imidazole ionization on the enzyme reaction could not be confirmed by the use of 
histidinamide and histamine, histidine analogues which have low imidazole pKa, because 
the specific activity graphs produced with these analogues  showed a shift towards the 
alkaline instead of expected acidic side for substrate with lower pKa. The difference in 
amino acid group of these substrates compared to histidine introduced another variable 
which perhaps made these substrates not suitable candidates to study the effect of 
ionization group on OvoA reaction. A 2-fluorohistidine which has a very low pKa of 
about 1.0 (Wimalasena et al., 2007) would be a suitable substrate, but the compound was 
not available in sufficient amounts to perform the study.  
 
Table 5.1: Michaelis-Menten kinetics of OvoA substrates 
Substrate 
 
Vmax 
(x10-9M/s) 
OvoA 
(x10-9 M) 
Kcat 
(s-1) 
KM 
(x10-6 M) 
kcat/KM 
(s-1M-1) 
Histidine 943 ± 45 289 3.26 339 ± 22 9617 
Cysteine 920 ± 44 294 3.13 347 ± 27  9020 
Histidinamide 156 ± 3 371 0.42 308 ± 27 1364 
Histamine 99.9 ± 1.4  377 0.26 227 ± 6 1145 
D-Histidine  121 ± 0.06  346  0.35 818 ± 12   427 
 
 
Initial characterization of OvoA revealed the enzyme promiscuity towards sulfur 
acceptors while showing high specificity towards the sulfur donor. Histamine and 
histidinamide were turned over at about 5 times less efficiency than histidine, which is 
believed to be the enzyme’s natural substrate (table 3.1). The use of 4(5)-
methylimidazole as OvoA substrate and other histidine analogues bearing various 
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modifications at the amino acid part, indicated that the enzyme does not require the 
amino acid moiety for catalysis. However, the results provided some important 
information about the role played by the amino acid part in this reaction. When D-
histidine was used as substrate, the enzyme lost its selectivity towards C-5 as 
transsulfuration target location, because 2-D-histidyl cysteine sulfoxide was also 
identified as one of the reaction products (figure 3.11). It appears therefore that by 
changing the orientation of the amino acid functional group the specificity of the reaction 
is significantly affected.  
 
Histidine analogues that have modifications at the α-amino group were all sulfurated at 
the C-2 position of the imidazole ring, including 4(5)-methylimidazole, which does not 
have an amino acid group (figure 3.18). A further observation was that an increased 
degree of methylation on the histidine α-amino group resulted in increased formation of 
the C-2 sulfoxide product while reducing the amount of C-5 sulfoxide product (figure 
3.19 and figure 3.20). These results place interaction of α-amino group at the center of 
transsulfuration location in the enzyme. Perhaps the same interaction is the one 
separating ovothiol from ergothioneine biosynthetic systems, because the main difference 
between these two systems seems to be the position of transsulfuration (figure 3.2). 
 
Initial characterization of OvoA did not find a substrate kinetic isotope effect, suggesting 
that hydrogen abstraction was not a rate limiting step for the transsulfuration step 
(Braunshausen and Seebeck, 2011). The results reported here also did not find a solvent 
isotope effect because reaction in water was found to be only 1.2 times faster than in 
deuterium oxide under similar conditions (figure 3.8). Lack of solvent isotope effect 
perhaps means that proton exchange is not a rate limiting step for the OvoA mediated 
transsulfuration step either. Another important finding of this study was the fact that 
OvoA used 2-fluorohistidine as substrate, converting it into 2-fluorohistidyl cysteine 
sulfoxide at nearly the same rate as histidine (figure 3.14). The presence of fluorine at 
histidine C-2 was found to reduce the pKa of histidine imidazole group almost seven 
times, which makes the 2-fluorohistidine imidazole much more electron deficient 
(Wimalasena et al., 2007 and Yen et al., 1975).  
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The lack of a substrate kinetic isotope effect previously found by Braunshausen and 
Seebeck in 2011, lack of solvent isotope effect, and efficient turnover of electron 
deficient 2-fluorohistidine substrate found here led to a proposal about mechanistic 
aspects of the transsulfuration step catalyzed by OvoA. In some nonheme iron-dependent 
enzymes, the iron-metal complex generates high valent iron(IV)-oxo species which is 
believed to be the main initiator of substrate oxidation by abstracting a hydrogen atom 
from the substrates. However, such a route would be unlikely for electron poor substrates 
such as 2-fluorohistidine (pKa of about 1). Observed efficient turnover of 2-fluorohistide 
to the respective sulfoxide prompted a suggestion of a different mechanism from the one 
followed by many characterized nonheme iron-dependent enzymes scheme 3.1 
(Bruijnincx et al., 2008). The mechanism proposed here suggested that the cysteine thiyl 
radical, generated by enzyme iron(III)-superoxide, is the initiator of the transsulfuration 
reaction by attacking the histidine double bond, leading to homolytic cleavage of the C-H 
bond through hydrogen transfer to the iron(II)-superoxide to form iron-hydroperoxide. 
Through electron rearrangement, oxygen is then transferred to the sulfur and the iron 
returns to its ground state. 
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Scheme 5.1: Proposed catalytic mechanism of OvoA 
 
Inhibition of the OvoA reaction by histidine analogues revealed 5-fluorohistidine as a 
superior inhibitor resulting in 80% OvoA inhibition at inhibitor concentration 100 times 
more than the histidine substrate. Also, OvoA did not turn over 5-fluorohistidine into the 
respective 5-fluorohistidyl cysteine sulfoxide. Determination of inhibition constants of 5-
fluorohistidine would have provided crucial insights on inhibitor-enzyme interaction. 
However insufficient amounts of 5-fluorohistidine prevented such a study at this time. 
Other 5-halogenated histidines showed poorer inhibition of the enzyme from undetectable 
levels (5-iodohistidine) to 20% (4-chlorohistidine) (figure 3.9). It is speculated that this 
may be due to steric hindrance caused by the bulkier halogens.  
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Although OvoA turned over 4(5)-methylimidazole into the respective sulfoxide the 
enzyme did not use similar compounds, 4(5)-bromoimidazole and 4(5)-
hydroxymethylimidazole as substrates, and was not significantly inhibited by these 
compounds. The enzyme was moderately inhibited by imidazole, which showed almost 
50% inhibition. Because no measurable turnover was observed with imidazole substrate, 
the inhibition was not linked to two substrates competing for the enzyme activity. 
Imidazole and imidazole containing compounds are known metal chelators, so it could 
not be out ruled that imidazole inhibition of OvoA was through coordination to the 
enzyme metal center.  
 
OvoA promiscuity towards sulfur donors was however not extended to other aromatic 
compounds, as substitution of imidazole by pyridine and indole rings did not result in any 
measurable turnover of 2- and 3-pyridylalanine, and tryptophan, and none of the 
compounds exhibit significant inhibition of OvoA. Perhaps these results pointed to the 
small and restrictive catalytic pocket to which only imidazole can bind on OvoA. On the 
amino acid side, the enzyme did not turnover histidine analogues bearing α-N-amidation, 
and none of these compounds inhibited the enzyme, as seen with α-acetylhistidine and 
carnosine (figure 3.9 and figure 3.21). Perhaps, oxygen of the amide group dislocates the 
imidazole ring by interacting with other distant side chains of the enzyme or perhaps the 
active side consists of hydrophobic side chains which push oxygen containing compound 
away or again pointing to small and restrictive catalytic pocket of the enzyme. 
 
Sulfurization of 3-methylhistidine would suggest a possibility of another route to ovothiol 
biosynthesis, one which begins with methylation of the histidine imidazole prior to the 
sulfoxidation and lysis steps. However no measurable turnover by OvoA was observed 
with 3-methylhistidine substrate. Interestingly 3-methylhistidine inhibited up to 50% 
OvoA activity, perhaps suggesting a strong affinity to the enzyme (figure 3.9). This was 
an interesting result because ovothiol also contains a methyl group at a similar position. 
Although without sufficient data support it, such a modification may allow ovothiol to 
bind an allosteric site on the enzyme to regulate ovothiol biosynthesis in a feed-back 
inhibition mode. 
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When evaluated as potential inhibitors of ergothioneine biosynthesis in mycobacteria, 
halogenated histidine showed moderate to poor inhibition, ranging from 5 to 40% when 
used at 250 μM, with 5-fluorohistidine being the superior one (table 4.1). Because of 
observed high toxicity towards M. smegmatis, the concentration of 2-fluorohistidine was 
400 times less than others tested. It is possible that a 500 nm concentration was too low to 
evaluate 2-fluorohistidine as an inhibitor of ergothioneine biosynthesis. High toxicity of 
2-fluorohistidine was also observed in malaria (PANTON et al., 1988). The compound 
was also found to be incorporated into proteins (Eichler et al., 2005). With all the 
enzymes involved in ergothioneine now readily available (Seebeck, 2010), a new study of 
halogenated histidine on ergothioneine is possible. 
 
Availability of sulfoxide synthases (Seebeck, 2010 and Braunshausen and Seebeck, 2011) 
coupled with easier methods to synthesis halogenated histidine, (excluding fluorinated 
histidines) and other histidine analogues described here, provide opportunity to study the 
physiological roles played by such important biological metabolites as ovothiol and 
ergothioneine, and ultimately development of new site-targeted drugs against bacterial 
and trypanosomal diseases. 
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CONCLUSION: 
 
During the course of this work, halogenated histidine derivatives were chemically 
synthesized and evaluated as potential inhibitors or alternative substrates of OvoA. 
Recombinant E. tasmaniensis OvoA was expressed and purified from E. coli cells and 
then characterized. OvoA retained more than 60% of its iron and its activity increased 
over 100 fold with addition of 2 mM ascorbate and isoascorbate. OvoA was characterized 
by L-histidine an L-cysteine KM of 339 ± 22 and 347 ± 27, respectively. Specificity 
constants towards it natural substrates was found to be 9.6 x103 s-1M-1 and 9.0 x 103 s-1M-
1 for L-histidine and L-cysteine, respectively. The enzyme was found to be most active at 
pH 7.5, achieving catalytic constant of up to 3.2 s-1.  
 
Sulfur acceptor specificity study revealed that amino acid moiety of histidine is only 
required for transsulfuration location targeting but not for catalysis as 4(5)-
methylimidazole was turned over into the respective sulfoxide product. OvoA was found 
to turnover histidine, histamine and L-histidine into their respective sulfoxide products 
just about seven times less efficient than D-histidine. Interestingly 2-fluorohistidine was 
turned over at the same rate as L-histidine despite its imidazole ring being almost seven 
fold less electron deficient than that of L-histidine. There was no observed solvent 
isotope effect on OvoA reaction and 80% of the enzyme activity was inhibited by 5-
fluorohistidine. Modification of L-histidine at α-amino group resulted in increased 
transsulfuration at C-2 position of sulfur acceptor.  
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EXPERIMENTAL 
 
 
General Procedures 
 
Preparative: All solvents were freshly distilled. Benzene and toluene were distilled over 
sodium wire under nitrogen. Diethyl ether and tetrahydrofuran were distilled under 
nitrogen and dried over sodium wire with benzophenone. Dichloromethane was distilled 
over phosphorus pentoxide. Other solvents were purified according to standard 
procedures (Perrin and Armarego, 1988). The water used in the experimental work was 
distilled and deionized.  
 
Reactions were monitored by thin layer chromatography (tlc) using aluminium-backed 
precoated Merck silica gel 60 F254 plates and were visualized by dipping in 2% 
ninhydrin in methanol followed by heating at 150oC. Column chromatography was 
performed using Merck silica gel 60 (70-230 mesh) or Dowex 50 WX 2-200, H+ form. 
Typical work-up involved threefold extraction with organic solvents. All reagents were 
purchased from Aldrich, Merck or Bachem.  
 
Analytical: Melting points were determined using a Riechert-Jung Thermovar hot plate 
microscope and were uncorrected. Nuclear Magnetic Rosonance spectra were recorded 
on a Varian Unity 400 (100 MHz for 13C, 376.3 MHz for 19F) or Varian Mercury 300 
MHz (75 MHz for 13C) and carried out in d-chloroform unless otherwise stated. Chemical 
shifts (δ) were recorded using residual chloroform (δ 7.24 in 1H NMR and δ 77.00 in 13C 
NMR) or tetramethylsilane (δ 0.00) as an internal standard. For D2O, dioxane (δ 3.75 in 
1H NMR and δ 67.19 in13C NMR) was used as an internal standard. For CD3OD, the 
residual methanol peak (δ 3.31 in 1H NMR and δ 49.00 in 13C NMR) was used as an 
internal standard. All chemical shifts were reported in ppm.   
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tert-Butyl 1-(methoxycarbonyl)-2-(5-chloro-1H-imidazol-4-yl)ethylcarbamate (47a) 
 
                                        
HN N
O
O
HN
Cl
O
O
 
 
To a stirring solution of tert-butyl 1-(methoxycarbonyl)-2-(1H-imidazol-4-
yl)ethylcarbamate, 46, (0.2 g, 0.74 mmol) in acetonitrile (5 ml), N-Chlorosuccinimide 
(0.1 g, 0.75 mmol) in acetonitrile (2ml) was slowly added. The reaction mixture was 
stirred for two hours in the dark (flask covered with aluminium foil) under nitrogen. The 
reaction was stopped by removing the solvent in vacuo. The crude product was dissolved 
in small amount of dichloromethane and quickly transferred to a 50 ml column packed 
with 20 g of silica gel in petroleum ether. The column was eluted with ethyl acetate: 
petroleum ether (7:3) solution and the evaporation of the solvent afforded the product in 
as colourless oil (142 mg, 63%). δ H (300 MHz, CDCl3) 7.48 (1 H, s, H-2), 5.43 (1 H, s, 
N-H) 4.48 (1 H, s, -CH), 3.75 (3 H, s, OCH3), 3.09 (2 H, ddd, J 6.3, 15.3, 22.3, -CH2), 
1.41 (9 H, s, 3(CH3)). δ C (75 MHz, CDCl3) 171.91, 133.36, 120.64, 52.81, 29.58, 28.21, 
27.94, 27.59. 
 
2-Amino-3-(4-chloro-1H-imidazol-5-yl)propanoic acid (5-chlorohistidine) (7) 
 
 
 
 
 
To a solution of tert-butyl 1-(methoxycarbonyl)-2-(5-chloro-1H-imidazol-4-
yl)ethylcarbamate, 47a, (0.1 g, 0.33 mmol) in methanol (5 ml) was added LiOH (0.024 g, 
0.99 mmol) and the mixture was stirred for 3 hours at room temperature. Water (30 ml) 
was added and the aqueous mixture was extraction with ethyl acetate (2 x 50 ml). The 
organic phase was washed with saturated NaCl solution (50 ml) and dried over MgSO4. 
N NH
NH2
CO2H
Cl
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
115 
 
HN N
O
O
HN
Br
O
O
Evaporation of the solvent afforded an oily residue which was dissolved in 20% TFA in 
DCM (5 ml) and stirred for 2 h. The solvent was evaporated and the resulting oily residue 
was dissolved in 1mM HCl (3 ml) and transferred onto an ion exchange column (Dowex 
50 WX 2-200, H+ form). The column was washed with water until the eluent pH was 
neutral before the product was eluted with 10% NH4OH solution. Evaporation of the 
solvent afforded the product as brown solid (40.7 mg, 65%).  M + H: 190.0 (exp), 190.1 
(obt).δ H (300 MHz, D2O) 7.52 (1 H, s, H-2), 3.84 (1 H, t, J 6.0, -CH), 3.11 (2 H, qd, J 
6.4, 15.6, -CH2). 
 
 
tert-Butyl 1-(methoxycarbonyl)-2-(5-bromo-1H-imidazol-4-yl)ethylcarbamate (47b)  
 
 
 
 
 
 
 
To a stirring solution of tert-butyl 1-(methoxycarbonyl)-2-(1H-imidazol-4-
yl)ethylcarbamate, 46, (0.2 g, 0.74 mmol) in acetonitrile (5 ml) in a 25 ml two necked 
round bottomed flask covered with an aluminium foil, under nitrogen atmosphere, N-
bromosuccinimide (0.13 g, 0.75 mmol) in acetonitrile (2 ml) was slowly added. After 
stirring for two hours the reaction was stopped by removing the solvent in vacuo. The 
crude product was dissolved in small amount of dichloromethane and quickly transferred 
on a 50ml column packed with 20 g of silica gel in petroleum ether. The column was 
eluted with ethyl acetate: petroleum ether (7:3) solution. Evaporation of the solvent gave 
the product as colourless oil (172 mg, 67%). δ H (400 MHz, CDCl3) 7.56 (1 H, s, H-2), 
5.47 (1 H, s, N-H), 4.48 (1 H, s, -CH), 3.62 (3 H, s, OCH3), 3.08 (1 H, dd, J 5.7, 15.2, -
CH), 3.02 – 2.89 (1 H, m, -CH), 1.38 (9 H, s, 3(CH3)). 
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2-amino-3-(4-bromo-1H-imidazol-5-yl)propanoic acid (5-bromohistidine) (8)  
 
 
 
 
 
To a solution of (tert-butyl 1-(methoxycarbonyl)-2-(5-bromo-1H-imidazol-4-
yl)ethylcarbamate, 47b, (0.1 g, 0.29 mmol) in methanol (5 ml) was added LiOH (0.021 g, 
0.87 mmol) and the mixture was stirred for 3 hours at room temperature. Water (30 ml) 
was added and the aqueous mixture was extraction with ethyl acetate (2 x 50 ml). The 
organic phase was washed with saturated NaCl solution (50 ml) and dried over MgSO4. 
Evaporation of the solvent afforded an oily residue which was dissolved in 20% TFA in 
DCM (5 ml) and stirred for 2 h. The solvent was evaporated and the resulting oily residue 
was dissolved in 1 mM HCl (3 ml) and transferred onto ion exchange column (Dowex 50 
WX 2-200, H+ form). The column was washed with water until the eluent pH was neutral 
before the product was eluted with 10% NH4OH solution. Evaporation of the solvent 
afforded the product as brown solid (42 mg, 62%). M + H: 233.98 (exp), 234.0 (obt). δ H 
(400 MHz, CD3OD) 8.99 (1 H, s, H-2), 4.39 (1 H, dt, J 7.3, 30.5, -CH), 3.39 (2 H, qd, J 
7.6, 15.6, -CH2). 
 
tert-Butyl 1-(methoxycarbonyl)-2-(5-iodo-1H-imidazol-4-yl)ethylcarbamate (47c) 
and tert-butyl 1-(methoxycarbonyl)-2-(2,5-diiodo-1H-imidazol-4-yl)ethylcarbamate 
(56) 
 
 
 
 
 
 
 
To a stirring solution of tert-butyl 1-(methoxycarbonyl)-2-(1H-imidazol-4-
yl)ethylcarbamate, 46, (0.2 g, 0.74 mmol) in acetonitrile (5 ml) in a 25ml two necked 
HN N
O
O
HN
I
O
O
47c
HN N
O
O
HN
I
O
O
I
56
N NH
NH2
CO2H
Br
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round bottomed flask covered with an aluminium foil, under nitrogen atmosphere, N-
iodosuccinimide (0.20, 0.9 mmol)  in acetonitrile (2 ml) was slowly added. After stirring 
for two hours the reaction was stopped by removing the solvent in vacuo. The crude 
product was dissolved in small amount of dichloromethane and quickly transferred on a 
50ml column packed with 20 g of silica gel in petroleum ether. The column was eluted 
with ethyl acetate: petroleum ether (7:3) solution. The products were obtained as 
colourless oil, 47c (170 mg, 58%) and 56 (116 mg, 30%). 
47c: δ H (300 MHz, CDCl3) 7.59 (1 H, s, H-4), 5.41 (1 H, s, N-H), 4.52 (1 H, d, J 7.3, -
H), 3.15 (1 H, dd, J 5.3, 15.4, -H), 3.01 (1 H, dd, J 6.4, 15.4, -H), 1.47 – 1.38 (9 H, m, 
3(CH3)).  
 
56: δ H (300 MHz, CDCl3) 5.41 (1H, s, N-H), 4.56 (1H, m, -CH), 3.79(3H, s, OCH3), 
3.42 – 2.94 (2H, m, -CH2), 1.45 (9H, s, 3(CH3)) 
 
 
2-amino-3-(4-iodo-1H-imidazol-5-yl)propanoic acid (5-iodohistidine) (9) 
 
 
 
 
 
To a solution of (tert-butyl 1-(methoxycarbonyl)-2-(5-iodo-1H-imidazol-4-
yl)ethylcarbamate, 47c, (0.08 g, 0.2 mmol) in 5 ml methanol was added LiOH (0.014 g, 
0.6 mmol) and the mixture was stirred for 3 hours at room temperature. Water (30 ml) 
was added and the aqueous mixture was extraction with ethyl acetate (2 x 50 ml). The 
organic phase was washed with saturated NaCl solution (50 ml) and dried over MgSO4. 
Evaporation of the solvent afforded an oily residue which was dissolved in 20% TFA in 
DCM (5 ml) and stirred for 2 h. The solvent was evaporated and the resulting oily residue 
was dissolved in 1 mM HCl (3 ml) and transferred onto ion exchange column (Dowex 50 
WX 2-200, H+ form). The column was washed with water until the eluent pH was neutral 
before the product was eluted with 10% NH4OH solution. Evaporation of the solvent 
afforded the product as brown solid (36.5 mg, 65%). M + H: 281.97 (exp), 282.0 (obt). δ 
N NH
NH2
CO2H
I
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H (400 MHz, D2O) 7.69 (1 H, s, H-2), 3.96 – 3.83 (1 H, m, -CH), 3.11 (2 H, ddd, J 6.5, 
15.5, 23.1, -CH2). 
 
N-(1-hydroxy-3-(1H-imidazol-4-yl)propan-2-yl)benzamide (73) 
 
 
 
 
 
 
Into a stirring solution of methyl 2-(benzamido)-3-(1H-imidazol-4-yl)propanoate, 72, (5 
g, 18.3 mmol) in anhydrous methanol (50 ml) at 50oC, NaBH4 (2.8 g, 74.0 mmol) was 
added in portions, every portion added after the effervescence had stopped. The reaction 
was allowed to stir at the same temperature for 2 hours. The solvent was removed in 
vacuo to afford crude product as a white solid. The crude product was treated with water 
(200 ml) and then neutralized with 2 M HCl solution. The product was extracted with hot 
ethyl acetate (4 x 200 ml). The ethyl acetate was removed in vacuo to give the product a 
white product (3.1 g, 68%). δ H (300 MHz, CD3OD) 7.84 – 7.73 (2 H, m, phenyl), 7.57 
(1 H, s, 2-H), 7.54 – 7.37 (3 H, m, phenyl), 6.88 (1 H, s , 4-H ), 4.36 (1 H, dq, J 5.6, 8.0, 
-H), 3.65 (2 H, t, J 5.7, CH2), 2.94 (2 H, qd, J 7.0, 14.9, -H2).  
 
 
N-(1-hydroxy-3-(1-tosyl-1H-imidazol-4-yl)propan-2-yl)benzamide (74) 
 
 
 
 
 
 
 
A stirring suspension of N-(1-hydroxy-3-(1H-imidazol-4-yl)propan-2-yl)benzamide, 73, 
(2.5 g, 6.26 mmol) and triethylamine (5.45 ml, 37.56 mmol) in dichloromethane (40 ml) 
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was cooled to 0oC on ice bath before a solution of para-toluenesulfonyl chloride (2.5 g, 
13.11 mmol) was slowly added. The ice bath was removed and the mixture was allowed 
to react at room temperature for 24 hours, at which point tlc (ethyl acetate and petroleum 
ether (9:1) as eluent) showed complete consumption of the starting material. The reaction 
was quenched with saturated NH4Cl solution (100 ml) and extracted with 
dichloromethane (3 x 100 ml). The organic layer was washed with saturated NaHCO3 
solution (100 ml), once with distilled water (500 ml) and then saturated NaCl solution 
(300 ml). The organic phase was dried over MgSO4. The solvent was removed by 
evaporation to afford a crude product which was purified by silica column using a 
mixture of ethyl acetate and petroleum ether (9:1) to give the product as colourless oil 
(1.65 g, 66%). δ H (300 MHz, CDCl3) 7.96 (1 H, d, J 1.3, 4-H (imida)), 7.75 (4 H, ddt, J 
1.8, 6.9, 9.7, phenyl and tosyl), 7.52 – 7.44 (1 H, m, phenyl), 7.43 – 7.33 (3 H, m, phenyl 
and N-H), 7.30 (2 H, d, J 8.0, tosyl), 7.13 (1 H, d, J 1.2, 2-H (imida)), 4.32 (1 H, dd, J 4.5, 
11.9, -H), 3.74 (1 H, dd, J 4.5, 11.4, -Ha), 3.62 (1 H, dd, J 4.5, 11.4, -Hb), 2.94 (2 H, 
dd, J 5.5, 6.9, CH2), 2.41 (3 H, s, CH3, tosyl). δ C (75 MHz, CDCl3) 167.62, 146.37, 
140.91, 136.33, 134.69, 134.16, 131.47, 130.43, 128.46, 127.30, 126.98, 115.04, 64.56, 
51.33, 29.13, 21.67. 
 
 
 
4-((4,5-dihydro-2-phenyloxazol-4-yl)methyl)-1-tosyl-1H-imidazole (75) 
 
 
 
 
 
 
 
 
Method A: To a stirring solution of para-toluene sulfonyl chloride (5.85 g, 30.68 mmol) 
in dry dichloromethane (40 ml) on ice, triethylamine (15 ml, 107.6 mmol) was slowly 
added. The resulting mixture was stirred for 20 minutes until brown colour developed 
before N-(1-hydroxy-3-(1-tosyl-1H-imidazol-4-yl)propan-2-yl)benzamide, 73, (5.85 g, 
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14.64 mmol) in DCM (12 ml) was slowly added. The mixture was stirred for 20 minutes 
before the ice bath was removed. The stirring continued overnight before the reaction was 
stopped with saturated NaHCO3 solution (100 ml) and extracted three times with DCM 
(200 ml). The organic phase was washed with water (400 ml) and saturated NaCl solution 
(200 ml) before dried over MgSO4. Upon removal of the solvent by evaporation the crude 
sample was loaded on silica gel and eluted with ethyl acetate-petroleum ether (7:3) 
mixture. The product was obtained as white crystals after the solvent was removed (4.58 
g, 82%). mp 133oC. M + H: 382.1 (exp), 382.1 (obt). δ H (400 MHz, CDCl3) 7.96 – 7.86 
(3 H, m, phenyl and 2-H (imida)), 7.80 – 7.70 (2 H, m, tosyl), 7.55 – 7.44 (1 H, m, 
phenyl), 7.44 – 7.37 (2 H, m, phenyl), 7.29 (2 H, dd, J 0.5, 8.5, tosyl), 7.13 (1 H, d, J 1.3, 
4-H (imida)), 4.60 (1 H, dtd, J 5.3, 7.5, 12.8, -H), 4.44 (1 H, dd, J 8.5, 9.4, CHa), 4.20 
(1 H, dd, J 7.5, 8.5, CHb), 3.04 (1 H, dd, J 4.6, 14.8, Ha), 2.76 (1 H, dd, J 7.6, 15.0, -
Hb), 2.43 (3 H, s, CH3, tosyl). δ C (101 MHz, CDCl3) 164.19, 146.07, 141.53, 136.27, 
136.16, 135.08, 131.41, 130.40, 130.28, 128.32, 128.23, 127.72, 127.31, 127.20, 114.59, 
114.48, 72.05, 65.90, 65.78, 34.06, 21.69. 
 
Method B: Into a stirring solution of 5-iodo-4-((4,5-dihydro-2-phenyloxazol-4-
yl)methyl)-1-tosyl-1H-imidazole, 80a, (0.17 g, 0.33 mmol) in THF (2 ml) in an acetone-
liquid nitrogen bath under nitrogen, n-butyllithium (300 μl, 0.48mmol, 1.6 M in hexane) 
was added drop-wise over 3 minutes. After 3 minutes a sample (about 50 μl) was 
quenched with water and analysed by tlc using ethyl acetate-petroleum ether (2:3) as the 
mobile phase. TLC showed a complete metal and halogen exchange after 3 minutes. 
Water (2 ml) was added into the reaction mixture and the reaction mixture was allowed to 
warm. While at room temperature, saturated NH4Cl (50 ml) solution was added followed 
by extraction with DCM (2 x 50 ml). The organic phase was washed with 50 ml distilled 
water (50 ml) and then saturated NaCl solution (50 ml) solution before dried over MgSO4 
salt. Removal of the solvent by evaporation afforded a brown residue which was purified 
by chromatography using ethyl acetate-petroleum ether (2:3) as the mobile phase to give 
the product as a white solid (63 mg, 50%). δ H (400 MHz, CDCl3) 8.14 (1 H, d, J 1.0), 
7.98 – 7.87 (2 H, m), 7.83 – 7.72 (2 H, m), 7.53 – 7.45 (1 H, m), 7.45 – 7.38 (2 H, m), 
7.33 (2 H, ddd, J 0.6, 8.6, 27.5), 6.92 (1 H, q, J 1.0), 4.65 – 4.52 (1 H, m), 4.45 (1 H, dt, J 
8.2, 9.4), 4.03 (1 H, dt, J 7.2, 14.3), 3.18 – 2.69 (2 H, m), 2.48 – 2.38 (3 H, m). 
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4-((4,5-dihydro-2-phenyloxazol-4-yl)methyl)-1H-imidazole (76) 
 
 
 
 
 
 
A solution of 4-((4,5-dihydro-2-phenyloxazol-4-yl)methyl)-1-tosyl-1H-imidazole, 75, 
(6.5 g, 17.06 mmol) in mixture of anhydrous methanol (30 ml) and THF (2:1) was 
transferred in a flask containing Cs2CO3 (6.11 g, 18.8 mmol). The mixture was stirred at 
50oC for two hours, at which point a tlc showed total consumption of the starting 
material. The product was purified by flash chromatography using ethyl acetate and 
methanol (8:2) and the evaporation of the solvent afforded the product as a colourless 
wax (3.33 g, 86%). δ H (400 MHz, CD3OD) 7.95 – 7.84 (2 H, m, phenyl), 7.60 (1 H, s, 4-
H (imida)), 7.52 (1 H, t, J 7.4, phenyl), 7.43 (2 H, dd, J 6.9, 8.2, phenyl), 6.88 (1 H, s, 4-
H (imida)), 4.59 (1 H, dd, J 7.4, 14.6, -H), 4.48 (1 H, t, J 9.0, CHa), 4.31 – 4.19 (1 H, m, 
CHb), 3.06 (1 H, dd, J 5.2, 14.7, -Ha), 2.81 (1 H, dd, J 7.8, 14.6, -Hb). δ C (101 MHz, 
CD3OD) 135.05, 131.75, 128.62, 128.37, 128.13, 127.35, 125.79, 117.37, 72.11, 65.92, 
48.45, 48.03, 47.81, 47.39, 32.49. 
 
4-((4,5-dihydro-2-phenyloxazol-4-yl)methyl)-5-iodo-1H-imidazole (78) 
 
 
 
 
 
 
 
Method A: Into a stirring solution of 4-((4,5-dihydro-2-phenyloxazol-4-yl)methyl)-1H-
imidazole, 76, (3.8 g, 13.71 mmol) in anhydrous DMF (15 ml) in the dark (flask covered 
by aluminium foil) under nitrogen atmosphere, 1.5g N-iodosuccinimide (1.5 g, ) in 
acetonitrile (15 ml) was added. After 2 hour of stirring at room temperature, tlc indicated 
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a complete conversion of the starting material. The solvent was removed in vacou and the 
crude product was purified by silica gel chromatography eluted with a mixture of ethyl 
acetate and petroleum ether (9:1) to give the product as a yellow solid (1.4 g, 29%). M + 
H: 353.0 (exp), 354.0 (obt).  δ H (400 MHz, CD3OD) 7.93 (2 H, dt, J 1.7, 8.5, phenyl), 
7.64 (1 H, s, 2-H (imida)), 7.57 – 7.48 (1 H, m, phenyl), 7.48 – 7.38 (2 H, m, phenyl), 
4.58 (1 H, ddd, J 6.8, 9.4, 13.2, -H), 4.52 – 4.42 (1 H, m, CHa), 4.27 (1 H, dd, J 6.8, 8.6, 
CHb), 2.96 (1 H, dd, J 6.2, 14.7, -Ha), 2.84 (1 H, dd, J 7.0, 14.7, -Hb).  
 
Method B: Sodium methoxide (0.374 g, 6.92 mmol) was reacted with thiophenol (0.71 
ml, 6.92 mmol) in isopropanol (10 ml). When all the bubbling had stopped, 4-((4,5-
dihydro-2-phenyloxazol-4-yl)methyl)-2,5-diiodo-1H-imidazole, 77, (1.5g, 3.13 mmol) 
was added and the reaction mixture was allowed to continue stirring overnight at room 
temperature. The reaction was stopped with addition of saturated NaHCO3 solution (100 
ml) and extracted with ethyl acetate (3 x 50 ml). The organic phase was washed with 
water (200 ml) and then saturated NaCl solution (100 ml) before dried over MgSO4. The 
solvent was evaporated and the residue was purified by chromatography using ethyl 
acetate-petroleum ether (9:1) to give a yellow solid (0.82 g, 74%).  
 
 
4-((4,5-dihydro-2-phenyloxazol-4-yl)methyl)-2,5-diiodo-1H-imidazole (77) 
 
 
 
 
 
 
 
Synthetic procedure is the same as Method A for 78 above (3.7 g, 56%). M + H: 479.9 
(exp), 479.9 (obt). δH (400 MHz, CD3OD) 7.90 (2 H, dt, J 1.6, 8.5, phenyl), 7.56 – 7.48 
(1 H, m, phenyl), 7.42 (2 H, tt, J 1.1, 8.3, phenyl), 4.55 (1 H, dt, J 6.6, 13.6, -H), 4.49 – 
4.41 (1 H, m, CHa), 4.26 (1 H, dd, J 6.7, 8.6, CHb), 2.96 (1 H, dd, J 6.0, 14.6, -Ha), 2.78 
(1 H, dd, J 7.6, 14.5, -Ha). 
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4-((4,5-dihydro-2-phenyloxazol-4-yl)methyl)-5-iodo-1-tosyl-1H-imidazole (80a) 
 
 
 
 
 
 
 
Into a cold (ice bath) mixture of 4-((4,5-dihydro-2-phenyloxazol-4-yl)methyl)-5-iodo-1H-
imidazole, 78, (1.045 g, 2.96 mmol) and (triethylamine 1.8 ml, 40 mmol) in THF (10 ml), 
para-toluenesulfonyl chloride (0.85 g, 4.44 mmol) in DCM (10 ml) was added. The ice 
bath was removed and the mixture was stirred overnight. Saturated NaHCO3 solution 
(100 ml) was added into the mixture and the extraction was done three times with DCM 
(200 ml). The DCM layer portion was washed with water (200 ml), saturated NaCl 
solution (200 ml) and dried over MgSO4. The evaporation of the solvent afforded an oily 
residue which was purified by chromatography to give the product as a white solid (1.3 g, 
86%). M + H: 508.0 (exp), 508.0 (obt). δ H (400 MHz, CDCl3) 8.38 (1 H, s, 2-H 
(imida)), 7.91 (4 H, ddt, J 1.7, 4.0, 8.7, phenyl and tosyl), 7.52 – 7.43 (1 H, m, phenyl), 
7.44 – 7.32 (4 H, m, phenyl and tosyl), 4.64 (1 H, tdd, J 5.0, 7.2, 9.1, -H), 4.48 – 4.38 (1 
H, m, CHa), 4.27 (1 H, dd, J 7.3, 8.6, CHb), 3.06 (1 H, dd, J 5.0, 14.5, -Ha), 2.68 (1 H, 
dd, J 9.0, 14.6, -Hb), 2.46 (3 H, s, CH3, tosyl). δ C (101 MHz, CDCl3) 164.22, 147.65, 
146.50, 140.95, 134.03, 131.31, 130.16, 128.60, 128.35, 128.26, 127, 65.95, 65.51, 34.58, 
21.79, 
 
tert-Butyl 2-((benzyloxy)carbonyl)-1-(methoxycarbonyl)ethylcarbamate (59) 
 
 
 
 
 
To a stirring solution of, 58, 20 g 32 (20g, 61.85 mmol) in DMF (100 ml) at room 
temperature under an atmospheric air, K2CO3 (9 g, 65.12 mmol) was added. The 
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suspension was stirred for further 15 minutes before a cold (4oC) aliquot of methyl iodide 
(12 ml, 192.67 mmol) was slowly added. The reaction mixture was stirred for two hours 
when a tlc with ethyl acetate: petroleum ether, 7: 3 as mobile phase showed the complete 
consumption of the starting material. At this point water (400 ml) was added and the 
product was extracted three times with a total of diethyl ether (40 ml). The combined 
ether fractions were washed twice with water (500 ml) before dried over Mg2SO4.  The 
diethyl ether was removed in vacou to afford 20.3 g the product as a white solid in (20.3 
g, 98%), which did not require any further purification. δ H (400 MHz, CDCl3) 7.41 – 
7.28 (5 H, m, aromatic), 5.11 (2 H, dd, J 4.8, 10.1, CH2), 5.52 (1 H, s, N-H), 4.59 (1 H, s, 
-H), 3.69 (4 H, d, J 5.3, OCH3), 2.95 (1 H, d, J 0.4, -H), 2.87 (1 H, t, J 2.0, -H), 1.44 
(10 H, s, C(CH3)3). 
 
 
 
tert-Butyl 1,4-dihydroxybutan-2-ylcarbamate (60) 
 
 
 
 
 
 
 
 
 
Into a tert-butyl 2-((benzyloxy)carbonyl)-1-(methoxycarbonyl)ethylcarbamate, 59, (20.3 
g, 60.17 mmol) in a 500 ml round bottom flask fitted with a condenser, methanol (100 
ml) was added followed by THF (25 ml). The reaction mixture was stirred to afford a 
complete dissolution before NaBH4 (12 g, 317.21 mmol) was added in portions. Caution: 
care should be taken when adding NaBH4 to avoid losing material through effervescence 
as the reaction mixture gets hot and bubbles. After all the NaBH4 was added the reaction 
was incubated for further 20 minutes and a tlc with ethyl acetate: petroleum ether (7:3) as 
mobile phase showed a complete consumption of the starting material. Ethyl acetate (100 
ml) was added and the reaction mixture was stirred for one hour before all the solvent 
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was removed in vacuo. DCM (400 ml) was added in the mixture to form suspension 
which was filtered over celite and the celite was washed with DCM (50 ml). The solvent 
was reduced by evaporation before silica (100 g) was added. The solvent was removed 
and the dry silica was transferred on to a column pre-packed with a 130 g of silica. The 
column was first washed with ethyl acetate-petroleum ether (3:2). The product was eluted 
with H2O-MeOH-EtoAc (1:2:17). The eluent was dried over MgSO4 before the solvent 
was removed in vacou to give the product as an  of oil (12 g, 74%). δ H (400 MHz, 
CDCl3) 5.02 (1 H, s, N-H), 3.82 (1 H, s, -H), 3.64 (4 H, ddd, J 5.8, 11.1, 15.6, 2(CH2)), 
3.36 – 3.04 (1 H, m, O-H), 2.81 – 2.52 (1 H, m, O-H), 1.78 (2 H, ddd, J 4.8, 9.3, 18.7, -
H2), 1.42 (9 H, s, 3(CH3)). δ C (101 MHz, CDCl3) 157.02, 79.96, 65.38, 58.81, 49.47, 
34.84, 28.34. 
 
 
 
tert-Butyl 4-(2-hydroxyethyl)-2,2-dimethyloxazolidine-3-carboxylate (61) 
 
 
 
 
 
 
 
Into a stirring solution of tert-butyl 1,4-dihydroxybutan-2-ylcarbamate, 60, (11.95 g, 
58.22 mmol) in DCM (30 ml) under nitrogen, 2,2-dimethoxypropane (60 ml, 502.42 
mmol) was added followed by p-toluenesulfonic acid (1 g, 5.82 mmol). The reaction 
mixture was left stirring overnight at room temperature. The solvent was removed by 
evaporation to afford a yellow solid which was purified by a silica column to obtain the 
product in yield as a white solid (6 g, 42%). δ H (300 MHz, CDCl3) 4.19 (1 H, s, -H), 
3.99 (2 H, dd, J 5.5, 8.6, CH2), 3.68 (2 H, d, J 8.6, CH2), 1.91 – 1.64 (2 H, m, -H2), 1.53 
(3 H, s, CH3, oxa), 1.48 (12 H, d, J 2.6, 3(CH3) and CH3, oxa). δ C (75 MHz, CDCl3) 
93.62, 80.89, 68.22, 58.68, 54.00, 37.74, 28.32, 27.72, 24.35. 
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tert-Butyl 2,2-dimethyl-1,3-dioxepan-5-ylcarbamate (62) 
 
 
 
 
 
 
 
Similar reaction conditions to those described for the synthesis of 61 above were used 
here, (2.7 g 19%). δ H (300 MHz, CDCl3) 5.14 (1 H, s, H-H), 3.73 (3 H, ddd, J 7.0, 12.4, 
13.4, -H and CH2), 3.63 – 3.44 (2 H, m, CH2), 1.84 – 1.60 (2 H, m, -H2), 1.45 (9 H, d, 
J 7.7, 3(CH3)), 1.31 (6 H, d, J 4.8, 2(CH3)). δ C (75 MHz, CDCl3) 155.13, 101.37, 79.25, 
77.41, 64.00, 57.98, 48.61, 35.83, 28.39, 24.87, 24.70. 
 
tert-Butyl 4-(formylmethyl)-2,2-dimethyloxazolidine-3-carboxylate (63) 
 
 
 
 
 
 
 
 
Oxalyl chloride (0.74 ml, 8.5 mmol) was added to DCM (18 ml) and the solution cooled 
to -78oC in an acetone-liquid nitrogen cold bath. To the solution, DMSO (1.14 ml, 16 
mmol) in DCM (5 ml) was slowly added and the reaction was stirred for 30 minutes. A 
portion of tert-butyl 4-(2-hydroxyethyl)-2,2-dimethyloxazolidine-3-carboxylate, 61, (1.3 
g, 5.3 mmol) dissolved in DCM (10ml) was added drop wise. After stirring the reaction 
for another 30 minutes triethylamine (4.3 ml, 31 mmol) was added. The reaction mixture 
was allowed to stir for 30 minutes at the same temperature before allowing it to warm up. 
Water was added and the mixture was extracted three times with DCM (200 ml). The 
organic layer was collected and dried over MgSO4 before removed by evaporation. 
Material was loaded on a silica column and eluted with ethyl acetate-petroleum ether 
O O
NHO
O
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(1:9) mixture. The product was obtained as a white crystal (1.1 g, 84%); δ H (400 MHz, 
CDCl3) 9.79 (1 H, s, COH), 4.36 (1 H, s, -H), 4.18 – 4.01 (1 H, m, CHa), 3.73 (1 H, dd, 
J 1.5, 9.3, CHb), 2.85 (2 H, d, J 124.3, -H2), 1.58 (3 H, d, J 17.8), 1.48 (12 H, s). δ C 
(101 MHz, CDCl3) 200.34, 67.90, 67.54, 52.68, 48.36, 47.46, 28.41, 27.51, 24.48. 
 
 
tert-Butyl 4-(2-(4-((4,5-dihydro-2-phenyloxazol-4-yl)methyl)-1-tosyl-1H-imidazol-5-
yl)-2-hydroxyethyl)-2,2-dimethyloxazolidine-3-carboxylate (82) 
 
 
 
 
 
 
 
 
A 80a (1.01 g, 2.0 mmol) was added in a dry round bottomed flask (flamed dried under 
nitrogen)). THF (20 ml) was then added and the solution was stirred vigorously. The 
flask was cooled over acetone-liquid nitrogen bath and left for about 20 minutes. An n-
butyllithium (2 ml, 3.2 mmol, 1.6 M in hexane) was added drop-wise over 10 minutes. 
The reaction was monitored by tlc every 20 minutes by sampling 50 μl from the reaction 
mixture, quenched with water (500 μl) and extracted with DCM (200 μl). When all the 
starting material was completely converted, tert-butyl 4-(formylmethyl)-2,2-
dimethyloxazolidine-3-carboxylate, 63, (0.73 g, 3mmol) in THF (5 ml) was slowly 
added. The reaction mixture was left stirring for 1 hour at -78oC before allowed to warm 
to room temperature. The reaction was stopped with saturated NH4Cl (50 ml) solution 
and extracted with DCM (3 x 100 ml). The organic phase was washed with water (100 
ml) and saturated NaCl solution (100 ml) before dried over MgSO4. After the solvent was 
reduced to minimal level, the residue was transferred onto silica gel column and eluted 
with ethyl acetate-petroleum ether (2:3). The product was obtained as yellow oil (237 mg, 
19%). δ H (400 MHz, CDCl3) 8.12 – 7.96 (2-H (imida)), 7.97 – 7.71 (4 H, m, phenyl and 
tosyl), 7.32 (5 H, t, J 26.0, phenyl and tosyl), 5.36 – 5.20 (1 H, m, CH), 4.14 (8 H, s, ), 
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2.45 (3 H, s, CH3 tosyl), 2.38 – 2.08 (2 H, m, -H2), 1.76 – 1.34 (15 H, m, 2(CH3) and 
3(CH3)). δ C (75 MHz, CDCl3) 137.05, 131.95, 130.50, 128.52, 128.45, 128.36, 127.23, 
127.13, 72.28, 68.22, 66.00, 65.75, 54.91, 29.64, 28.39, 24.39, 21.67, 14.15. 
 
 
 
2,5-dibromo-4-((4,5-dihydro-2-phenyloxazol-4-yl)methyl)-1H-imidazole (79) 
 
 
 
 
 
 
 
 
Into a stirring solution of 4-((4,5-dihydro-2-phenyloxazol-4-yl)methyl)-1H-imidazole, 76, 
(1.1 g, 4.84 mmol) in acetonitrile-DMF (1:1) (10 ml) mixture in the dark (aluminium foil) 
under nitrogen, N-bromosuccinimide (0.8 g, 4.84 mmol) in acetonitrile (2 ml) was slowly 
added. After two hours of stirring, tlc showed complete conversion of the starting 
material. The solvent was reduced by evaporation before 10 g of silica was added. The 
solvent was removed in vacuo over silica and the dry silica was transferred onto a packed 
column and eluted with ethyl acetate-petroleum ether (2:3) to afford the product as a 
yellow solid (933 mg, 63%); δ H (400 MHz, CDCl3) 7.95 (2 H, d, J 8.2, phenyl), 7.62 – 
7.38 (4 H, m, phenyl and 2-H), 4.69 – 4.49 (2 H, m, -H and CHa), 4.23 – 4.11 (1 H, m, 
CHb), 3.07 (1 H, dd, J 3.9, 15.0, -Ha), 2.77 (1 H, dd, J 8.4, 15.0, -Hb). 
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5-bromo-4-((4,5-dihydro-2-phenyloxazol-4-yl)methyl)-1-tosyl-1H-imidazole (80b) 
 
 
 
 
 
 
 
 
A mixture of 2,5-dibromo-4-((4,5-dihydro-2-phenyloxazol-4-yl)methyl)-1H-imidazole, 
79, (0.64 g, 2.08 mmol) and triethylamine (2.24 ml, 16 mmol) in DCM (10 ml) was 
cooled to 0oC on ice bath before a solution of para-toluenesulfonyl chloride (0.61 g, 3.2 
mmol) in DMC (5 ml) was added. The reaction mixture was stirred overnight at room 
temperature before stopped with saturated NaHCO3 solution (50 ml). The mixture was 
extracted with DCM (2 x 50 ml), and the combined organic layers were washed with 
water (100 ml) and saturated NaCl solution (100 ml) before dried over MgSO4 salt. 
Evaporation of the organic solvent afforded a crude solid which was purified by 
chromatography using ethyl acetate-petroleum ether (1:4) as the mobile phase.  The 
product was obtained as a yellow solid (843 mg, 88%). M + H: 460.0 (exp), 460.0 (obt). 
δ H (400 MHz, Pyridine) 8.13 (1 H, d, J 0.9, 2-H), 8.08 – 7.98 (2 H, m, phenyl), 7.86 (2 
H, d, J 8.4, tosyl), 7.55 (1 H, dd, J 4.0, 10.7, phenyl), 7.51 – 7.39 (4 H, m, phenyl and 
tosyl), 4.83 – 4.70 (1 H, m, -H), 4.39 (1 H, t, J 9.0, CHa), 4.33 – 4.24 (1 H, m, CHb), 
3.17 (1 H, dd, J 6.2, 14.8, -Ha), 2.92 (1 H, dd, J 8.6, 14.8, -Hb), 2.50 (3 H, s, CH3, 
tosyl). δ C (101 MHz, CDCl3) 164.42, 146.85, 137.50, 134.46, 131.49, 130.68, 128.46, 
128.32, 127.56, 125.91, 120.36, 71.64, 66.02, 60.37, 30.37, 21.76. 
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tert-Butyl 1-hydroxy-3-(1H-imidazol-4-yl)propan-2-ylcarbamate (64) 
 
 
 
 
 
 
Into a stirring suspension of LiAH4 (0.423 g, 11.14 mmol) in THF (18 ml) at -10
oC, tert-
butyl 1-(methoxycarbonyl)-2-(1H-imidazol-4-yl)ethylcarbamate, 46, (2 g, 7.43 mmol) in 
THF (5 ml) was added drop-wise over 15 minutes. The reaction was complete after 20 
minutes (showed by tlc). A mixture of water-THF (1:1) (5 ml) was slowly added into the 
reaction mixture to stop the reaction. The mixture was quickly neutralized with 2 M 
NH4Cl solutions and extraction was done with DCM (3 x 300 ml). The organic phase was 
washed with water (100 ml), saturated NaCl solution (100 ml) before dried over Na2SO4 
salt. The solvent was removed to give an oily residue which was purified by 
chromatography using methanol-ethyl acetate (1:4) to give colourless oil (1.33 g, 74%);    
δ H (400 MHz, CDCl3) 7.53 (1 H, s, 2-H), 6.79 (1 H, s, 4-H), 5.18 (1 H, s, N-H), 3.82 (1 
H, s, -H), 3.71 – 3.66 (1 H, m, C-H), 3.63 – 3.51 (1 H, m, CH), 2.88 (2 H, qd, J 5.8, 
14.7, -H2), 1.41 (9 H, d, J 8.1, 3(CH3)). 
 
tert-butyl 1-hydroxy-3-(5-iodo-1H-imidazol-4-yl)propan-2-ylcarbamate (65b) 
 
 
 
 
 
 
 
Method A: To a stirring solution of tert-butyl 1-hydroxy-3-(1H-imidazol-4-yl)propan-2-
ylcarbamate, 64, (0.1 g, 0.41 mmol) in acetonitrile (2 ml) at room temperature in the dark 
was added N-iodosuccinimide (0.092 g, 0.41 mmol) in acetonitrile (1 ml). The reaction 
mixture was stirred for 2 hours and tlc showed a total conversion of the starting material. 
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The solvent was removed by evaporation to give a yellow waxy residue which was 
purified by chromatography with methanol-ethyl acetate (1:4) as the mobile phase to give 
the product as a colourless oil (1.5 mg, 30%). δ H (400 MHz, CDCl3) 7.56 (1 H, s, 2-H), 
5.14 (1 H, s, N-H), 3.88 – 3.76 (1 H, m, -H), 3.71 – 3.57 (2 H, m, CH2), 2.94 – 2.70 (2 
H, m, -H2), 1.39 (9 H, s, 3(CH3)). 
 
Method B:  Into a stirring solution of thiophenol (0.61 ml, 5.9 mmol) in isopropanol (20 
ml) at room temperature, NaH (0.23 g, 5.9 mmol) in isopropanol (2 ml) was added. The 
reaction mixture was heated up to 35oC and then a solution of tert-butyl 1-hydroxy-3-
(2,5-diiodo-1H-imidazol-4-yl)propan-2-ylcarbamate, 65a, (2 g, 5.4 mmol) in isopropanol 
(5 ml) was added. After 30 minutes the reaction was complete (confirmed by tlc). 
NaHCO3 saturated solution (50 ml) was added and the aqueous mixture was extracted 
with DCM (3 x 100 ml), the organic layer washed with water (100 ml) and saturated 
NaCl solution (100 ml) before dried over MgSO4. The solvent was removed by 
evaporation to give a yellow waxy residue which was purified by chromatography with 
methanol-ethyl acetate (1:4) as the mobile phase to give the product as colourless oil (595 
mg, 30%). 
 
 
tert-Butyl-5,7,8,9-tetrahydro-5,5-dimethylimidazo[1,5-c][1,3]oxazepin-8-
ylcarbamate (66 and 67) 
 
 
 
 
 
 
 
 
 Into a stirring solution of tert-butyl 1-hydroxy-3-(5-iodo-1H-imidazol-4-yl)propan-2-
ylcarbamate, 65, (0.33 g, 0.9 mmol) in DCM (3 ml), 2.2-dimethoxypropane (3 ml, 24.4 
mmol) was added. Para-toluenesulfonic acid (0.034 g, 0.18 mmol) in DCM (2 ml) was 
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added to the stirring mixture and the mixture was heated to reflux and stirred overnight 
under nitrogen. The mixture was poured into a saturated NaHCO3 solution (50 ml) and 
extracted with DCM (3 x 100 ml). The organic phase was washed with water (50 ml), 
saturated NaCl solution (50 ml), dried over MgSO4 salt and concentrated. Purification by 
column chromatography using ethyl acetate-petroleum ether (9:1) as eluent afforded two 
products: 
66 as yellow oil (3.66 mg, 26%). δ H (400 MHz, CDCl3) 7.47 (1 H, s, 2-H), 4.59 (1 H, s, 
N-H), 4.14 – 4.04 (1 H, m, CH), 3.99 (1 H, s, -H), 3.70 (1 H, dd, J 4.1, 13.0, CH), 3.19 
– 2.94 (2 H, m, -H), 1.77 (3 H, s, CH3), 1.68 (3 H, s, CH3), 1.41 (9 H, s, 3(CH3)). δ C 
(101 MHz, CDCl3) 136.20, 94.97, 89.89, 67.70, 48.50, 29.79, 28.57, 28.41, 26.58. 
 
67 as yellow solid (70 mg, 19%). δ H (400 MHz, CDCl3) 7.62 (1 H, s, 2-H), 4.09 (1 H, d, 
J 7.2, -H), 3.87 (2 H, dd, J 9.4, 14.9, CH2), 3.05 – 2.80 (2 H, m, -H2), 1.52 (3 H, s, 
CH3), 1.47 (9 H, s, 3(CH3)), 1.45 (3 H, s, CH3). δ H (400 MHz, CDCl3) 7.47, 4.59, 4.09, 
4.07, 4.06, 3.99, 3.72, 3.71, 3.69, 3.68, 3.10, 3.03, 3.02, 2.99, 2.98, 1.77, 1.68, 1.41. 
 
 
 
tert-Butyl 1-(methoxycarbonyl)-2-(1-((benzyloxy)methyl)-1H-imidazol-4-
yl)ethylcarbamate (68) 
 
 
 
 
 
 
 
 
A stirring mixture of 3-Bom-α-N-Boc-His-OH, 44, (10 g, 26.64 mmol) and K2CO3 (4.05 
g, 29.3 mmol) in DMF (120 ml) on ice-bath was treated with methyl iodide (1.82 ml, 
29.3 mmol). The reaction mixture was stirred overnight at room temperature and then 
poured into water (500 ml). The aqueous mixture was extracted with DCM (2 x 200 ml). 
N N
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O
O
O
O
O
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The organic phase was washed with saturated NaCl solution (200 ml), dried over MgSO4 
and concentrated to afford the product as a yellow solid (9.75 g, 94%) which did not 
require any further purification. δ H (400 MHz, CDCl3) 7.44 (1 H, s, 2-H), 7.36 – 7.24 (5 
H, m, phenyl), 6.83 (1 H, s, 4-H), 5.25 (3 H, q, J 11.1, N-H and NCH2), 4.54 (1 H, s, -
H), 4.41 (2 H, s, OCH2), 3.68 (3 H, s, OCH3), 3.11 (2 H, ddd, J 6.3, 15.5, 22.5, -H), 1.37 
(9 H, s, 3(CH3)). 
 
 
tert-butyl 3-(1-((benzyloxy)methyl)-1H-imidazol-4-yl)-1-hydroxypropan-2-
ylcarbamate (69) 
 
 
 
 
 
 
 
To a stirring suspension of tert-butyl 1-(methoxycarbonyl)-2-(1-((benzyloxy)methyl)-1H-
imidazol-5-yl)ethylcarbamate, 68, (1.3 g, 3.1mmol) in THF (15 ml) on ice-NaCl bath, 
LiAH4 (0.23 g, 6.1 mmol) in THF (3 ml) was slowly added. The reaction mixture was 
stirred for 15 minutes and the ice-NaCl was removed. After stirring for 2 hours at room 
temperature, water was slowly added to stop the reaction. The slurry was MgSO4 
extracted with DCM (3 x 200 ml) and the organic phase was dried over MgSO4. Removal 
of the solvent afforded an oily residue which was purified by column chromatography 
using DCM-methanol (9.5:0.5) as the mobile phase to give the product as a colourless oil 
(852 mg, 76%). δ H (400 MHz, CDCl3) 7.47 (1 H, s, 2-H), 7.42 – 7.25 (5 H, m, phenyl), 
6.88 (1 H, s, 4-H, ), 5.32 (2 H, s, NCH2), 5.09 (1 H, s, N-H), 4.46 (2 H, d, J 6.3, OCH2), 
3.84 (1 H, s, -H), 3.66 – 3.49 (2 H, m, CH2), 2.96 – 2.81 (2 H, m, -H), 1.41 (9 H, s, 
3(CH3)). 
 
 
 
N N
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tert-Butyl 3-(2-methoxypropan-2-yloxy)-1-(1-((benzyloxy)methyl)-1H-imidazol-4-
yl)propan-2-ylcarbamate (70) 
 
 
 
 
 
 
 
 
 
A solution of para-toluenesulfonic acid (0.105 g, 0.55 mmol) in DCM (3 ml) was added 
into a mixture of tert-butyl 3-(1-((benzyloxy)methyl)-1H-imidazol-4-yl)-1-
hydroxypropan-2-ylcarbamate, 69, (1 g, 2.75 mmol) and 2.2-dimethoxypropane (1.7 ml, 
13.75 mmol) in DCM (10 ml). The reaction mixture was stirred at room temperature for 3 
days and poured into saturated NaHCO3 solution (50 ml). The aqueous mixture was 
extracted with DCM (3 x 50 ml) and the organic phase was washed with water (100 ml), 
saturated NaCl solution (100 ml) and dried over MgSO4. The mixture was concentrated 
and purified by column chromatography using ethyl acetate-petroleum ether (9:1) as a 
mobile phase. The product was obtained as a  colourless oil (0.441 g, 37%). δ H (400 
MHz, CDCl3) 7.67 (1 H, s, 2-H), 7.29 (5 H, ddd, J 4.3, 8.3, 25.9, phenyl), 6.85 (1 H, s, 4-
H), 5.33 (2 H, s, NCH2), 4.79 (1 H, s, N-H), 4.48 (2 H, s, OCH2), 3.84 (1 H, s, -H), 3.35 
(2 H, d, J 4.0, CH2), 3.13 (3 H, s, OCH3), 2.83 (2 H, dt, J 7.3, 14.5, -H2), 1.34 (9 H, s, 
3(CH3)), 1.28 (6 H, s, 2(CH3)).  
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Histidine methyl ester (35a) 
 
 
 
 
 
 
 
Thionyl chloride (1.59 ml, 26.3 mmol) was added drop-wise into a stirring cold 
anhydrous methanol (50 ml). Into the solution, L-histidine 1 (3.4 g, 21.91 mmol) was 
added in four portions to form a suspension. The cold bath was removed and the 
suspension was refluxed overnight. The mixture was allowed to cool before concentrated 
to afford a pale yellow paste. Additional methanol (50 ml) was added and the solution 
was evaporated again to afford a white solid. A hot ethyl acetate (3 x 30 ml) was added to 
form a suspension which was filtered. The solvent was removed in vacuo and the sample 
was dried on high vacuum pump to give a pale yellow paste (3.4 g, 76%).   
 
 
 
methyl 5,6,7,8-tetrahydro-5-oxoimidazo[1,5-f]pyrimidine-7-carboxylate (36a) 
 
 
 
 
 
 
A mixture of histidine methyl ester, 35a, (0.5 g, 2.96 mmol) and 1.1-carbonyldiimidazole 
(48 mg, 2.96 mmol) in acetonitrile (20 ml) was stirred at 80oC overnight. The solvent was 
evaporated to give a yellow oily residue which was dissolved in saturated NaHCO3 
solution (50 ml). The aqueous mixture was extracted with ethyl acetate (2 x 100 ml). The 
organic phase was washed with water (100 ml) and saturated NaCl solution (100 ml) 
before dried over MgSO4. The mixture was concentrated to give as an oily residue which 
was purified by column chromatography using methanol-DCM (1:9) as the mobile phase 
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to give the product as a white solid (468 mg, 81%), mp: 162-163oC. 1H NMR (400 MHz, 
DMSO) δ 8.56 (s, 1H, N-H), 8.13 (s, 1H, 2-H), 6.85 (s, 1H, 4-H), 4.47 (t, J = 4.7, 1H, 
N()-H), 3.66 (s, 3H, OCH3), 3.26 (d, J = 4.5, 2H, C-CH2). 
13C NMR (101 MHz, DMSO) 
δ 172.11, 148.72, 135.03, 126.43, 125.34, 53.40, 52.56, 23.26. 
 
 
Synthesis of 37a 
 
 
 
 
 
 
 
 
To a stirring suspension of methyl 5,6,7,8-tetrahydro-5-oxoimidazo[1,5-f]pyrimidine-7-
carboxylate, 36a, (0.1 g, 0.51 mmol) in acetonitrile (5 ml) was added methyl iodide (0.1 
ml, 1.53 mmol). The reaction mixture was refluxed overnight and then cooled down to 
room temperature. The yellow crystals precipitated out of the reaction mixture were 
filtered and the product was recrystallized from acetonitrile to give a yellow solid (79 mg, 
74%), mp: 175-176oC. 1H NMR (400 MHz, DMSO) δ 9.77 (s, 1H, 2-H), 9.52 (s, 1H, N-
H), 7.64 (s, 1H, 4-H), 4.69 (s, 1H, ()N-H), 3.92 (s, 3H, N-CH3), 3.70 (s, 3H, OCH3), 
3.42 (s, 2H, CCH2). 
13C NMR (101 MHz, DMSO) δ 171.11, 145.21, 136.23, 128.77, 
121.16, 53.82, 52.03, 37.31, 22.22. 
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1-methylhistidine (14) 
 
 
 
 
 
 
A solution of, 37a, (0.05 g, 0.24 mmol) in 6 N HCl (5 ml) was stirred at 70oC overnight 
and the solvent was evaporated in vacuo to afford a yellow residue. The crude product 
was dissolved in 1 mM HCl (2 ml) and applied to an ion-exchange column (Dowex 50X 
2-200, H+ form), 1 ml bed volume. The column was washed with water until the eluent 
pH was neutral before the product was eluted with 10% NH4OH solution. Evaporation of 
the solvent gave a pale yellow crystalline product (22 mg, 55%), mp 245oC. 1H NMR 
(400 MHz, D2O) δ 7.42 (s, 1H, 2-H), 6.76 (s, 1H, 4-H), 3.79 (t, J = 6.6, 1H, ()N-H), 
3.41 (s, 3H, NCH3), 2.79 (qd, J = 6.6, 15.1, 2H, CCH2). 13C NMR (101 MHz, D2O) δ 
174.02, 138.62, 133.53, 120.27, 53.57, 33.68, 30.07. 
 
 
 
Synthesis of 39a 
 
 
 
 
 
 
A mixture of methyl 5,6,7,8-tetrahydro-5-oxoimidazo[1,5-f]pyrimidine-7-carboxylate, 
36a, (0.2 g, 1.02 mmol) and 2-bromo-2’-acetonaphthone (0.21 g (1.02 mmol) in 
acetonitrile (5 ml) was refluxed overnight. The reaction mixture was cooled to room 
temperature and the formed precipitates were filtered. The crude product was 
recrystallized from acetonitrile to give the product as white crystals (264 mg, 71%), mp: 
193-194oC. M + H: 323.1 (exp), 324.2 (obt). δ H (400 MHz, DMSO) 9.83 (1 H, s, 2-H), 
9.65 (1 H, d, J 4.0, N-H), 8.86 (1 H, s, 4-H), 8.32 – 8.02 (4 H, m, aromatic), 7.86 – 7.67 
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(3 H, m, aromatic), 6.27 (2 H, s, CH2), 4.76 (1 H, d, J 5.1, -H ), 3.75 (3 H, s, OCH3), 
3.52 (2 H, d, J 3.9, -H2). 
δ C (101 MHz, DMSO) 191.21, 171.17, 145.17, 137.11, 136.36, 132.80, 131.64, 131.31, 
130.47, 130.20, 129.64, 128.67, 128.23, 123.93, 121.61, 56.88, 53.83, 52.14, 22.30. 
 
 
methyl 1-(methoxycarbonyl)-2-(1-(2-(naphthalen-2-yl)-2-oxoethyl)-1H-imidazol-4-
yl)ethylcarbamate (40a) 
 
 
 
 
 
 
 
To a solution of, 39a, (0.1 g, 0.27 mmol) in anhydrous methanol (5 ml) was added 
diisopropylethylamine (0.1 ml, 0.55 mmol). The resultant reaction mixture was heated to 
reflux overnight, at that point tlc showed a complete conversion of the starting material. 
The solvent was removed by evaporation and the residue was dissolved in DCM (20 ml). 
The solution was washed with water (50 ml), and the saturated NaCl solution (50 ml) 
before dried over MgSO4. The solution was concentrated and purified by column 
chromatography using methanol-DCM (0.5:9.5) the mobile phase to afford the product 
(56 mg, 52%) as white solid, mp: 66-67oC. 1H NMR (300 MHz, CDCl3) δ 8.48 (s, 1H, 2-
H), 8.13-7.88 (4H, m,  aromatic), 7.72-7.58 (3H, m, aromatic), 6.76 (1H, s, 4-H), 6.32 
(1H, s, N-H), 5.45 (2H, s, NCH2), 4.04 (1H, m, -H), 3.70 (3H, s, NCOCH3), 3.67 (3H, s,  
OCH3), 3.22-3.08 (2H, m, -H2). δ C (75 MHz, CDCl3) 191.36, 172.30, 137.99, 137.59, 
136.03, 132.35, 131.47, 129.79, 129.59, 129.24, 129.14, 127.92, 127.31, 123.19, 118.03, 
54.03, 52.47, 52.23, 52.14, 30.18.  
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7,8-dihydroimidazo[1,5-f]pyrimidin-5(6H)-one (36b) 
 
 
 
 
 
 
To a suspension of histamine, 35b, (0.5 g, 4.5 mmol) in acetonitrile (10 ml) was added a 
solution of 1.1-carbonyldiimidazole (0.73 g, 4.5 mmol) in acetonitrile (10 ml). The 
reaction mixture was refluxed overnight. The solvent was removed by evaporation and 
the residue was dissolved in DCM (40 ml) which was then poured in a saturated NaHCO3 
solution (60 ml). The extraction of the crude product was done with DCM (3 x 40 ml) 
and the DCM phase was washed with water (50 ml), saturated NaCl solution (50 ml) and 
dried over MgSO4 salt. Purification by chromatography with DCM-methanol (9.5:0.5) 
afforded the product (512 mg, 83%) as white solid, mp 220oC. δ H (400 MHz, DMSO) 
8.20 (1 H, s, br,  N-H), 8.07 (1 H, s, 2-H), 6.82 (1 H, s, 4-H), 3.42 – 3.36 (2 H, m, NCH2), 
2.91 (2 H, t, J 6.4, CH2). δ C (101 MHz, DMSO) 149.13, 134.73, 128.06, 125.40, 39.47, 
20.04. 
 
 
Synthesis of 37b 
 
 
 
 
 
 
To a suspension of 7,8-dihydroimidazo[1,5-f]pyrimidin-5(6H)-one, 36b, (0.1 g, 0.73 
mmol) in acetonitrile (5 ml) was added methyl iodide (0.14 ml,  2.25 mmol). The 
resulting suspension was refluxed overnight. The reaction mixture was cooled to room 
temperature and the formed precipitates were filtered and recrystallized from acetonitrile 
to afford the product as white crystals (87 mg, 78%); mp: 197oC. 1H NMR (300 MHz, 
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DMSO) δ 9.63 (s, 1H, 2-H), 8.94 (s, 1H, N--H), 7.59 (s, 1H, 4-H), 3.91 (s, 3H, CH3), 
3.49 (td, J = 2.8, 6.5, 2H, N-CH2), 3.03 (t, J = 6.1, 2H, C-CH2). 
 
1-methylhistamine (38b) 
 
 
 
 
 
 
 
A solution of, 37b, (0.1 g, 0.657 mmol) in 6 N HCl (5 ml) was stirred overnight at 70oC. 
The solvent was removed by evaporation; the residue was dissolved in 1 mM HCl (1 ml) 
and applied to an ion-exchange column (Dowex 50X 2-200, H+ form). The column was 
washed with water until the eluent pH was neutral before the product was eluted with 
10% NH4OH solution. Evaporation of the solvent gave a white crystalline product (57 
mg, 69%); 1H NMR (300 MHz, CD3OD) δ 7.48 (s, 1H, 2-H), 6.84 (s, 1H, 4-H), 3.67 (s, 
3H, N-CH3), 3.38 – 3.26 (m, 2H, N()-CH2), 2.67 (t, J = 6.8, 2H, C-CH2).
13C NMR (75 
MHz, CD3OD) δ 140.44, 138.64, 118.84, 40.95, 33.56, 29.63. 
 
 
Synthesis of 39b 
 
 
 
 
 
 
To a solution of 7,8-dihydroimidazo[1,5-f]pyrimidin-5(6H)-one, 36b, (0.2 g, 1.46 mmol) 
in acetonitrile (10 ml) was added  2-bromo-2’-acetonaphthone (0.36 g, 1.46 mmol) and 
the reaction mixture was refluxed overnight, at that point a tlc showed a total conversion 
of the starting material. The reaction mixture was cooled to room temperature and the 
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formed precipitates were filtered and recrystallized from acetonitrile to give the product 
(331 mg, 74%) as white crystals; mp: 192-193oC. 1H NMR (400 MHz, DMSO) δ 9.75 (s, 
1H, 2-H), 9.18 (s, 1H, N-H), 8.89 (s, 1H, 4-H), 8.21 (m, 3H, aryl), 7.75 (m, 2H, aryl), 
6.30 (s, 2H, N-CH2), 3.59 (m, 2H, N()-CH2), 3.17 (d, J = 6.4, 2H, C-CH2). 
 
methyl 2-(1-(2-(naphthalen-2-yl)-2-oxoethyl)-1H-imidazol-4-yl)ethylcarbamate (40b) 
 
 
 
 
To a solution of, 39b, (0.2 g, 0.65 mmol) in anhydrous methanol (5 ml) was added 
diisopropylethylamine (0.228 ml, 1.30 mmol). The resultant reaction mixture was heated 
to reflux overnight after which tlc showed complete conversion f the starting material. 
The solvent was removed by evaporation and the residue was dissolved in DCM (20 ml). 
The solution was washed with water (50 ml), and the saturated NaCl solution (50 ml) 
before dried over MgSO4. The solution was concentrated and purified by column 
chromatography using methanol-DCM (0.5:9.5) as the mobile phase to afford the product 
(105 mg, 48%) as a white solid; mp: 147-149oC. δ H (300 MHz, CDCl3) 8.48 (1 H, s, 2-
H), 8.05 – 7.86 (4 H, m, aromatic), 7.63-746 (3 H, dddd, J 1.4, 6.9, 8.2, 14.7, aromatic), 
6.75 (1 H, t, J 6.5, 4-H), 5.47 (2 H, s, NCH2), 3.65 (3 H, s, OCH3), 3.51 (2 H, dd, J 6.0, 
12.2, N()CH2), 2.79 (2 H, t, J 6.4, CH2). 
 
2-amino-3-(1-((benzyloxy)methyl)-1H-imidazol-4-yl)propanoic acid (45) 
 
 
 
 
 
 
 
3-Bom-α-N-Boc-His-OH, 44, (2 g, 5.33 mmol) was added to 20% trifluoroacetic acid in 
DCM (20 ml). The reaction mixture was stirred for 2 hours at room temperature after 
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which tlc showed a complete conversion reaction of the starting material. The solvent 
was removed by evaporation to give a residue which was dissolved in 1mM HCl (5 ml) 
and applied to an ion-exchange column (Dowex 50X 2-200, H+ form). The column was 
washed with water until the eluent pH was neutral before the product was eluted with 
10% NH4OH solution. Evaporation of the solvent gave the product (1.26 g, 86%) as 
white solid. 1H NMR (400 MHz, DMSO)  7.75 (s, 1H, 2-H), 7.40-7.25 (m, 5H, aryl 
protons), 6.90 (s, 1H, 4-H), 5.55-5.42 (m, 2H, NCH2), 4.60-4.52 (m, 2H, Ar-CH2), 3.62 
(m, 1H, ()N-H), 3.31-3.00 (m, 2H, CCH2). δ C (101 MHz, DMSO) 171.00, 139.22, 
138.08, 129.05, 128.93, 128.38, 128.19, 74.41, 70.31, 54.06, 26.57. 
 
 
tert-Butyl 1-(2-aminoethylcarbamoyl)-2-(1-((benzyloxy)methyl)-1H-imidazol-5-
yl)ethylcarbamate (49) 
 
 
 
 
 
 
 
To a solution of 3-Bom-α-N-Boc-His-OH, 44, (2 g, 5.33 mmol) in THF (20 ml) was 
added N,N’-carbonyldiimidazole (1.04 g, 6.42 mmol). The mixture was stirred at room 
temperature until bubbling ceased and the reaction mixture was cooled to -10oC (ice-
NaCl bath). Ethylenediamine (1.79 ml, 26.65 mmol) was added. The reaction mixture 
was stirred vigorously for 30 minutes and the ice bath was removed. After 2 hours the 
solvent was removed and the residue was purified by flash chromatography using acetone 
as the mobile phase. The product (1.9 g, 86%) was obtained as yellow oil. M + H: 418.2 
(exp), 418.3 (obt). 1H NMR (400 MHz, CDCl3) δ 7.50 (s, 1H, 2-H), 7.41 – 7.29 (m, 5H, 
aromatic), 6.89 (s, 1H, 4-H), 5.34 (dd, J = 10.9, 23.1, 2H, NCH2 ), 4.53 (d, J = 11.9, 2H, 
aryl-CH2), 4.38 (s, 1H, ()N-H), 3.17 (m, 2H, CCH2), 3.09 (d, J = 7.1, 2H, amide-CH2), 
2.65 (d, J = 12.2, 2H, amine-CH2), 1.42 (d, J = 5.6, 9H, C(CH3)3).
13C NMR (75 MHz, 
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CDCl3) δ 170.85, 138.35, 135.94, 129.39, 128.72, 128.40, 128.09, 127.28, 73.11, 70.11, 
54.10, 42.10, 41.04, 30.84, 28.26, 27.10. 
 
tert-Butyl 1-(2-aminoethylcarbamoyl)-2-(1H-imidazol-5-yl)ethylcarbamate (50) 
 
 
 
 
 
 
 
 
Into a stirring solution of tert-butyl 1-(2-aminoethylcarbamoyl)-2-(1-
((benzyloxy)methyl)-1H-imidazol-5-yl)ethylcarbamate, 49, (0.2 g, 0.48 mmol) in 
anhydrous methanol (1 ml), 10% Pd-C (0.2 g) in anhydrous methanol (2ml) was added. 
To the stirring suspension hydrazinium monoformate (0.2 ml, 2.3 mmol) was added. The 
mixture was stirred overnight. The mixture was then filtered over celite and washed with 
methanol (10 ml). Evaporation of the solvent afforded a yellow residue which was 
dissolved in ethyl acetate (20 ml) and washed with saturated NaCl solution (50 ml). The 
organic solvent was dried over MgSO4 and the solvent was removed. The residue was 
dissolved in 1 mM HCl (2 ml) and transferred onto ion exchange column (Dowex 50X 2-
200, H+ form). The column was washed with water until the eluent pH was neutral before 
the product was eluted with 10% NH4OH solution. Evaporation of the solvent afforded 
the product (60 g, 42%) as a yellow oil; 1H NMR (400 MHz, CD3OD) δ 7.58 (s, 1H, 2-
H), 6.84 (s, 1H, 4-H), 4.25 (s, 1H, ()N-H), 3.30 (d, J = 1.7, 2H, amide-CH2), 2.95 (d, J = 
57.1, 2H, CCH2), 2.42 (t, J = 6.7, 2H, amine-CH2), 1.40 (s, 9H, C(CH3)3). 
13C NMR (101 
MHz, CD3OD) δ 126.80, 49.53, 46.77, 35.91, 28.41, 21.21, 19.14. 
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2-amino-N-(2-aminoethyl)-3-(1-((benzyloxy)methyl)-1H-imidazol-5-yl)propanamide 
(17) 
 
 
 
 
 
 
 
tert-Butyl 1-(2-aminoethylcarbamoyl)-2-(1-((benzyloxy)methyl)-1H-imidazol-5-yl) 
ethylcarbamate, 49, (0.5 g, 1.2 mmol) was dissolved in 20%  trifluoroacetic acid in DCM 
(10 ml). After 2 hours of stirring the solvent was removed by evaporation and the residue 
was loaded onto a silica column. The column was washed with acetone and then eluted 
with a mixture of methanol-water (4:1). The solvent was removed to give a residue which 
was dissolved in 1 mM HCl (5ml) and applied to an ion- xchange column (Dowex 50X 
2-200, H+ form). The column was washed with water until the eluent pH was neutral 
before the product was eluted with 10% NH4OH solution. Evaporation of the solvent 
afforded the product (278 mg, 73%) as yellow oil. M + H: 318.2 (exp), 318.2 (obt). 1H 
NMR (300 MHz, cd3od) δ 7.73 (s, 1H, 2-H), 7.39 – 7.22 (m, 5H, aryl protons), 6.87 (s, 
1H, 4-H), 5.52 (dt, J = 10.7, 21.3, 2H, NCH2), 4.49 (s, 2H, Aryl-CH2), 3.88 (dd, J = 4.0, 
7.8, 1H, ()N-H), 3.32 – 3.27 (m, 2H, amide-CH2), 3.20 (dt, J = 4.9, 17.0, 2H, CCH2), 
2.77 (dd, J = 8.4, 15.6, 2H, amine-CH2). δ C (75 MHz, CD3OD) 176.09, 139.51, 129.56, 
129.52, 129.04, 128.99, 128.83, 128.79, 78.04, 75.29, 71.34, 59.02, 43.06, 41.39, 26.41. 
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2-amino-N-(2-aminoethyl)-3-(1H-imidazol-4-yl)propanamide (16) 
 
 
 
 
 
 
 
A solution of tert-butyl 1-(2-aminoethylcarbamoyl)-2-(1H-imidazol-5-yl)ethylcarbamate, 
50, (0.2 g, 0.67 mmol) in 20% trifluroacetic acid in DCM (5 ml) was stirred at room 
temperature for 2 hours. The solvent was evaporated and the crude residue dissolved in 1 
mM HCl (2ml) and transferred onto ion exchange column (Dowex 50 WX 2-200, H+ 
form). The column was washed with water until the eluent pH was neutral before the 
product was eluted with 10% NH4OH solution. The column was washed with water until 
the eluent pH was neutral before the product was eluted with 10% NH4OH solution. 
Evaporation of the solvent afforded the product (69 mg, 52%) as yellow oil; 1H NMR 
(400 MHz, D2O) δ 7.41 (s, 1H, 2-H), 6.66 (s, 1H, 4-H), 3.35 (d, J = 6.6, 1H, ()N-H), 
3.12 (d, J = 8.9, 2H, amide-CH2), 2.66 (t, J = 20.8, 2H, CCH2), 2.45 (dd, J = 11.5, 18.0, 
1H, amide-CH2). 
 
Alternatively, 16 could be synthesized from 17. Thus, into a stirring solution of 2-amino-
N-(2-aminoethyl)-3-(1-((benzyloxy)methyl)-1H-imidazol-5-yl)propanamide, 17, (0.15 g, 
0.47 mmol) in anhydrous methanol (1 ml), 10% Pd-C (0.2 g) in anhydrous methanol (2 
ml) was added. To the stirring suspension hydrazinium monoformate (0.2 ml, 2.3 mmol) 
was added. The mixture was stirred overnight, then filtered over celite and washed with 
methanol (10 ml). The residue was dissolved in 1 mM HCl (2 ml) and transferred onto 
ion exchange column (Dowex 50X 2-200, H+ form). The column was washed with water 
until the eluent pH was neutral before the product was eluted with 10% NH4OH solution. 
The column was washed with water until the eluent pH was neutral before the product 
was eluted with 10% NH4OH solution. Evaporation of the solvent afforded the product 
(35 mg, 38%) as yellow oil.  
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4,5-diiodo-1H-imidazole (52) 
 
 
 
 
 
Hexane (75 ml) was added into a solution of imidazole, 50, (1g, 14.5 mmol) in 0.04N 
NaOH (300 ml) and stirred vigorously. The mixture was cooled to 0oC before a solution 
of iodine (3.72 g, 14.5 mmol) in hexane (300 ml) was added. 0.2 N NaOH (300 ml) was 
added drop-wise over 1.2 hours and the temperature was raised to about 8oC. The 
reaction mixture was neutralized to pH 7 using 4N HCl and refrigerated overnight to 
form precipitates. The crystalline material was collected by filtration and recrystallized 
from ethanol-water (4:1) mixture to give the product (3.1 g, 67%) as white crystals; mp: 
196-196oC. δ H (300 MHz, DMSO) 7.77 (1 H, s, 2-H). 
 
1-((benzyloxy)methyl)-4,5-diiodo-1H-imidazole (53) 
 
 
 
 
 
To a stirring solution of 4,5-diiodo-1H-imidazole, 52, (0.5 g, 1.56 mmol) in anhydrous 
DMF (10 ml) under nitrogen, K2CO3 (4.3 g, access) was added to form a suspension, and 
to this benzyl chloromethyl ether (0.22 ml, 1.56 mmol) was added drop-wise. The 
mixture was stirred overnight at room temperature under nitrogen. The suspension was 
filtered and the filtrates were dissolved into water (100 ml). The solution was extracted 
with DCM (3 x 50 ml) and dried over MgSO4. The solvent was reduced to 20ml before 
silica (5 g) was added. The dried silica was transferred onto a packed column and the 
column was eluted with ethyl acetate-petroleum ether mixture (3:7) and the product (475 
mg, 72%) was obtained as pale yellow solid; mp: 89-90oC. δ H (400 MHz, CDCl3) 7.65 
(1 H, s, 2-H), 7.37 – 7.24 (5 H, m, phenyl), 5.32 (2 H, s, NCH2), 4.47 (2 H, s, OCH2). 
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1-((benzyloxy)methyl)-4-iodo-1H-imidazole-5-carbaldehyde (55) 
 
 
 
 
 
Into a solution of 1-((benzyloxy)methyl)-4,5-diiodo-1H-imidazole 25 (0.2 g, 0.45 mmol) 
in THF (5ml) at -78oC under nitrogen, nBuLi (0.29 ml, 0.5 mmol) was slowly added. The 
reaction mixture was stirred for 10 min before DMF (1ml) was added. The mixture was 
allowed to warm to room temperature before it was quenched with saturated NH4Cl 
solution (10 ml). The aqueous mixture was extracted with ethyl acetate (2 x 50 ml) and 
the organic phase was washed with water (50 ml) and saturated NaCl solution (50 ml) 
before dried over MgSO4. Removal of the solvent afforded a yellow residue which was 
purified by chromatography to give the product (105 mg, 68%) as yellow oil; δ H (300 
MHz, CDCl3) 9.75 (1 H, dd, J 1.0, 2.1), 7.41 (1 H, d, J 0.9), 7.39 – 7.19 (8 H, m), 5.86 – 
5.78 (3 H, m), 4.57 (2 H, s). δ C (75 MHz, CDCl3) 181.19, 136.00, 130.89, 129.13, 
128.62, 128.40, 127.98, 127.82, 85.49, 75.73, 71.75. 
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APPENDIX: 
 
 
 
 
 
 
 
Figure S1: Analysis of OvoA reaction mixture. HPLC chromatograms showing 
increasing 5-histidyl cysteine sulfoxide peak at 3.2 minutes (A) and calibration curve 
from which product concentrations were determined. 2000 µM cysteine, 2.89 µM OvoA 
and increasing concentrations of histidine (12.5 – 400 µM) were used in a standard 
reaction as described in section 3.2.2. For B, the reactions were allowed to proceed until 
all histidine was consumed as monitored by HLPC (20 µL injection volume). 
Absorbances of completed reactions were plotted against the histidine concentrations 
(with histidine concentrations equal to 5-L-histidyl sulfoxide sulfoxide concentrations). 
Data plotted here were averages of three determinants. 
 
Figure S2: Effect of iron concentration on OvoA reaction (A) and activation of 
OvoA by ascorbate and isoascorbate (B). Reaction conditions were similar to those 
described on figure 3.3. For A, iron concentrations of 20, 62.5, 125, 250, 500, 1000 and 
5000 nM were used. For B 2 mM ascorbate and isoascorbate each was used. 
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Figure S3: Michaelis-Menten graphs of OvoA with cysteine substrate (A) and 
histidine substrate (B). The standard reaction mixtures contained 20 mM Tris pH 8.0, 20 
mM NaCl, 2 mM TCEP, 2 mM ascorbate and 1 µM FeSO4 in a final volume of 250 µL at 
26°C. For cysteine kinetics (A), 800 µM histidine, cysteine (12.5 – 1000 µM), 294 nM 
OvoA were used. For histidine kinetics (B), 800 µM cysteine, histidine (12.5 – 1000 
µM), 289 nM OvoA were used. At 2, 4, 8 and 16 minutes, 30 µL aliquots of the reactions 
were quenched by addition of 15 µL 1 M phosphoric acid and analyzed for formation of 
5-D-histidyl cysteine sulfoxide using HPLC method 1. Data plotted here were averages 
of two determinants. 
 
Figure S3: Michaelis-Menten graphs of OvoA with histidinamide substrate (A) and 
histamine substrate (B). 250 µL reaction mixtures contained 20 mM Tris pH 8.0, 20 
mM NaCl, 2 mM TCEP, 2 mM ascorbate, 1µM FeSO4 and 800 uM cysteine at 26°C. For 
histidinamide kinetics (A) 25 – 2000uM histidinamide and 371 nM OvoA were used. , 
For histamine kinetics 25 – 2000 µM histamine and 377 nM OvoA were used. At 2, 4, 8 
and 16 minutes, 30 µL aliquots of the reactions were quenched by addition of 15 µL 1 M 
phosphoric acid and analyzed by HPLC method 1. Data plotted here were averages of 
two determinants 
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Figure S3: Michaelis-Menten graphs of OvoA with D-histidine substrate. Reaction 
mixtures containing 20 mM Tris pH 8.0, 20 mM NaCl, 2 mM TCEP, 2 mM ascorbate, 1 
µM FeSO4, 800 µM cysteine, D-histidine (62.5 – 5000 µM), 346 nM OvoA in final 
volume of 250 µL were incubated at 26°C. At 2, 4, 8 and 16 minutes, 30 ul aliquots of the 
reactions were quenched by addition of 15 µL 1 M phosphoric acid and analyzed for 
formation of 5-D-histidyl cysteine sulfoxide using HPLC method 1. Data plotted here 
were averages of two determinants. 
 
 
 
Figure S4: Effect of pH on histidine specificity and kinetic constant. 250 µL reaction 
mixtures at 26oC contained 800 µM cysteine, histidine (12.5 – 1000 µM), 2 mM TCEP, 2 
mM ascorbate, 1 µM FeSO4, 20 mM NaCl, 283 nM OvoA in 50 mM Britton-Robinson 
buffer at different pHs (6 – 8.5). At points 1, 2, 4 and 8 minutes, 40 µL samples were 
quenched with 20 µL 1 M phosphoric acid solution and analyzed by HPLC using method 
1. (A): kcat vs pH, (B): kcat/KM vs pH, (C): log kcat vs pH and (D): log kcat/KM vs pH. 
 
